var title_f19_55_20336="Salter III fracture";
var content_f19_55_20336=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Salter III fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 447px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oblique view of the right ankle. Salter Harris type III fracture of the medial aspect of the distal tibia in anatomic alignment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David Mathison, MD and Dewesh Agrawal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_55_20336=[""].join("\n");
var outline_f19_55_20336=null;
var title_f19_55_20337="Mild OE";
var content_f19_55_20337=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F83227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F83227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mild otitis externa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 402px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGSAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCFgMZqI8EVOBmmMuK5z7GOgw9DQCOKUA4xmkAGak0FHTuKkiJDD2qPtzSoef6Ug5S4BuWkK5GKcnIzin8Z+lBndplWROKiK1bY1Dkc0WNIshXjripNueajPD81PGNy9aQ2OjHY9adIoK8gUHjp1pW5XNMhlGUbSfeqbNgn8q0ZVyO9Z8ynmlc1hLoSxHNPOBmq0T4AHcVYDZwT+VFwkiZATilwR060IRjNTYBGR36VUTJsjA/Kp4jgD1pgAzinxjmrRDZoW46d61bZRkd6zbXrWtaDkA1vFHBWeho26dOeKlupxBAxzz05qE3Cw8k9KwtXvjIjKvX2rVysjhUHORTvrtpmOOQe9RQglR9OtVrfLEce1aUCbQBXNdyZ2tckbEbIT+PPNAUAnrnFW/LNMkj5p2ZF0RQ/OcjntVC40VHvGuEJBfrg9auWYcTSxsOAcr9K0FUke/TiqRFVEYQso9cUSWpMZY4FadtCAuT355pt06qCPWmczn0MS6XYo28+tU2PzCrc/wAzHn2qi/36k06DZ3C4B7UwyLyc5NVb2Q/vMDlRxVaNmO0k8Ed6CXHQuSzDgjHSqbMzMSBipdnHNPSLKDGM1RFrEVtM0TkkZ+lS/aAwIBxjn60nkMsSkjJz+dVmhJkJGQPY0XsDSZfWVWGFPJ4zSshchVqksZUDFWoJcMN2cVadzOUWthZ7f5cHrWZd22E5PGa6JvLdM5BOKrS22V5HU8A0OI4TtuchNEQ20AAdjUOxl/Cuh1CyAxj1HFUbm12kfnWbR0c+lw099rj88Cujs33kcA1ykJ2TKPU9q6rSlyRSRhU7mkqBs+9VbqEY44rTjX0qrdDPFWznTMgjDYoKZWp5kwc9KjY8HHSkap3KRGD/AFqOQ5GcVK45IqvJ6Cg1RWmyfrVCccH9a0nGR/niqU44PHepZrBlHPGabJzUh6nNMfgH0rFmyIG9RzTW6Z7VJj1pCMj2qOpZWkyOQe1FK45xRUuwOlCbu0eiD0pSmfp2pUqQ9Aa1SPTehEU4Jx0pjCrW04PHFMdQO1JouLKp7+lMQ9iKmYcH0qAdag0SuX4W+XrmnlgD9agiOBzQ7d+9MhrUeWBGc8GoGPzH0/nTgc9TTJKClEQnjOOKmtzk4qIjK1LCNp6dKkJLQklyBTQ4K89aWQ4HHeoUbI5pmdhZD9OarSKD0qaT17dqhb+RpFRKpTaSQKmXGOtIVyKFHbtTRbdywp+WrCNuAHcCqig4NTQHnmqRm0T+vrUsXUVEGy2KmhXLjBrSJjI0bUZI9DWnH8gzVS1j4H61LcybUJ45rdaHBUd3YrXl0WbAPFZ75ck9aS6cq3qaZE24HOOn51nKRpGNkTWyZH41oRDpxg5rPtWzkdwcVoQ8HmlAyqNltI8mnNFUsHIx3p8vy84rY5nLWxlTRlWLKPm/nT7aUOnTlTzip5Dk9OKqRjZPIg4B5zUXLvzKzL63QVOOapTyMwJNPVRtJGcVBNlc8c+lF7mPKkysx5OKquCCffpVwjCmqNy20E5x7UWBvUz2xI0uenSooY98SccfyqaHD5x0bmn28ZUlc8BuBRYGxVj+QbjzToRljgVZ8vJxj3qe3gC/PjoKZm5FaTkgY6U9rZXgBHGO3eniLcxP1qW1jeUMVzgDj3polsy44XZWPGM+lNmsnKb/ADGAJ6Diujg0xmgLJknhm9qDpmInIOG/hBHGapRdiXU1OdtT9nKRElx3zzWoJI5TkenSpNK0pTcK9237t2+YL1Aq0LKKF38sZ5IBPXFWk7EykrmbqEaLbnC5fuaxZ4Ts55rqbm3yoAHU1TubQFeV5qJIqM7Kxwt0pjn6V0nh66EuF/i6Vka5AUlyBSaM7Qzgjisb2Zu480bndq4A96rzDJyabC+4A5pZGzjBq7nJaxTuF4/CqzcoKuTjI9KpyL2waRcWU3PJqA4BP86tSIQTmoH4Hpmg3iQN901VlGTyKuNUMgyM0NFJ2M2RcZOMAd6gccfrV2cAZFUn74rGRtBkRB70hHA9KVjj603P5Vmb2IX6milk69xRU6Fo9FxnH55qROp96aRz9akTg81rY9DccqjaM9BUcnfmpww6VC/XI6UmCRVkH1qv3x2q7KpIJzmqhHzCoaN4kqnC03dk85o6UpXg0kxiA4HvSFqVRg9KVl+UUxArZHtSq+BTOmKUKTxQJisxI6/SmLxSng80KeRQSIxwOfSozzkA1JJimA80CuRM3O0cccU9F+WkmAyGHbrQmV696S3C+hYAG3OeaFOM44NJH92nFeDV3IbJE+9mr9ovQ/hVCLr+FaloOnpWkdTGo9DXt1xH0x2qjfS4yMjjvWh0t+Oo5rnbqQlyM8k8VtJ2RxQXNIrSuZHYVJZnK7cUltHuJJHepdnkz5P3WrB66nR5E0AxKevPPFWml2CqqOolx36UMwkuAg6VadjOULnQWcitGPmGanv5YmC+V0K/rWVBbuB1wDV2OAYGTxWqdziqKKYwgbKoTErdQH+9lTWuUATjFY2rHYkcgOBG4Y49KmRMZXdiyGO32qBznJPSkMnPB47H1qCaQEevpQTLcZdTbWVUxzyazJ5NxJH3ewqa5kwDj7zfpRBErISTkj+dBLdilpSEpg5LBiK1VtG+f86k0u2CzyJgEb8/nW4kA3gAc4q4xM5zMiOEhM7ckDPFTQws4wOn0rWjtc7iBVq2tkB4GMir5DJ1EY8umyrCCO/UDtWhYQbLYJsXdjk1e2Fd4boDipo0VSwxjjOapQSIdRlMs0S4XgEYI9ao3O+ZlRCR1zWpJCdwJ9asWlqW3ysBtTjpV2I5rambBYEqD2UZOe9RPBsJHvwK6tbZGSQh1DBQVHqKzH02Wa/SPb8owcjuabdiFO7OeuonEkQ2HBNQ3cR8vlTtHtXU6jpsplVUGEi5I75NZ13E3lMrjOBWUkaKZwmqWe/5v4awiPInHGOea7y9gUocDtiuU1G2znNYSVjrhO6saFtKDEPcVLnBOcetZenyhoyhb514xVh5WUcmouS46lp5NzgdqV488E+9UIpSZQT1zVuRzz9KaYrEF2ABxWdKcHBq3M+Tz1qjcknPpTuaxIWkAXnrTS2eMfjUDvjNIZeetJM0SFnGQeTis+YY6c8VbeTK/ezVWUls1nI0hoV6aelPbgnjmmsQM1kzoTIW5HNFI7CipNEeolOKNvHH41OFpSldTVzrUrFUjA9hUbZ71aZMZ96ruCDzWdjWLuNI4GarOuGJ79qs9veoZKmSNIsiYDGRzSqeMY4pSuTwKbgjp3qbF3JYxk091GOajjJ3U5myBQZ6lduM+tSQnmo3HPH40sWQKGN7WHzY4I/Gq54appCDimBQxpE3IJHAB570JnAp1xGR0HTtRbKQMelJlXVgKnP1pSMEn1p0rAH0NMY5QnNBldkkZ4Ip5f5uetVy5GCCcY6U6M5YE1YNF1MZ5654rUs+g9ay41JPHWtW0wqgmtoI5qrL11J5dv8AhjisEfN2rQvptygds1Vs49zYNXLV2MKatqPtYyvBHvTr8ARK3fNXdnykgcis65LSSGNaGrIad2RWn72UZPbmrOnxFrvnOPWmWVuUlORjnrWvawiPJ79aiCbFVmoovRR4UEGnOdtQidUOT2qvPOz8L/8AqrbY8xtt6ksswIOKzrkiTIYBlYYxUgLHvx602SM5HGKW4J2KJhaNQsTsFHY81FliuRk+hNXwrMemaeLcleQMUlEpzMr7Nk5I5PerFvZ5PII9vSr725QZGMVagRNi4HJ6mrUTJz7DNOjEdwwcDOM5rTQgAd+apeWF2SqcleCPUVPayKGbzDg5yBWyVjnnqX4hg4H3e9SMoRT6hqjtJUmuBGDsVsAnsBVy/tWtpRmRZIx/EO4qmZXKru0xzjlutTjMZAdeO5qBHCXWf4ccYq6kkQlAYB+MmkhsbIAYvlOSOcVYEixoGXPlkAsfY0bI3hDocbSQQBWa8x+ziLj5Wz05p9CErnQNa3Aso79dvkNkbO4X1q1p1xDHf28hYIFQqzH3HFc0uoTvFHZyO3lRD14Ap5uV24U5qJQjNJSCzTvHQ6zVbuyeJ3Qb5SCu8cfn61y2ohZZQT1IBJFRXFzuVVB4Paqk0w6k8jgYptpD1k7szdSQfMRXM6mgIJ4H1rpryQFSoPvXO6kwKnjHFc8zpp3ORkuDb6jGR/E2OK2pGDgZrmNYJN5Gwxw1bkEoaNOc/Wue6OmUepLC2ybngVekOQcc8VmSffyDVm3m3jHpVRZDQTL1qjN05rTlHy5rPnUnOOnpVjizMlzk49aqu3zGrcw64PSqMpJBz1rNnRFXDdSHBHTmoVYkjFTDpwc/hUGiRG/fA/Gq78nmrD1XfrUSZrEjYnI9KKaxI544orO5qkevKQR3qQDIqFDjntU68jiu06GrEbL1qrIMnBFXWFVpFw1J6FQZAy8GoCOOatHp696ryjIx6nrWcjdDEGccUpQdBRHkE54qXipGV9vNNIwasMuMZqBuKB3HBQyH3qPbg1NGeORTX6n1pCbsQscUg45oZvmwTxSE4NIkdKAyD3pqfLntmnHkcUmOCPagRTunypOenJqETZQjNOnXClT0NUwpDnuM4pNlxSaLfmFhVy0IYdKzY2IYg9O1aNkPaqiTU0Whp2y5firwBUZqtarzVwjHFdMThqMryDeBU8C7MECrYtcW6sw5PSmeVj3rRLqYc62Gyy4GT3qtp6hyzk87j2p0yl2VSDip4I9jFSetQ9WDdo6Cyrg7hwP61YecAfL17VUuWIQgEk+lNXIAUnJxyRVJWOebuiUylm6EmpEQng8UtpDu21clgCcA807HNKdtCGNBuGCKsmMOQPSolRi2F496vRIFA7sa0UTGUiqbdRnApxh2rgdau7MZyBUMg5x6VagZ85WEWVx1zVZoXVyF+hrTRAc9afDbhnG4+5quUnmKtrEcfMOMccVeS0V4y3G/pgjtUiKoBXpzkGpkkA+5zkU7EOdzGmhks5grn7w4o+3tt2OxO7rnmr97tlBB6/1rnrqFo5D121MnYqNmakVwjk7ieeKuxXa7M45H61zQmC4Hc0ouHwRkjFZ85r7O5uy6iqwunHzelUF1FVuEdhlQc46Z9qy3kJYjOfpUbplgTzjpzUSqMpUka82pK8krLgb2zjPQelSw3SDnJrCTCnLHC/zNPWfLc1PtAdNdDeNwuck8gVA0ykfLgiso3HOM1NEJZziJWc5xx2pqVyfZ2Fnlzkf5Fc/q0xCNt5NdDq9obG1Ms8sYcjhM8k1xl/LuRs55PNZVGa0Utzmr7Mkpx1HeptPuXVdpPTvSXeB0PJqlECr/AI1gtzp0aOkFyrLnvTEnMcmc8VQRsjlscd6Vi361Rm1c6COdZUGCKgmb078VkwXDxtg/rVpbgP8AeHPbmtE7kpWG3AyazJxgcGteRcoSMY6cVl3Qx0okbwKRb5gKlQ8cHiq78GpEasWbpEjVXfHbrUxbgmoX/M9amRoitIfwFFElFZGiZ6/35GeKejYpHAPWmEnNdrOvcnzwKgm4NAOPahiD7CkxqNiuxI+mKjbvVhlGDUOMfhUGsSv/ABZ6VPEegFQSdfY0+FvyqS+hNKMdqrSLmrMh4qFxkd8UMlPUjVu3eiT16Uqj5jmlkHy0hSZUkPzHio5XGAO9PnGB6Z71TZjn5utJuw0rl2ElutSTZC57mq9hk7vQetWZzuGDTSM56My7okDqetVowwlB9a0biMbemTRBCvlgEYqbFKSSIPLwQQOfWr9rGcjHrUZUAcVZtOWHHNaRRnKV0alqMtzWnZwb51c42g1Us4suoPStZWCbVGMDvXVBHm152H3f+two+RelQMmPxq3t8x8AZJp1zAUCjv3rZo41OxnvCDk4+lQsjBuBzWmY84AHSkNuWbp7VDiDrW3MaRCGO7HNOhiJOTnrV25h2yhTSiLnpxU2InV0JLcbOe+Klc7jknJNQYI6E1YgBIGetaRVzllIdGoTmnbyh9v5UyQ4Y56UzeWUr0rVIzbZIZmLKvr3xTwGaRvbvURcLgEH1oWXany5OTyapEXZajdYwd4yT0p0chkckADjbVNGJOGJOOeaXzGQblxz60OwWLrNgjkcccU1ZQHHNUzPwc1HHJzk1LlYaRbnk3MfTrxVG7KuhB4oaVskA8ZqtK+5WwelZuRaRmSZ8wY6AZp2CSpGfQ07aMgnBOKf07Vgzogxvlcen1pGAGNx4FEjkNVaZz2qXKxaV3qOkccYqFptoNQF2YnjFKwI2nqc1k5NlqNhwkaXB+6PSrVrqF1ZZ+zTbM+2arO3Oe9VppNnJP8A9eiMmhSsxNWvHlZp7hyzHu39KwbqQuvHTrV65Iuc8FlXsBn8azLyTC7cjnjNXq9yNFoig8e5y2eKjIC1KTgdDj0qvJKA+SMDtipcClImjbHU8DvVlGGOapxHcDwOanjYD5ScGpaHcndQwyBzUW4owxkjNTpnbg8VFKgPJHWjVbDT7luCYGPHaqV5j5qW3cgkGorls1o3c0gtSi/XmlB6U05pT7Vi2dUUOJzTDz1PFGaCeKzZaKsnBxniiiWipsaJHtBHpTSnPrUmcmnDHpXaap2KzLTMYq0y9fzqCSpZtGVxoAPtULrwccCnhqQ859KgtFWRaZHweOlWm+71quOGqbGqY9idtAORig9KQUxMjYYOacDkUOMj8KjzipuZy1IbleKyzuL+gP61sTEMKq+V8wpNXKjKyGW2VB61ZzlhmnwQbjx0qXyTngdKpRuYzkmyEx7sDFDRFXxjIPpV+GI4GOnWpXt84wOa05NDJzsZiRZJ9auWkOHBxgVMIh1xVgKFUYFVGJEqhZjYRKD3qzDkjcaqwwvKckHaKsRHDbfSt4nFUNe2IjTcMZPGakf94Oeapo2VB7VNbOHmK56dR6VtHU4J6GjZWWcbhkmthbWG3tJg8SM8i4DHnbTdPjB7jAo1i5VY9q8HFVY45zbdjk9TULdsRzgfrVcNkcYqefJJY+tVdwRTnrWbLuxS2BkZx3przt0Q49TUbNvAVRx3pyIFByM1SYnqCK5P3/z7VZ4TJ42/zqN9iRg559BULTKdoY4B7VVySdpR1/IUhbGM8jvUJdOq1FIxYEYouFi0XHUngd6a02fb6VUZ+4NICcdelJsZYZ9x4/GkBwwwSB3qu0m1vr2ppmG3Pes5MpInyQMZwvWmSvmPYANv86gMvuSKgaZixOQBis3I1USViqEEHJ6ZqJ3LEAVAzlzgcDrzUiRsQAoPoSTWLZqopbhyTzSMpPSraxFR2/xpSMcCk0O9jP8AJPHYfzqORDkc9K0JBkVTlBJODxioaK5yrcOsaM7cKO9YF3f+ZNt4AHIGaZrd20zeWhbyQcdetV7q4sWghhtbLyJuskzS53fhWkIkSlcn/tWe3t5Le3kEaS/fIGSwrMDF25zgcgf41Erq0pOd2Dwe1WcqzfISD7+taLUnYUgsmWGM1WkiVXB7VeAzkMenemT7c4B5osSpWKakq2AOBSyEkZ7fyp0qEZOaVFLpk459ahotMs27bowTx61IwyuAKq27bDtI681ZQnJBNZspMgAKuajmOBUk3D5xVedxgc8UX0OiGpVY80n4YoPPPej2PWspM6kI36U0n3pjkdzSA8VGpaI5TwfaimSfzopGiR7h0NIW6VMUweOtRuuK77WLi0yMtUUh457085GaifnjkVnI2ikRt16U0nHWpAM+xFI64BP6VDNUQE5BqPqTnrT8560wkA9ak0HKMmh14xQntTpOh9MUCZBuz7VFI2BT8fN16VDKSetJkCBu1Ko3EVGp7mrFspMgzTSuxSRoWUXI9KsiDJPFWLGEkgCrKxfOfrmumMDgnVszPVNoFTRgEVJImC3oKZGOM571SM3K41oskqOfapY7VgQW5BPFWrKLzXz3Farwr5GCORVKFznnWcdDPUBIio6VmJJmbHeteeIiJiAcAE1haeC8hcjIzmhqxClzG5BkqM9Kt6fbIk7yAYZup9arQc444q9GQq/1FaxOKqzZtn+Rip+6Oay7ubzJTnkA04XQigdBjL96zZ5sd6pnNYjuCOQKotlmC1Y5fkmkCBcsc1LQxiIAOn40DG4jvSZqQDGDiiwyJoMncx6VE8W0ZFWXYkZ7VA7HvznjAqhFdjJjBIA7U2P73OemKfIT3HvUMW9icDg9KTYD+vA/ECkLMMcjkdqdvMYKqCc1AX8vBP5ZqGxpXCVsLmmlg3J+7UUs2447VFLNkBU6evrWUpHRFWJZH9OlQ7S74zxULyFRhSC2O3SrNpH8nzGo3LTJI0UMABz1q3EB1JxjtUcEW8cjr1PrV5UCINo6UJEuVhiRtIwVFYk+gqGQEMR6cVP58qKUR9qHnjrVZ2wT3pNIEyGQ8fKc1ia1dbFMMZ+Y/eNal9qK2cDMYkkkb7gcd/pXKyyz3DlrhxnJOAOBmmog5lJ4i7HdziqsttGqu5XOeBV+ZkCAHjNVWuBv2vEJkxhVBxg+tVZAmynDCq7j0UDJoieMN9/8aJPNEe3cvJyfpUbJ8uSOvWkiicyljtUnHrmmNkA4/GoWJT7hzxTxK+MMODxmi5JYQgryecU5R8nB5/Sq6P5Y24465xTxJhxngdqdyepI5PI4xToZs8N1H8qa3K5qtISr9SD6ispI1iW7g5HHSs65Y5549Ksh9yHBOap3WDjNQdENwjORSyEYzUMTYNLI+TWbbOxIZu5zTxjGahPWnjgfWldlojcc+1FDHn2oqeW5Z78yYFVZenFWZG+WqrHkZrvYoFd+tRSetWymc1CyHPQ4rNnRFkCj8qew+TinqnPFI4IHOMVDRfMijINp61ASd364FW5BntVbZhuazZrFjlHQdak25FNBx0oLdRTQSIM5c+lRSgZxmnSHEmaazZx6UmxEOME9Oav2C5mFUinOc1p6auZR9aumrszqy906XS4uRxiniMiU4qxYJtA6ZxUsUe5yfQ16EY6HiznqZNyu0uccGqsXTHrWlfgBWyD1qlbp0LfSs2tRxldGrpibFzVmds5x6U2FdsIXuatrbkhQRnPWtYqxx1JXdyg8qJG/mdMYrKtIFVmIGBnNX9fhMZhVQOW5+lMtkwgzUS1YlLS5PEBt9/enh+OeDSdBiomzmrSOaTuEr475/GqpBc1NKCcAd6SNeOn1pkgFA6DAHXNRTSY+WpGblgOgqoA2/J7880mALu3ADPNTbRGvOSevNSxR7RkjmkYKcFs8UgIM8eoqFkkz8vT1qeQBicdBTWbavqKGBVMCj5nZs+maVZBu2RjjvTmBc/vG+X0H8qjmlCLsjAXA/Os3IaVyOeVVOI/mc8fSqxUD5pDuc+tBYqMgfXjrUM77U5bnqahu5pGOpFK3mtwcLnk1C75GIe/8RpwDS8Dhe1XIrZUTpuNKxo5JFFIiAfUVo2kRZVaRvl/ugf1pm0L06kVYhYBQB2osLUuxYVfQCpGZBGSXGegXHWqokO33pjEck9fei9hco6RlH3enqapXM/loWJ4FPmk96wNXutyoquCpJyB1H1qEXsU724aWUu5BPYelVHcsMU12PPFENwkcoaVEkXoVY4H4mquIjdWYEcVGsCgHNWHkBLrlDznK9KgdtwO08U9A1K0kO5mIO7PpwKhZNtXSgAODzVeUE5pbFIgABYeppZPmwoxxT50ZRu2kDvVfkkEdKAHIXweOAOaTzTtHmdDTQ7Rk7SQGHP0pjBS3TNDCxPHIdxGc05sd+uKqofmx09qkVhn5qllrQeH61WuW4FW7crM+ADt9ah1FAnT0rFm0NygrH8qdmox39Kf1AHrWbZ3LYX370BuPWmrnoadjik2UMbqP5UUmDuFFK7NEfQbIah8sbq0GX8KhKDNegYRqFbywQeKieLAP+FaG0Go3TipauWqhn7cZpjqMfyq0wxmoJelJo1UimU59qimj71YJ61DMcqfSsWkbwbKp4pjEhqUnmg8nioNiORM9qiYDBqxJ92q7HNOxNwTl8VtaTGCymsO3JLc966XTVxtrakrs5sQ7ROksl6YGeKljXaW+tRWpI57VZKkQkjuetegtjw5vUxNUPp3OKZbpjHr3pt4S06qeTmp4cBmPasHuaK6iX7YF5FGO9dDbwjYCRz1rG0yPc+e9b0jCK3MnTjFbROGrLU5nXgHvVX+6KrR5AGBRcSCa4ZwepxmkZwOARUdSW7KwrMzNwakC881FH1zU3WrM2yN1+fjtzQ64jwOpqUAZqM5MnHT6UMm5XdCPlzTljHy7u/SpODuZs5zSN0znkUrjTImb5yOw4prHPHQetI2VJOOTURJwSx4HSpbKQTYRto54qEkLnNMMoA9fWq0kjOen0FQ5Fcos82SBkj0qu5VVJ2/NnrTiigl3GW+vSmtweRmobuUhjEr3+tV8edLsU/jT5yXIUEBScmnwbUxsGB6nvSsUWI4ki6ct6kUSMMelAIC7mqrJMZCSBhR096LjCeTbGdp+bpzUtvufaFwOPXpVE/Owzng1dhAC5JzWbZZKzYOMggUySQD8KC+BziszVL1beIYI3nIFFri1INWv/J+RDl2H5Vz808z4U4AH606WUl2YhmY8k+tRku3GOfc0WKIXDOed2KiaHIO4Haexq6q/Kd3PrimTAjGVZQemeM0DTsUz+66OyjoQOlTROqgH+EU19rDnHFVssvy88Gi47XL0rg9OF9Krs6nv04qHf/e/KnZDYA6U73FaxHM5LY6io/MI6VYaLrjkjrVVwee2KGBLvBAwvNMbk9PyqLOBnkc04Zzn9KVwBwAdy8YqByXY/rUsvBGB14xUUg2EHPJ4pSHEv2ACtwaj1Vhn2pLaQckGq+oOWY1m9jopq7Ki+gqTNQocmpxWW52hjvQe1KOtGKTZcRAOaKlhTLcjj1oqLXKufRTr+VQsAD3q1jNRSDB5r1LHBGRFUb9e1SGo26VJstyrKOT/ACqs/erknC1Uk4Bx9KmSOiDuVJOhqueQR2qy3vVVhg1gzpiRMvWmZqU4zzUZxwO1TY0uRymoG6YxUknXFNxnrQIIBlx9a6XTxjbXPwD51z610Vh0WumitTkxDujetSMEH0q7Kf8AQuneqFt0rQnH/Euz0PWu3oeJU3OcxmdiewqS3O4n0JqIMN8o7kYqxp0ZaVV9TWHU1btE6LTIvlUimeJLzyLUp36VftwsURzxXJ61P9qvHXPypx+NbbI4N3cow7u5qxHyc1CmBgCpIj1xn/GpQSZYUYOP5VMOBUEZwOacG5AJpt2M2Tk/u8nvULNx3okkyMEgKO9VpbhQQAcg1DY7FgcRHJoU8Djr+lVTLvIGcYqbeAvoTSuAr4AJxnsKzrliVCdcnkCrkzYUBSDx19KoSkCPcOp7mlJjiQOeTgcdKYCRwPzqN2LDI4HaklkVF5wBWZqhV4Jxkt0BqvdS+WSpOT1qGW8PmBYRk03YWYtLuznOKVx2FQ7skjgd6mLkc96gMgAOOcdgKdDG0nJJVeuTSuOxIzHZhjyT2pjkAYwcelTJEq9M9KbsBbp+JpF2I4otzqc8Dk1bICgnqB3ojTDHPAqK5cIhJICrSSAiu7hYomeQgKO3rXPTSG5cyEZPuelSyzNdylgcoOijpTGbapx+NVYCnKnU4OM9M/yqA9AV4/rVt3ww49+KhkYE5I/GkwTK2+VTkMARyDimzyzTy+ZNI0kmMZJp7LzyM05YWlB8tS2OTjsKl3KRSMeT83T09KaUOM1Z8oE8MRUZ/dggnJ96Vh3K0isD04pqqxb0FWyPMAIHt1pgjKsNx4qkhN3EVmGRk9OtV35bOenH1q+VXFVfJUnIzgetVYVyt27+oxTA+3naRU90FGMYFUmbPfI96Ww0WCysM9iOaryHLZpu7HSkBz61EpXGia2zzUdweTn1qxbDEZY9+KrXHU/WspM6qXcgUYqZPzpijrTx0qDqQ40qjJFIDUsPJpM0iWoUBoqSEYwe9FUij6APGTxTJOVp5BxwKjfpz+leieais+KiJyMU+XvioT0qGdUENkYYxnnFVJOfr1qdyR7VWlPtUSOiKIJOlVHPpViY4wBVRzzxWEjoghpbBppb9Ka/HembutSaCTHnPekTnpTHY8gVJAN1C3E9CaIYcH0resTkLWNEhYgVr2QIKiumnucdd3RuWzYrRvjs08AdxWXb9RU2qT/6MB6Cuy+h4817xjBic4HJNbehRfvN56L1NYEQLMBn3xXVaV8tsUx8zkVjHVjraRsWtbu1trN3PfpXGpcALIzfeIODWh4y1FGlitI24TlsHrWBE2enX61pKXQ40i/GxNT5AWqu7C8cUPLjrSJaLTS4XANKblI13PjPpms2S4CjP5A1m3Ny7tgnk9qhu4JGjd6iXbaowDyKd9shRcOoLdz3rDMbn5nP056VIkeFPp61Ny+VGwt4jN8q4H61PHcEEFVVyOx6GudjQhtzucAZ+laNg27DMfl9c0rhyo1Ly6adi7okZOOE4FZ882eAcH0qO7u4yGCMCenWqKzY3HPFIFEluJwhVV5NVCxY5Y5b09KjdwGLnjNOh+55jAjPQGky7EsYVMFsZPTFOdhkg5BNNRixJAFPVAOW5JqGUkJEAOvNW4YWcbmP0ogjXIZl+Y8c9quooxkmhD2ITGO5oCBRk1Zwc5AqGTBOBQJO5ERwAPxrG1dZZWVI1+QfePb6Vu7O9Yt9bsZiWYkfWmhN2M7ySgA3ZPcjionjOD8w45q6YiPeq8i7c8VdgvcovHzyelRONpwBzVmVCccZ9MVAy5IznJqWgRXc4YcDJp8KPJII4fmYgnAbb+ZoIwT3qM7cYPQ0ixSCeikH/aBH5Ux4xklsVYu9QubmOKOaQGOMYX5cHH1qpJISePwpMNREKrjnAznFE8yscEDaKqzEn5Qc+/SqkrMARnNCl2HYtvdqnAGQOp9qg+1kkhFO49qbBEzAluQR0qaOJFPy8VSuyWyMgkHf9arFMVfKjnOMGoriMKgIoaBSKDfLx6CnQgNHnqabMM/dzmlt2A4P5VkzTcvbgYRwBgYqm43ZNWtvyH0qqQdxBPSs5HTS2I89sUo6YpXHOfTrR9Kho7IgOKmg61CfpVi2XnmpNEi9H0GOuetFOQYXnp0zRVjPfz696hfn8an4qNh0r0rnlxZSlHt0qI4GR2qzKMA+tVWOCfyrNnVB6EMygCqclW5GyKpyGokzpiVLjPJx9aou2O/StGc/LnvWXcc1hI6YAWGMmm+tMBpxNQzWSIyefxqzb4FVSRu/nUsbHeACKcdzORr2absetalqmGGRVLT0G3IrWhXABxXdSiebXlbQsREDmquoSkpwal3fKcY4zWZdyHODWs3ZHEld3HWRHmjJ9q3ReraWzyE/MAcCuchkEILs3SoZbwzqzk/uwaxhKxFXUp3ErTTPLIcs5Jz/AEqWz6jFU5H8xvlPy9eKtWqnjnj+dVe7Od2Rdnk2c9+lU5ZX3ZH61NN1GRnPfNL5QwC/ApszKkisT1zmoghVjn8KtSOAeO9SRoFUbuWPOPWoYypMoULnrjOPSkRdxHXA7+tSzx5fJ7+1NdNsYAJ4pbFELrvZgvAHU06SRvKEa8L7U+GAEljn3p7IMnA7UmBnOMttUEnue1MA3AgnhecitIQhYmbHPaoVh3koQB3IqbsdzPIaQnCkR+/ep8MzAcZ9B2rRkhCIeOcVAkePmP8A+uok2VFiD92oC/8A66cmcn+tKck85wOwqeFM4qblbEltESQTkn1q6i89DimxjA9KkA+Tkk1S1IY2TIBAY471AeZB+tSyMc84x7VHDlnY4PoMU7agtESMCAMACqd0iHJJGc1oyqQh3HArOli8xjsyWx1rVK5m5GZLEclui1UkTLEdR3OOK3ktG48xNq/3mqO4uPKiMSNlM/d6A1XLYSkYLw/hUMluTnGCPersuGYkflUDDg5fA7c1BZQmi2Rfdxjg981UYAdR+NXLluRhgV7mqjyDPBFToaIryYI9fwqFyyggAYqVpOCP5VAXByD61m3YpIru2c8GmCIyPz0pLqXAwKs2ZYgFs4oirg3ZEiw7EHoaa8a5/vDvWkFXyiW446VlTXHlsQc/hW2xnqyvczJFg88dqrvdeaBjoPWmTTebcfN07U9EVQSBmpKQxSM5705UzICOtQ8+ZVy1Xd16Cs2aIlkwqY71TJ5FWbhuOBxVVvWspHXTA9/rTR64p3OKULx+FZNHVATGat269u47VXC881dgGAKFubIsYIXkUUrHA9T70VdhHvrdeDUR681KR256VETXoHlRIZenNUpR1xVyQ9aqS9etJo6ae5Vf+VVZO9WZTjJqpMetZSOyKK05/hrOmJzV6XrntVGYdawkdMERD73vT2xTV6+9I7VBciKUnNOgOZF9Ka2Cafb/AOtXHAzVxIb0Op04fuxWxAm7FZOnDha3LcYyfSu+keNiG7lNhtdh3NZV9xLjpxmtecfOSOlYGuSeWGbrxjiqqGEZGPc3bSSbFbCjripojlNoHB61mKPXqatQPtP0rBbkVHc0ljAHHWrdugVckYxVKBw2fXFX0b5QO1aROWQrqGIz2qvcuCcAnFW+AhJ/Ssu8O6Qhck9/amyESZUzrk8CrQkBlJ4IFYxRk53E896V7plKhTnA5FZ8xpa+xrEq7buvPSjCtyMY7+1ZQuZGO0Dk9xV+N8IgVCT3J9aHK4uWxaRQo4xmo32YwOTjtVmG4ihgfzovMLcD2pLcwicExGRFHAIxzSJIG+RQKZGBuLHkn2qeSOWdyyREIT26ConYx4UKS1A7kM2cjPU1AD+INEjO569KaBuwDxWU2axQuSe3Aq9Av+NUoz8/Aq/HwgrMssA9qc33MVAG5qY4KgHrWsSGQt3HU9hVu1QBMHr9Khgj3S5bgCrhYAYFWtSG7EEwXuSfaoJLxYbdkRIwx6yN1+gp91JhSMgH2rmNRut0wjzmr5rEpXL9xqDyYVXJzwc1n3sxsxgyJJn8TWfdXqQjAyztwAOTVRiz8EfMTyBUORpGFh895I75B29gRVcyOQdxLHvUqwueSh9sjrUn2fbt38560rFXRnyux4HPrkdKrO7AcDmtOaJR0AwaqTIpIXdjgk5qJItNFYEtz1561FJntxV2HCpuHboMVUly0rNjAqWirlSSMZ55qS3kKsF6E0siMxyo3Gm+WRtzwc9KuCsS9S9OJEhBZgVPQ1kXcnYc+pq9LLi3IyCx7Y6VlO207m5B61TJihPIJAelk3Rjg1Kki457Uyd1ZD0qWNXIg3fPPpWnAAsIPcis6yh8+VY1wSeM1pP8oCHHHHHeobNYIryHLd81G1K/LH6UmOuKzZ1wGjp604dqTGBTlGcelZNnVFE0SZq3GMDNQwjuOvarSKO/404osQ80U8Lz70VY7nvhaonAPFPz601uhr0Dyooqy9aglOQcVYlqrJjB9ahnTAoznkgVSlPOKsznmqjfrWMmd9Mgk746VUm6/Srbe/TrVaYZIzWTNkyEDpUMnBqbtUM3f1qR7jAcn2qW2H7we1Qg881YhYKw9KqO5EzptMYcVvxNmLj0rmtObIHNb0DYTrXoUjx8SrsbPyjGuZ1kb1YGujuT8mBWBqKblaio7nPFGCq8HvzUqYA6U1Vwc44pwI9axMZPoXLdSMnPSrsTYVQTkiqULjpg5q1HkEHBNXEyZLPOB8vVj2pkcQ+8ep60u0tJntUr8Hg9KpkXsV7iNShGOPSsy4jwy4GK1WPOSKrPgse9QxxZWXahLHgdPxrSQ5jXH61nyhRG2QCKt2riQKinpUWsU3ctJ3JPTtVq5lRkgEK7QBhvrUCoSpA5wMk+lATJ5J9s0yS4NTmEKRxRDCjknvWbcOXYsxyxp8mUyVJx0GBmquSwOeppNvqNKxE5+bAPFRs27OOp4p5wox+tRDkdeTWUmax2J7ZR1/WrbHooNV0IRKcjEkmpSGWk5wO1TDqOlVUb369anjYb8nnFaxIZIpIkI7dacXLLwcAdarTMT9w/N6moXd8c8j0FWtCXqR38+xGx19qoJYD7JJdzYCnhVzyx9hV61txdXShz8ucmpdemTz0iVE8qFflVfWqtfcXNbYn8F+GdT1r7TcWR0/T7KNSGuZ4jLI57hVBHA9TWbJYW0chjjd5LpD87dAR6gVpQ67qt1p/9l29wLOxP3/IUCRh3Bb0py6elqkW8sARjLfe/Ct1G67mTm07ydjIliXBUFpWAyVUfdHuay+DLiOMkH+LsK7i10h79xp2jCVruY5klkOERfVvema34PtdEEaLrdxd3zOqzwxwAxxjucgcH2JqHBPZh7W25xE1q824bcDsaqtppjDSzEAdc+1djcaar3iLZoFiPJ8xjg+v407UYLRXij0yCe2ZfmuGuJBIS3ogHT8aTpaFKrfY89kgfcx2soHTPWoWtW3DLBQW69q6PU44pZ3jtlk6/M7n5unQ9qzbqJUhx0MYwfc1jKJspleC1ElykETrucY3seKo3dtNZ3LpOY2K9dpyDmrMJSQEE4c9T0H0qdUDwnIz2x607C5tTnrgHzGyMZ6Cqcy9M4/GtK5haKQ5Ukds1lz5Mh96zkzWOpDI2DjPHSoCxwR1qbb8xzzmlC44AFZNmmwunMyygDNaUrZPb8+tVrOLBLYqdjzyO+KTZtTQwn8qCc4x0o+nbrR396zkzpihAeKcgz6UY/OnxrlgCOKi9zpiW7dc9OlXUX27dqht1wOOlWfQVpEUiIrzjpRTmGSB2zRVFHurL37fyqJjgVO3SoZMY969Cx5cWVZCMGqU7cHBwatXDcVmzucmsm7HbSiVpmGT6VVc56cmnTtyT6Uw8/jxWEmdsI2Im5qGQZ9qsYHtUEtQaFd6rymrElVZDzyaQAB+lPDY5pi4OemacOvvVLcmRu6TIdoBzxXRwH5B0rlNMcA4zzW/BN8orsps8zEQuya5fK1lXwzx7VdlY5wemaz7thvHTNVUZyJGSAAxB9eacYhu46ZpHP71utSrg9wfUVCOWejEUFT+lW/MCr1qE/dHHIpoUsSemKoybL0ZymQDQ33c1XtmPrUsrEDauST3ouIZJlhx+PtUPTg1Kv3MEZ9zTHTceOlSxplK5JCFQeDT7J9uOfmp0oBYccdzVRHKzuB930qGi07m9G4bjJx3HvU2VJJY/hWbayg7R0Udferm9SM5GKLia1NCC8kjiaGCOIFyP3j87fwrIlOyR1PJB5PqfapfPCtkcgc1UuJWmlLsAuf4V6UNiSsRu+c9hUWf3gA5okwpAwaIeXJP4Vg9WbLRE7HnApYiCW5yRUWf3h9KRH4PaqSEXI3OAOlWU4AqrbkbO1Sq4z2rVIhscxKt6g0kuI4y5OMDp60rOAM4BFZWoXwUFHYBjwMVTdhKLY06jKkh8pzGvqvU1FCHvrwBiSrdSTkmq0LLJlcgAcZxVnTmEUwCnLHpSi7ly0R6D4b8NFreKSygvQSf37uA//fKnpXfGw03RLGS9ntzIyqN7yYd/wB4H4V5tp3iPxBa2TRabJbRh/vT3EfmNGB6DP860tP0SXVrcS+I9Tv5bGM7y7jDTk+nt9K1jTk9Zs5HUjDXqdTHrGkJa3eoWl5BF5i4ihjIiYnHf1JP4YFYuqLdp4X2XF6ZAZBIUt0wGJ5+Yjk1lz2mgi+L6fp0k0EAAE0wLfN6Cul0++uL1YLaS2WGJhsjVWAP1I/rVuSpq5n70nYytHVdUaGC1tYA8HyvGTywPdj2qn4y0drOdVtLPyhKp3zAbU3d8dzXodtpa2WmGzsWWAkZMoX5i3dj61zXjm8uJI00pbfK4Ez3Ik3BcHpjqCadOo6m6LlS9nrc8f1lFQiCLP+0T1PqQaxX8iQLDETwePf8AGux1y3tvte5rGexgKjCOdzu3972BrjLqONdTAt0aGD+HnjNZ1FZmsXdEIthFc/MpZcd+9WpbdUiYMdozke1SvZz3LYT/AFyHsOaseLNF1Lw/DYx3rQzS3Cs6mNslV9xU8ulwur2OX1ny4k8vzVd+uFPT3rn24Jz19a01ihNvLK0rC5V9qxlcgr657VSlUEknpXPM6oKxULYbJNLCDI+B0JzQ65YYrSsrcIoYjk1mbJEmzy0C+gqBjlsdqszNjOfwquODk96hs6YoYwH4Uq8mjGf60qjBqGdMELjPQVYhTke9RIM96uQj5hQrXNUWYVx0Haptozg9aZGcDgVMgyK1SJkQyL+NFSSLjIoosNM9vLYwKgkPHvTs81G4rvPOiinc9KzZz6961J14rLuMg/SspbHbRKEpyTj8qbnGKVzyfemdutc0tzuWwOeOlQS1KTxVeZv50gIn5H1qrID+NWMjv1qJ+aRRFHkEinE4NIOGzRJxn3pohlqzl2uMdc9K6C2kJAyePauVtmO4Y610Fo/yD3rops468S/IfnX0rNv32kNmrZfJxWdqxzbswHIOa0bPPkrFDzN789zzUyuemMY9KoQnPX6VdhG49aSOSZaTLAH19aeqk8GkjPykfhmnxnB5zj1qjFkLOY5dvbuamjDdTnkdzVWX/Xbx2NTxyjcdx+goETIu7qePWkkVNp3NyOnvSO6oueuaZ9/k9KQCOBj3qs8WWZgcHqPSrlnALm6MZlEQ2lixHQVRmuI037ZN6g4DAdallRT6ECyMMqfvZ61bjkbIJJI9Kz45RLISOO4zVhW/i7CoNWtDQEoyNozj170yVxuJxjPOAKrQXC5Yk9sZqNZS7sSc9aVxctyS4bBGe/IFOtFGOc1Vd9zZJyKlWXYMCp6l20J5CAT64qJG45qEyElsnrRvGOSRTuSkaULYTA60hlqsrN5ec8ZqKWXHJq7i5bk09xtXO6sueTcuTzSzyl5c54AqEncwAAz0qW7lJWLWnRNLn5gAOo7mtqxmWG0ktLXS7Z5Xbcbx8mVPYdhVawtyqAKcZ71s2dtGBuYnf2xW8ImM3ck0p5YZhwWk+nFdDdanr17bw6dapCVVgfMAy49gegFYs8sqR+XHEzStxtiXJouLuaztQs0zw3DDA2tz+netbtHO0mzeATTAJL2U3NwDkW0fTPqcV2XhvMmkHUECfap/vFj8qKO3HavM7JI7QxSsHeSUAjL55969K0jVre2t1hvmW3jYZSVsBHz1Ax0rlqqUqifQ0pWT1L+kag12k7tteOJtomiU7ZD3x7Vy+o6ddancajLcRGw063QvbPEfndhyxbPapPEHjyy0+B49HhF1Io4kGEiU+g7n8BXn2oeKtX1eyltpZTDYlsyIowzk9s+ntXVTTjqwqvmVkSXbfaiGvLktFjh/vMR9O4rlY4YrmcxzZCqcD5cfT8au3M5uzDHEjlk4wByfpW3d+Gb6KKD7QgtxKizBWOJevTFNrnITUNGZWmwR2lwY3YFmG4ydyPQ+9YviqTzEjBJkSHJVj1APWum8SmTT9NFsLOT7U7bi4GG2/TvXn97q8ot5IsghxtI29Kio7aFU1zO5kzujjCcc5zVScoRjP1NWWjf7P5ow0e7bwec1nNndXJI7oodaQeZNnBIrWChVxS6Zb+Xbl25J71FK3JqGrG8NWRStkmom6n0p+OabjNZs6Uhvb2oAORkU4jjHpSxjJH86ho6Y7E0K8ZxVpBjrTIRn8KlxluOufSqiiiaIZyelW4x7dqrxjHUVZjbAFaoiRHOOODRRNzxRTBHsxNNbpxg0+omIwfWuyxwIgmHX0rMvF64rTk5HWs+5Ulcd6iWx00mY8uc/4VCx4q5MvPFUJxj6VzTVj0YO4M+BVZ35xkE0jN69aY+Tg1BrbQUEZ70j/jUe75h1zUucjn8qRDIvp3pk2cgf5FSY4PFRyHjH+c00ZtkcJw/FbFtNgIPwrHwQ2au2snTNaQdjGqro2HfAyaq3bb4pB2oEm5ajlfbG5PcVscFSNjLXO7A7dKuW3WqSkbs9Ac1ajkUcZoOCaNDPQDpSM/v+dVhMu3ikDZySDVXMWiSZjsJHNZHnStcEseAa1ANyknnjr71TlTLgAY9aTBaMnSVpCCxyAOBVn7SqDmsgTGObYq9BjPpVW/vCSI48n1NIu1zTuL7aSIZDvIw2D2rPQsxOTzniq8Ee3LMTk+9WI5FyMkYqG77lqyLcJCJxjNSBhjHPrxUaoX2tng9h2qYRZU8gEDihIGyNNx3E9AaUdefrSKSgKkZzUZJBHJ+lDBakhBd8DnnkmmOXV/0NTWpxnp60hAMnPfilYZHvAbPoM04NUMm1W68jjFMyR04FTYC+G+QYqtNJl8E5HQ0qS8YJNQynLAD0pyBEcjAMM9TVqzgWVs5wT61nkbpPnI445Natg0JOZJtm0fKB3ohuE9jXhAT5BxirUFwEcbzg98VlRSiUqHbDZ4anTkQsQ3LYyGBzXQpWOdq50tpqnlNKYCRM67A2egrCvGAiZJJN7A5GeufXNZ0N0FyCwVgflfuKrtequ9gPMlc4z/WhzuJU7Gzpt8xwdQfITgDOOK17rxHcNYmz3xtaH7qsvK/T1rlYc3LrbzyiOY42v2PtVv7EFcG9Yqinl0OSw7ge9awctiZxV9R29Xdyg3KOrnk1o29rPLdw2iwMZZMFF7ketdDd6N4YitbXUvtn2XTAoM0Vy2xiffufYVc8N6poN8/kWq3WmlZjLbXsgCKUHRct0HsavlUdZGDqfyopp4WuIfE9hbC72yGMzTvGvyQIOm4+pPSn69qdwkypayLqGpTnyYZBxhQe3pW1rcmrxounKscN1qjMkSmVW81V6uzdASCOO1Y5sdN0IyN5k1xrfl7W2f8ALBvUE8VTaSIV29Tj/Gur3Ml21zJOqXUQ2bE4IbvzXm9w6yQtIwKzliWPrXTeL2tTdotuWM7czv13H1rkLs7CQvf19K4as9T0KUbIhaTIOB+NT6TZSXlxhRlR1qO2t3uJVjjUkk4Nej+GNJjsIN8oCsRznvUwi3qzac1FaGBdWv2eEAdKw5YyXrrPFbxs6+Qcc/d71gRwM2AAcdelKcTai9LsqLFheetV2BBrTni2cH86qi3aQ7iDj1x/KsWjspspsOeKljQ8H1q0LYBvnXNStAo5U8dxUcp0RkuhBFwOetWUGPrmoVHODUqA4GKpFEy5p6scfSox74pcn8qvYT1FdvTrRUZ59QaKVwPbG/P8aYTj3p56Uxq7zzkQuMiqkq5Bq49VpB1qZI3gzNnTn371nXMeK2JhnJqhcqCKwnE7KcjElGDSEZHWpJ1/A1Fu6DNYWsdad0Iw5zTuqjPWjr3pegxSIkMI4OaYR+VSsO9RDnr+VMzuNK5+valjGOetOxzUqoMVokZyZPaEng59ai1WbyISeufSrVmu1vwrL8TKTCNvPzVqcNZ3ZjSXrEbUIxnt1qxaSOcjk/1rOjUtJz0rVgTEeB36UkzilY0bUKF3Hnmrf/LEnn1rMV9oBJ9qsGQ7MEmrMJIvbk8jkgcd6rQYkPmdjWXG0s8h2sQgOK1Yl2IoFBNrBJCu/cBzVKe0DEHGPwrVAGSHIGKrz4ZSFz9adibsy1tXllKg4Uegqx9hVTyParqokaLtOSeaty2Ey6abwEeWrYIPU1NrlcxmxLs46e3tUgfjpUJfDDPJNMmlVAQTjIpXsXuJPOqMCT0qCBi53nk91qtGWeRmPU5rRgXYu488dfSpWrLegkhZdjDAXuM9KasgMu4EY7VJLkqSBnArPR9oHU49f5UpAiQtmRjx16+lPUg/c+pOajjTeT+f1qTyzGmRnHoKSQMVWyxyeBTJHO7Jx1qKQnJI+opjMzLznj2psNhScnLdTWjZRh0BAA96y87iAegrZ0912bQe1EQkFwWXjjHXNVXvHERBOUPtzVm5GXIHIpq24IztJJ71djO9jMlG75t+faniZVQxquOOhrRFmitnaMmni1+04WcZXsw5IoSByRli4cIVuDui7YXlT9atJqD2jxTSvvEbcOOQR7imahYy2uFV90R5yOv41lXEJRxhtw6kds072FZSOwhure4vBfXuy5+XEcZ5VD6kd60J/P1ewlmMIkslyjtjKEjqMiuNj8yGCMrsaBz2PzKfeun0rX7iz8PXGkWmBp8xLSJjBJ78+hraE77mM4djr9CV9c8HzabO0dxqdtGTZpPJsLxcfKG7Edvw7VzfiFZPD6Pa2cyXDSRqXDy+Y0ZP8JYcEin2UOg6romrz61f/ZltERbXy3w28jnC9T6Vzvk2r2iiEGztI+DGDuJPfk05zTRnTg1I5qWRSZJN7NMx+fPP61n2qST3Z8oFnIxtxmrEqmfUPJtcyFmwox1r0Xwz4Yh0q3W7uhvlbnb3rBQcmdkpqBneHPDf2VUefAcjIGK09auEgtyEBZvYVqy3JKZbaATwF7VjXdu93cpmNmTPODz9a25bKxEPed5GDZW8s8ryTJljwM/pV65s4reIYGMDLZrqY9MFpGHfaB1yTz+Vcx4gu43BBHzDj61lJWRvCTnL3Tlrh98nAOM8CrCIEAHWooU3Ss2O/epZn2525BHHTjFczZ6Sjsitdbeg49MVX3nP9KV3Jb1pnoKhu50xjZDu9SDHFMBHGKcDyOnpTQyVeh2inEYxTAc8Z4pw46dKrcQjDkZPBopSvyjOetFFieY9qJqNj1NDN2qMmu44UhTUEtTE9cVDJk96mRrDcqTdKpzLV2QVUl5JFZyR1QMi6TqcgVRYbT7eta1wuRWdNGQDn6VzyR1QkRoeeanK5GcVVwQ38q0rU7kAxz2pIc9rlKQYHNQgYI96t3MZBOe9Vsc/jRYyTHKMtirKJ2xVdMZGavxLwBWkDGbH26Yb6VV1mHdAflzj2rSiUYouY98ZHU1skcVTVnC7SGbIq1G4AHNP1KAwynI6mqIc+vFTaxyyRe35x6A5p1xKTFhD854GKzzMU+bP0FSWUhklDuTjPGTRcyaNi0hEMIXvirkeCM+nOKoeeJJVVOnrT7u6S0jz98+1UmZtEk8pLe3rmq89yIk4yAeMiobdxPIZG+70FWJLdCnP1zRcNEJbSHcHck8dKmu7+5e3+zrKVt92dnc/jVdF2D2qKZ1CsxODSvYNwll2rk/SsyWYyNnPy9qjvLhpDtjbpSQKSemEAwKzeprHTVl+1IADdquLNgEn9KzPMVV5pkl1k4U/lRew7XNCe6wmF78Vnq5LnmgPlfrQ4ITOACBnNS9dR2toXIJMLjuaueYBGee1ZMMjEVJNMVG0HimmJrUazncc8CrSOGXB71QR8n3p8bZkxuOBQgsWFTEv1HSrMcRQDaSpPpVVTiXlq2bOESpuJ5q46kTlZDEDRqfmLEnvSwzNFKCUJ74q00W1eaiZ19Pwq7Gd7li4uRIuNoU+1RKxQDYSB6iqzDJwM80iuFAVz70CsJLcspdXAIPHIqi0UezBUiNvTrV1ykxOCKpTyGMFRg47Gk2UQSusDEQkEdyR1qD+0XMJijUKG6YOO/WmTOd4C4HrVW4wygou3B44pXKtfQ1rnTrbT75A13BfHaH82IfdyOmfUVSuZLnUbgWltxEew4qmsrzYgT5TnjFdn4W0hWb0Yjn1Bpp8zC3LuaXg/wAOWemgz3kkTXGNwyegrVvLppJmC3UAj67Ack/hUcaoI43YgSICp9CPQ00yRScQliehBUcH61veyMbXdwYDYzSZ9NoHFWLGaGIqGU4Hp2qq/wBoj4Z4/Lz0YEHFZmpX2BgPj6dazc7G0KfNsaGu6tGsbGMqT6gVwN3cGeQseRnpUt9dNMfvcelUCx3ZBzXJUqXZ6dCgoIn8zYMA81XkmJ4zTXb9Ki4PNZXOyMAJpwOTTQOM0A8e1M0FbgUik5GCaMFh60saHPemJlhDxz+dS+lMRRjP6VMg46c1cUZyFAzwelFOVe5/WimQetnOOpNJmjFGMV2nIApjU/mmP3qWUnqVJu9UpSMnNXJyefSqMh5qGdVMgkGTz2zVWWPtVthgVGwHQ8c1lJHRF2M1k6+oqS1l2NipJlGSaqHhuB0rLZl35lY1JVWRDVCWPb7VJDMdoU0TsO2c4qzFpohjGSB3rQiXAHPeqMONxq/GegFXAymTqOal7YqMfeNSjNbI5JGVq1oJ4iwGWAri7ndAzKw/GvSGXIIIz9a5TxDpmSZE+nFTJGEtDmnlLmrEDMABnHHWqqJiTa4BPar8SbQdxHtWaRnKxMs2wf1qeNhOxVumPWqqIGfngCrsI+RgMAe1UjJk1uuHAx8oH4VccDZwelQ2wUEbyAM81b1doJLhUs06JzjvVJaGbM6WTCnB9qzbqXJIBOT2qxNJkhe/f0FNksZkthdvs8tn2gd6RS0M+KE7iWzycmrJyo46dqtJaTPs8uJm3jIwOtQE/wALDDA8ilYd7lKSN2PJ4qPGPr71fkwqksAKzGk3SEn14qJWNos0rFFZTu7CpLwL5ZAxkCmWTARt+dVr6Ri4A6ih7E2vIcrhV44I/WoZHaRs9Oxpsbfu2J/Wo45M8Hp3qLo0SsTA4fGaVZMSYLcGoWYB8k8U2VsZJOTRcouLPtkO44H1rY06++QHPIrlXc5yTVhLhkQbT+dClYicFI7M3gkDAnrVKWQqxIPH8qwU1E4HOfXmhr8sSASe2a05zJU2jUa8Oc5wc8GrKzI5BJBNc1Ld8ehH86YuoMBgEUc4/Zs6tnVcEkDjtVK8YOfl696xE1E4OeRV1JzMvGcU1K5LgxsyDkg4NVJZGI+X8/WtCO3mnO1FJra0/wAPBWElyVwozRa407GZ4c0mS4ufOdSF7e1d3A0VjETu2nHNZUl8tspiskDY/irNuFuJ2LTsxz0HQVSfKHI5u7NO4123jdliG7nLNjOacniASriSFD6shwfyrBMAU5I5/SoGjVfrj1rN1ZHRGjE19Q1N23BZC6+pPSsKeZmOWbcaWQ8Z/rVaRsGs3Ns6adNR2EcGoGIUe3tTnl9T2qtId1ZM6ooGYk9aFHf+dNAp4HbtQbWEJpQOnpSYpc0wHDnpUi9cUxfvYqYdfeqSJbJYxjtU6fWo0XipUHPetErGMmh2OeP8KKUj0P4UVRFz1gr14FKAMGnEcUu33rsOPmItuM4+tRSd/WrDDioZB9allxepRuM1RcVfuBzVJ8Z9KykdlNkW3rUTrtPt1qwcelQyn1rNmlyrNjnjis+Q85q/KcnviqEy5Yn1rNo0gxqEipGk469qj6VG7UgZIrYNaFs+R9Ky05I5rStR07itIbmc0aERyPl61YjHNVou2DjirUX3hXRE4pkjR/LnBqleQB05HWtI4K4qOVQVNU4nO2zg9S08QTeYBgGs1n3yEdq7fUrcPEwIya4q+t2t5DxhexFYSViWh6P8vFTRuVPWqAfCknpUkcmfvHilzGfKaqzDcFA4PrUsVz9mmLbdxxgc1lCQggj9aleQPyTTuQ0X9OtlubtELBfMbk46VHrsb2E5tlnLxqd6g9OfaqkFy8L742KsOhA6VSuZDLM0jsWdjyx6mm3ZEqOpfOp3BSFN4RYlIGwYNUBKWkOMnuT15qtPKcqq/wD66WJtmScZNZ3ua8o+6cgYzkGqJOB1wakuJQT1xUAO9hUs0irIvW90ViPsKjLmQ7yc55qIDC7R09RTUYAsCTSAlmfaBzmo42wdwPFMlfMfPUVGsoCH1qW7FK4+WQl+PzpkknzgZGars7M5K4xVy0EQSV5wGJXC+xpbjvYiEgZgP1onl6KDj3qusmW56UF8sMUrjJlJIAzUu4lwFySe1OsrWS6dVjUkHqcV2OnaRDCg3oGfqSe1aRjciUrHHiyupiNkT7T6iri6BqATckO5e5Bziu7SFcAADirMYKnjdirUEZObWxwNv4dvZGAZdgPUnmuj0zSEs8LKck9c10AXj0HtUEkO4ndk85FWo2FzN7jGWGIARD5h1qKecyLtYnb6DpQ428HmoWAPbikyoxQxnxwo4qNiznnmpwBk5pCQvpUGsUVzHgc1SnCrk/lVu4nUDrWTdTZyc8ZrOTOiESOWTAz19KqSsT9aSWXNREkjFZ3OqMRvfFKo4oAzU0a8c0JGhGFpdhxntUmKQj1qrDI8HJ+lCqQafjgdjQBRYLiqPTrU8SjOOM0xV5FWUU8d60iiJSFUZPJ/OpUHyj04zQiYGT1/lT+mc9DV2Mm7iYI//XRSsBxwc0UWRNj1w4yKUf5xTM5anZx3rrOEGwc5qtNxmrDfdyKrzcCkzSO5nztkk44qk55q3cHkjNU2+9xWUjtpi546VDKetS4xUMo9c1DNLlR+evaqsgBzzViTjOKrN39qhotDCvBqJl596nA4qNhz71BVxifKc8HFaNscDGazyOKt2hq4MzmasQHHPSrEZGQaqwnjvVmPrntXRE4pFkH5aTt/KgHK8UoHpWpzlWdN6kY4rnNStA+4EV1LjBNZ99DvGRis5oR51eI8Mu08D+dLA+RnPbrXQazYCVNwUbh3rl5CYSQQciudppiaLm/gjNAfOB0xVISHA4wacsgHU0XJcTSLRmL7+Gz0qnIcHoPaot2Q3PFKHDj6YpXuJRIlBMuWHHWpGIA7fSp76S3FnCsA+cfexWaXyOc8Um7DWo++tZreKKWUALNyuPSoo+MHuaW7u3ufKWQ/LGMLTFIHekWk7E2/A71Fv+duRTWbr7VGxxjmkx2HSPlT61XVyQRx9PSnFsDnrUB6n0NQ2VsWY8HkDNOkYquO5qGFs8Z5pJ35B7U+ghm75sZyTXR6Povnqskx4POKqeH9JkupVmdfkHIz3rv7K1EaAAYHpVQhcmc+hFYWMcCDYgArQSMAY6H61IF4ApwX5jW6VjEdHHzwKs+SF+bBohCoDmnPNgEdq0SRMhvljacEcVXkwtJNP6daptKWPOTSbKimMuSSc84qqZNoP8sVZdsg8mqcg5x296ykjeCI3uCpx+VQPOT0NJMOSOMVTlcevNZNm8IDbibOee+KoTSk55pZ5etU2Y5+tZs6oRsBJJ56VIBnjt61GoweKmRfypJGzdiRE5qYY29Kavy9s0rH0qydxTz6YphHFP7+2KQjmgBhA6mgL0707GQP6mnouO1UkDdh8S8HsKuQoMDIqGJQferiLjj9K0SMJSuMKkdKjbj7v1Gank6ZHFQYyefX8qqxNxB789KKco7/AJUUrIVz1fdS7v8A9dQh807Jrouc3KOJ64qvKeakdsVBIe1Js0irFWfnrVTac5q1N6VCR1qWdMXoM7cioZ/umpiR3NRP7GpGjPmHHFQEdaty/pUBXPbioNU9CMj0qOQYFT8AEE81FIc1mwIG6VNbPgiom5psZIPHFNDZtQPmrsZyax7eXp9a04JAce4reLOOpHUurkDmpEORUKvkCnKe4I4rZHNJCvVd1yDkcVOTzTSuelMkybuDk5FYGo6UshLKOeorrZk556VSuoQv0rKUQtc4O50948gZ9TWfIrI2GHSu6u7UNlsA1l3WnJMhKjBrGSGkctv9KQybQcVLeWsluxDD5c9apyEg88Cs2GhM7ZUmq5b9aQS7SOOKWbg5HQ9MVFyuUaWAPFLu71AWyxPT2pQ1AErNx14qKQndzTd+T1602U5x60mxiseeKa5IFAyTxVqDT57g4RTz7UWuGxUjzn61raRpcl7OpYfID+daOneHG3AzZIPOO9dVaWaW8YVVwMVUYEOQ+wtVhRVUYAFaUWMjiqoOPwqxE3pxmt4pIyauWQRkZqZUHWqobC5NNM5HFVewuUuM4UDJqncTg5weKrzXGcfrVV5c5ocilTJWlJbrTS+OapvJjOc1G0/GKycjZQuXDOBwTz9KqzzAE47c1WlfIJGapSzle/NS5GsIFm6uAc1lXE/PHWmTTk9O1U2csc1m3c6oQHyOSSDxTByc0n1oHWpN0idKmTpVdTk1OrYFUhNEy9qXHNNBGKUU0SONJk0cmkPUVSAeM+uamUE1FEKtRr35q7GUnYmiXj/OasdM1EnA6Zz60/OBya0sYsZIfw/lUWD1OOakJJJPBBNIF64GaBhwAPyop4QnOaKVjNyPREfnvzUofA96oo9Thq1uNxJmeoGPJ9aC+Acdaru3PtQXGNxzHNRNS7+1NJ4pGnKyFz6//qqNuPSnyHk1FnPpU2GkRSDn+lQMKtPjbjvVeQDkYqDSOhA3Tn86hkxng81I55xjFRSYFQw3Ij19/WkNK2M80x+/HOKkolhl5rSt5sYwawwTvOD0/WrdvMeMn/61aRkRKDZ0UUm4Zqbd61kwS8e31q8kucc10Rkck4NFk464pFJU0xGGOuaCcCruYcrHyrnp1qpcAMu2pyT3qCU8dSDUMLFQrkEEcVWeMLnHSrjPzzmonweD+FQ0UjOu7OOYEMvPaue1PRiFJToPSutcHqaidM//AKqmwnG+x5tPZyxn7pNROWChTkfWvR5LKGVfmUZrOu9Cik5XNZumK7RwxHGTTTnaQQa6WfQHVvlzj65p0ehcfMKjkY7nKhSTipYrWWZsKpxXYQaJEvBArSt9Pii+6gzRyCuc9pOh9GmBrqLS1jgUFUH1qREA4HGPSn4PXmtIxsJ6jyRS7uOai5/Kmlj3qhctyXeM1KrcZrNllZTUkU2OvFIfKXmlIXGahlmyvHaq003Ht9arPLwcZ6etJsagTSTY71A84PFVpZs8A9uarGXnvzWblc2jAvB/M4HU+9MaNl6nAqtDNsbP41PcXS7OMD+tBXK+whlVTz9Ko3TBiSKhmnJPHT0qtJLletQ2bwpkTt8xOaaeetOYfnTfWpOlKwoooGaXH/16Ckh6EdBmpVODz19agGc1KvQnpmmS0Tq2M8nnnmnbsE571Ap54qReh7YqkQ0S5zRwTSDtxxSr1+vtVIh3ZPEB0q3H+QqtGOB/WrMZ+uK1iZS0Jh90Uq45P41GTk5IwPWjOcbc896oybJD1wKfChZj+Z5pEXAHXPvViEY5xigmTBgM4HpRSSEFqKZB144bAqYdKKKcPhRo/gQ09TUMlFFUTEZSiiigshk61EKKKkBG6Gqjd6KKg0RXfrUQ6t9aKKzkNEXpSN2oooKK7dTT4CfNHNFFCAvQk7x9a0IeoooraBzT3LY6U7sPrRRWpgwPb61A/wB1qKKliRVbqPpTe9FFSwEbpTD0NFFIB8fKUNRRQSQ0hAyaKKRAh6GkTvRRSGhXJBGD3pxJ3HmiiqAYx61E9FFJlxK7UgooqShCSS2aqyE5fnp09utFFSxx3KMp+aoycdKKKxZ1ID2+tRTcDiiimVHcrt0P1ph6/jRRUmnUb/BnvTR0oopGqHev0pVHSiihDQo6U9PuiiiqJZKAMdKcg5H1oopkscOrf71SL2+tFFXEzLEXUVZAGDxRRWqMZ7in71Kn3j9KKKZBcAGeg6VOvT8KKKZlLchfoTRRRQI//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel G Deschler, MD, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_55_20337=[""].join("\n");
var outline_f19_55_20337=null;
var title_f19_55_20338="Agenesis right lung";
var content_f19_55_20338=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Agenesis of right lung in newborn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cardiomediastinal silhouette is completely shifted into right hemithorax. Multiple rib anomalies and vertebral anomalies are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_55_20338=[""].join("\n");
var outline_f19_55_20338=null;
var title_f19_55_20339="Proximal humerus fractures";
var content_f19_55_20339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Displaced fractures of the proximal humerus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bigliani, LU. Fractures of the proximal humerus. In: Rockwood, CA, Matsen, FA (Eds). The Shoulder. Philadelphia, W.B. Saunders, 1990, pp. 278-334. Copyright &copy; 1990 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_55_20339=[""].join("\n");
var outline_f19_55_20339=null;
var title_f19_55_20340="Flurandrenolide: Drug information";
var content_f19_55_20340=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flurandrenolide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/24/12676?source=see_link\">",
"    see \"Flurandrenolide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F173009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cordran&reg;;",
"     </li>",
"     <li>",
"      Cordran&reg; SP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F173010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cordran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F173017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F173011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Therapy should be discontinued when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Steroid-responsive dermatosis:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cream, lotion:",
"     </i>",
"     Apply sparingly 2-3 times per day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Tape:",
"     </i>",
"     Apply 1-2 times per day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F173014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Therapy should be discontinued when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Steroid responsive dermatosis:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cream:",
"     </i>",
"     Apply sparingly 1-2 times per day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Lotion, tape:",
"     </i>",
"     Refer to adult dosing",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F173012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F172996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical [emulsion-based]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cordran&reg; SP: 0.05% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cordran&reg;: 0.05% (15 mL, 60 mL, 120 mL) [contains benzyl alcohol, menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tape, topical [roll]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cordran&reg;: 4 mcg/cm",
"     <sup>",
"      2",
"     </sup>",
"     (24 inch, 80 inch)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F172983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F172999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream, lotion: For external use only. Apply a thin film to clean, dry skin and rub in gently. Avoid contact with eyes; generally not for routine use on the face, underarms, or groin area. Use of occlusive dressings is not recommended unless used for management of psoriasis or recalcitrant conditions. Do not use tight-fitting diapers or plastic pants on children being treated in the diaper area. Shake lotion well before use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tape: Apply to clean, dry skin (allow skin to dry 1 hour before applying new tape). Shave or clip hair in the treatment area to promote adherence and easy removal. Do not tear tape; always cut. Use of occlusive dressings is not recommended unless used for management of psoriasis or recalcitrant conditions. Replacement of tape every 12 hours is best tolerated, but may be left in place for 24 hours if well tolerated. May be used just at night and removed during the day.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F172997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pruritic and inflammatory corticosteroid-responsive dermatoses (medium potency topical corticosteroid)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F173023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cordran&reg; may be confused with Cardura&reg;, codeine, Cordarone&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F173015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, acneiform eruptions, allergic contact dermatitis, dry skin, folliculitis, hypopigmentation, hypertrichosis, itching, maceration of the skin, miliaria, perioral dermatitis, skin atrophy, striae",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Secondary infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F173002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to flurandrenolide or any component of the formulation; not recommended for lesions exuding serum or in intertriginous areas (tape)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F172987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact dermatitis: Allergic contact dermatitis can occur. It is usually diagnosed by failure to heal rather than clinical exacerbation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin infections: Use appropriate antibacterial or antifungal agents to treat concomitant skin infections; discontinue flurandrenolide treatment if infection does not resolve promptly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Avoid contact with eyes; generally not for routine use on the face, underarms, or groin area. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F172992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F172993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13277396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some corticosteroids were found to be teratogenic following topical application in animal reproduction studies. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13277398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13277397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic corticosteroids are excreted in human milk. It is not known if sufficient quantities of flurandrenolide are absorbed following topical administration to produce detectable amounts in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F173003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Cordran SP External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (30 g): $204.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Cordran External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (60 mL): $394.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tape",
"     </b>",
"     (Cordran External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mcg/cm",
"     <sup>",
"      2",
"     </sup>",
"     (1): $152.95",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15666315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If HPA axis suppression is suspected, evaluate patient using the following tests: ACTH stimulation test, AM plasma cortisol test, and urinary free cortisol test",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F173004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Drenison (BR);",
"     </li>",
"     <li>",
"      Haelan (GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F172986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F173001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Adequate with intact skin; repeated applications lead to depot effects on skin, potentially resulting in enhanced percutaneous absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine; feces (small amounts)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/55/20340/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8468 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-67DC1C7482-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_55_20340=[""].join("\n");
var outline_f19_55_20340=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173009\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173010\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173017\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173011\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173014\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173012\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172996\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172983\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172999\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172997\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173023\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173015\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173002\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172987\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299356\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172992\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172993\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277396\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277398\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277397\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173003\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15666315\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173004\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172986\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173001\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8468\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8468|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/24/12676?source=related_link\">",
"      Flurandrenolide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_55_20341="Global distribution of plague";
var content_f19_55_20341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 614px\">",
"   <div class=\"ttl\">",
"    Global distribution of plague",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Data reported to World Health Organization (WHO).",
"     <br>",
"      &Delta; Dot placed in center of reporting country.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention, Division of Vector-Borne Diseases.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_55_20341=[""].join("\n");
var outline_f19_55_20341=null;
var title_f19_55_20342="PVOD venous obliteration";
var content_f19_55_20342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cross-section of a small pulmonary vein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 265px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEJAYEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1m98F3FxA0SojKhx8owVPoOP8+vc8tqPgewinSSSErcY5KjaXz1GMcj656+vJ91yT/hVe8srW9QLcwpKB0JHI/GumNeSPUp5lUWkldHz14yv7+xSGG2077XGF2I8iswcY6N1yOc4Oc7uh70dHtdebTpGnitbVG+ZnWHAIPTGRnjj0/HPP0A/hbS3P72JpB6O2Rj0Apt54T0i7gMUtuwU8fLIe/X6dT+ZrZYpJJJG6x9Jb3/Q+dbW4h0+aaSTXbdBnlmfcYcDqqg8kYA4/u9emez0y8vdY0u1S1uodRSVNsTwg4IHf3PGO+CB0OCJr/wDZ10Ce/M1pq+pWkBOWhXa598Mwz/OvTvBvhDSfB+kw2OkRuQmczTPvkYnqSe34YFKriru0VfzMvr8b83Lr/XoeG2/wk8RX2sPdJdLbRSy+Yzuo81fYHt+PqOPT134feAYfC9u8l1cte38r75JmGB7ADsOT0xnv2x1zX9ss3ltPHv3bcA5OfSrOayq4mpNcr2OGrVlKXNa1yOa3inGJUVu/I6V534n+GdpfS3l5p0kkF3KpUYY7c+pHQnpzjPHBHOfRycZ5FKpGDzWdOrOm7xZnGpKO2x88aVomu+DPMU23nSPG2W52ybSSu7HU84Gc/QHkz+BbzxVrmqXIv5Rc6d5ThwI8bZeyD1HPI5GDyOa97nt4biPZMisvvWdqF7pXh2zNxciK1i6ZSPk9z0HTvW08RKq9tT0aWOjGnyKF5dDy7VNB8WwzLNFdPDboMhYyByfXP68jqeG6Hm9R8dal4cs44723SW+JOfkJAA6dxzgZPT7vWvSvE/xN0fS9DnvhBdXMaL91Y8EseFHJ4ye/4815N4d8fJqmum41jw3a/wBmklVliO91JwRznBPIBxz82Oc4PbQ5pxvOGiMXUqOXK002dd4en1HU7OK51KzAkuPnW2ZTiIHPXJ46fgVHIxkdPDpEaSwL80YGWZSQPMODjPqBzxz/AAnHHy9Bod9p2pRL9i8vfGMgHBIHGDnv1B/GszxJd21jbMP7Rja9U8pGuT+OPoOvp2xkccpOUrWsdiruUuS1ixHrNppEVy806kDlmZgAT07np3z/ALX4V5P8QJvC3i++F0NLeaaJTGLy3ZkHHJAA4br3x39gbN7BCbv7V4pV74AFpDnbHAM8KqDqBg9fT8F1tD0D+1GF3ajy7eUCQhCVUdRgL2Pb8e/IreMIQXMylShCXNNHO+C9O0e0sJhaJdwJL8zRzocHGeRxwfy+71H8XVNZPdWnlRW8duCwMmzDELnsfw9zwOT1rYTwlGmyS1aTzIhuVWOQeOo9/wD4o8+s+nac93avsU+VuKs2dvI7E9/16H61m5r7Ju60N0yj/Y0945uEfESAAYGcpjAY+pPPrww4OOMDxPpVrrNjNbX6ma5yVDMpwwzxnnIGcdxjPAOMV6XpcS2l7KpkbbkBd5JJyOR7/wD1vyuz6HZTOzMhUnOdjYyP6fhUKrys5Xi4xdprQ8J0ad21A6PDaPYSrCA5mz5QQdGUjGCSB2Xp15we60bwfqkLWSNGYkBXe+QNg9R6EADoOqA8cGus1vQdOS0WWG1SJomG14xhhk/mck+55/A53hrVLqG4bTSZLlIlIhkfBLYA/Pqp79evrcqvOrxKeKnODdLbzJvGVkv2Q+Ref2cqr810XJZvQd/Q+vTpxkcrZ2GqrIk93qUeowMCo/dkbgcDj0yeOoGG6cDb115psGp3hW6mmkiB3yQO26NTxjj8jg//AFxoJpsf2VRHtKDIG3sPQc/oMdPYYSqKMeU5ac3TacmclbifEIKl2j+Xd/EAcj+ue33j9BqT6PBqN2SwRWWP7pjBWQA8bux7c8n37U64zDcutsCGH8JXO71I4+v5D8I2trt90wlljJYYJHH0PqDnvnrU3OuUubVOw5tNj0neQsccixgqiZxGPUDPIGB1OPlHArDl0SQ77w5y0jF0wR34weMdD/d7dOos6np+sC5V4JHT1k2dBxjk846ccDk4qk0us29t+8vEmgjX5nZQpjHHOBjHQdMYweR2pX6MumuqkrjLawuftzyC0dDnEb/wj8D689v4vxG/HPdRRCG4xKjuMkDh8j0OeuRnOc7j9ay9KjublFa5kVkf7qqccnH8ufptHT+HpbDS7mWGX94saEnhjuzzz/M9fbgdlN9xVqkV8RkeIdEjuIHv7CZ1dmAcnsCR93B9ccdDzwc4PB+KPGOmeFLU281jekPkh4QAScDGG7Y/Dlep5z6vJaNBGYnZ2X+JUPVs8D8fT3rlPHGgW+t6NHYqiTLJIPMUnB78j3Jx065PJ5zVKSvaWqIhUbjy39GeG6t8SbrxC5tG0GGSym+V4DIf3g6dAMZ/PGB+Pqel68LTR7G0gsfmSNYkt1ckDjATI/hGenPDdB3wU8AWGgW7ymRZJCCAucOw5zgdM/n396n06xBlZozIm0YCk8xgA884OMEjtyOPbd8rR1UKXu3qSubB1LU3v2kkjXaw3Bl5z+XYkg444c8HPzbOnanb6rpH2e+j8qYtujI6HuD0PXIJ4Pfk5y2Fc6dfWccTeW8/lDcVGV2gk5xj6sOPb1rV0/yLy1cw27o7bmcO+Qx6kcjufr9735zaVrlVOS2n4DZ9StfsZRARKuSxHIweoBJOTgD+9naOvfh9L+JY06eWPUoEihicpFOhJEg/u7umQOOvGBx2rt7rT/IsppHVMMMF93Uk5569flPJPU8HqeAufh3Z37sZvkjlJk2pMQmecsRwA3A7evWtKfs7PmRnJc0fcf3npei6xYazaw3NhOk8TqXwGOfTGPXnHQdevYpp+iTMBP8AboxBIo2hCQcZ4yeh6j1+82OuG4rwn4YbQrGOE3DFjJvTLdUyQSO3TI4/xFer6fZR3qCOFxuTmRj/AB9v/ih+P551LQfuvQxc3CN5aHlvhTTorLWfF0mu6YyLK4+x3E8eQ8eOoPqDhuo69s4PE+LtGhgu1n0Z2tr1EDKiMyBxjkZUjb7Hjpn3P0xqWkWRtGN4DIiDdlmwB14+h549/wADyF34ZF25mt41ZAM7ZBjYccFSPwzjPfnrmo4i75go1aM4uM9mePP8QtS8P2dvo10C9pcQ8TzAvJFLu+YEg8qOvQnGPrXU+DPEFxe6AuraTo76tKLxbSXbMI3iU8GRuuU9j/e6VbuPC2mR6de3p0lL+SyDy26knmYJhB79BwT/AAnp24T4TW0tj4nf7dpOoT395bpcLcQRm2jt0YlZNyEgMo4xweRx60TrK/LbcyqU5Rqe67p/1/Wh6r4v1CS4sjbWTXc0sp8lGgJG7n7pP8OcjqBnJ69GxtO0u6sb2wvlnZIpMxmMIB52QBuOMnI4yTnq3PPzYFxp/wARbm01MSnT4bRJh5dnARJLKhYqSpHJHzFjkg88dq6XTNCvdBurZbqWGayiiBWQ8vJOT82RyApBJHX73/fW0ZxjDli/wM4qUp6qyR1H73/nzb/v/RXVfYIP+eqf9/T/AI0Vx86Nfbr+rnFal8UIbefYsbZzjPbPoP8A9Z/njofBvj6w1uNw0qRurY2swB/H9PT6dceA/EDSk069LSGQqzHYRnDHnqfX8TnH5cza21y96j2sMnK8lfl5789v0rhxFaMHbt+P4f1qegstpVYWit+p9q21/b3AzG4wB1zirQPGcV86+DW11ZYnM0zwoDui9AOMc49PboOR2928PyzS6dGbgHf05oi21dqx4+OwCw3wyuanO72pCQw9jxxVG41BrfHnRhMlsAfNkZODx6jBx1574qlb+JLGdZFMyRED5XkYKCfz47de9Wou1zjVGbV0jxP4mawfC/iN5LO6eabfuWIMQEbtnnp09OvWsCz+MHiCCc/ab9pY5GG44GPwOBgdOgHXn1qb4x6XK2ty3akOjqTuGCPX8PrxwPf5vK41ckkxM0SYwdvA/pTxFaUJcq2sfU0KMKlOPOlJ+h7/AKf8e7RpILe9spNnSS4WQCTr1CkYz7Zr1fwn4u0bxTbtLo90JGQAyRMNrrnPUfgema+ILxk80FE3qo2syjqf8mvcf2araca9c3CnbC0RJA5DDpg8cc4+vv2xlUd0pR37Hm4jCUJRqOGjjr6/I+jieao6vplpq1sIL6JZY1YOAwzgirxNeW/GP4oT+ArqwtrTT4ruW5QuxlYqFAOO3WtqcZSfunhqXK7o6G68CadJAYYsrEwwwYbsj27Dt27VxepfCnRrW7Er3MzRE5a3A4ck8ngZJ646npwejb3g34oWOv8Ahq71G4WG3ms1zcIkoZEyMg59D64474rz62+NEus+L4tMtdFtJ7WWQwrcNMd7cfeAxjHt83fr0PZT9vG+p206k5NKevY6/Xrg6RYT3Nk/kzMhRhb/AHtgGSB79e/pgE/e474Z+NNA12/8lkuLS5UeZvu5Btxnruzx2446/Su5OqrbvKr2kTtOu5JZVydp46Htz0J554PRvKtT8K6ZZX/2jT7bZtbe6t6Z5I6Y6+3IAHXkWqsz2aVKpUfKnZHtWpy+HrLRnvpoRc2Ua7t8KhsdD07Hhew/TI5LRfi5ocuoJp82n3VgsmJEcIGQoSRu+X6eh6c+1PwnqMa2Gq6ZcQ74XU3CoBlVAXkYOPfsOinPevEvCulT6zr9wsTjymmZmZl2gZbpj6dufy5FQVNK1Q56mDqc/Inc+ub/AFZrXTjNbvGVmTMTjn3yMdeM9M9vobOg29zLF9qunDCYY8tWyo65P1/HP0ri7G9ums4dNgnhCwypHDKBuGQoxgnOD0zy3f0IEOnx38OtNFG7QXLH/SDE5KsMHJYZ56jHPrgCsHDQzlhfdaTSZteINSurLW103T7dduwKlwz5YOTkg54HUdSOv0NVrTVtThvhE3iG3upmbasAh5x/eY9uMe3Jxx0lTR4XtJracMkZ+aVkPzg5656g/Tb0H44mr2MOipd3MX+mmRfLMjx4K5zk4Xn15x6HPetI2fuiVKk0lJ6o6nULubUdKniWRZom/wCWkUg4bPCjGec54wenfociyH2hVlulmtrzIDLG20OcEZHJx1boT265w/kHgWTUNH8Q6jpel3zzae8gmV1IcF2xjHXOec8MMEdec+9aJpk80ZuLi4CO6jDMgzz/AHh69OpPU++brUvY6XJp1FGDb0LthelIxbLYyLIoGWPVsd+eeufz9+dOzL7P3wSMA5A4xyc/0/Ws6+WRI2aBDK0SEllU5wBx06/Qenvg/Oeg+MfiLqnieNUtLq4R5d00TQMIkiLYYFsYUAdCeTgfjnCj7RNp2sctRx08z6X1Sa2R4w5GM5Kjnf8AX19ae2qWsowky7T1x29q5SWSUgiSVPMJxjHB6jHfPf17exrNuIreI/aby5unmXhUiGAevH/1s856HqIjTT3N/q0bK7PQWv4H3BhgjruXt71lXiaLczZnijJYg4DEA+5A688Zrh7fWbzVFZIri1toF4Vt3mSKT0yMcHkcEY5Iy3eTUobhYLSG2vp7uORiWXYRKmOjZXqM88559elaKhyu17EKlGD0bO9K2HlSfZyik5Hycbunf8vp7dp9PmaNGUq2F6bsDAHr2HGPTvx6eE3eheIbS8aSC/1hJ0IMd1FKZQ5HOG3HAXPb6DjOK9R0vxTdIlpFr1h5Uoj/ANJlhBKK49D6ZzycY4/B1aCik4u5DhNppxua/ie4uTp0w0pUe+K/uhKCFB9SMZx/njrXnfirxtpvhewEXiRbr7ZOn/LuhfB74JPXrjrxj616HPrelOrMLjCKQC+0nqeBjt/T2xxhPrHhi61aST7DY3N9tAFzKiMcfU846dPf0OJo2XxRui4xqqFqcdShoVlf6jpkeo2ca3MMyl1W4JLsrDnB5I79zn361LYaMbaUB8/aRwo4AX2yegyB6H3/ALuR4uTXNQ40W8ZZCA0flzeXgf8AAT6duO/HpmeHrHxBbMser3d4J0DNvdg3HByvcdwCME4HPpoo3Td0d3vdWtTrfEGqWul2v2YmC4uE+aPbw6kAY56cYHX0PTHy5Wh65bXDTPcB7YHgNIu1VIGCPrx/47jA5FVNTtJmzGqATSNvyw4I9Dj6Hnn+HkYGyvPp8WxYlkDxIcO5QAZHUYyB6gc9COFxgCirWNYU4KNm9To5ooNRgimE2yDcTjfhuM8n0HXjjqPXJkMdrMHjiaK4ZSQGQDhuTwB05B7d+vevPLqdYD5VnEwYtgyEZCZ+6ozjJxjPQDnpzXWWVmbLTLdFMsRRPvR8EkjPzDHPHPQ8g8jrQ426jnScFuHiOGW5SJpmaIDCrIv3s5HJx0Gdp4z3+q9F4JuZftbXF7Ku0p5Rz/eBGD+I47fdPB7c3a3Lt9pmu1J3oV2d/wAfU8Hue31HL+Kr7VTpU1xZb1ljT5zGCdiH+EdgBg+nbrgFRQ5/cIqUueDgz2zUQ900drKIyrNuYjpjsOep/DsfpWnFbRfZ/JKjaVwf5Gvmb4X/ABSmj8RJYancNcwyFRbzyjDbj1B9Aex684PHT6btrqG5hjmiYbJBke3sa561N09E7o8erpFcjujwnxLBKut2MdpezxTQ+d5Db/lEvIBcZ+Yckc/3hx2rf8Ea6Ne0EX0wZHgfy5UXoCp2luPcZ7AUvjzwz/atrdFN4limPkyINjbupG4HuD0JH3cYzwb/AIC0e2TSYbK3hltkgUZVxhi3c47c59Pr3rslOLpeZ3Tle0k9LamhevDbxSXbzBBHjnoCPf3HHY/d/Gi4tLS/+yXdlLHJGzAhuq/TPt/7L0qx4+0yO48H6pbr5SPJEwUuMZbBzz3/AM9Dgjyv4Z+IJb/whcXd1ceRJZxur4PySbByOenTPp83TjIzhHmjzIzhLndkz3v7Sn91fy/+vRXzL/wviH/n0vv+/wAlFZ+w80c37r+Y9i8X+CLfV3zcRuyht4I7H6/5+lZ8PgqLS9ME0wt4tmFEz4wMnAyfyz+PWuv8a6y+nQCKGJ5GYbmAGB7DP514P4o8c6hqRutJ1KNobd3H7lG5jPZu/HU98g9T1rBUIzaqz0R62C+t16dqex2kVjq2nPfGO6dIpZBJE0cQwVGMcjgZAB49DzXpXg/XI9RthDOUjvF4+U/LJ15X8jx7fgPnPwj481Pw3qj213ONS0wFh5Jfa8eBkMM55PpkjmvT3vbWR9O1TRPu3T7gemHGCODwO3Ge3T06a1G2nToyK8frF4TVpI9Yv7NLyFo5R8pBBHrXiXxF0oaJqGbu4aK1ugf9IZcrGBnt+OP+Bc57+weHtYi1e3yP3dyg/exHIK/ng+3Qcg8CsT4o+HYvEXhiSCWJnaFt6lR8yjGDjn/Pt1rjs2nTfU4sHXnhayjLY+TtQ8V6mZRFBeSyWxIwpiU7D6qcfjzzyc55zsaP4h02dIor218lmZUlkjHyuCepXHbqep9Md+Z1XR7nT7iaNoZvKRyn7xNrevTv9enT2zr+CfDo1++SM3KW44wzSAFj6AZ57Doev58tbET+F77f0j3sMqkZPXTf+metaH8HtD8RXD3KXN0NMkYyF45eTk9F44z3znp0zXr+j6Do3g/TfL0q1W2iAAZgxZmA6ZJ5NN8EaY+h+GbaznCYjUAPjazDsW9DjH+AqzqVxDODGCd2flABwfrXVGUppcyPArS9pXko/Dfp19SdNb0xrhIGvYEnddyxvIAWHtmuf+I/gzQvHGkpBq0hjlgBeC5hcB48/wA1PGf0Irk/Fdnp8OpW91PDGtwqM2eSAueuAMnuOM/jWZca3FDa+XbbrpSQxlDEGT2UZOc+2fvDr33jTtaUGbRyz2lpJnJp4I0nSLTVLDTZrmVL238q5dnChlGT6devPYqenUR+B/A1kqNfW6SJdQ5Cs8uSOCG46c8gd+Bx1rYmma5updkSpBjGeueQR39cd/Xp2taJPMl41vCTHKf3SIBgRL0JI46Y77fuHgY+TbpZdD2Xh4QjzKKuvIvWMgm1UjUnclyAJmb/AFnqOfXkY9GHB5Bf4t0Ocql5YpJN5eS0YXO0eo7jr7cE8kn5tS00iCw1GNjvlKHYEfgJxjge2D2H3fy6bzP3JQKo77RzuzkH+Z9eo5PfNys7oxnX5JJwPFxeJDdxTWzOJACRuHzLxyM/gDntg89zjafFNe63KUjOyaQBVUbSx/vY7ng9Qfug9sj1HX/CkVyZ57S1lM8hyXUNgnrnA65P1+91H8UHhfw3Bp960t2GaQbWKHrkYIJPQdjj9BgGqcr7HdHG01TbW5rQaWlram0eSWQiEzPKq5ZpQOx9eoAPbHHHHQ+FbRILf7XqkoN4zZVUwPlA4Bweep9PpXPXN7aTXEyQSsZFGyVvNB2A8leD1AAz06dDXTaJbS3KxmOMW1uwB2kZYLz0Hv0/LrUSvbU8bEyvC8nuSyANMzwx7VbkEnB/H0H5d/xr+IdDS68LamFuDaySW0qrIxGI2ZSN3HccH8PXmtbU3stPy87xoi/OcnliD0989P8AOK82+KHi/WrvQ47PwRZSXL3BImuNoGwDtg8H6/yopxlJqxxc7klyJnNfDjwY/hK7jjvbhriOTbJu8vaobaevU4IDdz0H1HsGnyX155qywiFhkMxBCjnGQfz6+o968/8AhZe6lrmkxwa5e2UutxkqUQqsqxDBAYAjJyueMfd6cZHW6t4rtdC1Oz03WZEhmu9yQoehHHoOP0Hyn321UutOxtNxaUYqz7G1d60luiR2zK0uQGODgc9eBzn+o+hz77WDc3fkQFh9oXgMOp4wf5Hv0P45j3X9nW00ktjI0IUlXlOEBPXP0Geeeg96yZNXEmoRzSxxSy7Su6P5foo65zk85PDe/MqCNKeGjukdisuj2RQKDNLjBZWJIbqcn/P+NQ3mnFJBdMJA5+XzDyMe/GCPw7fWseCd7uEW/lIAQQGC7XK9fmbPHXuR1qEaWrkMrA7OFjYggEfxnGOnHpjHUU1FdWUqCV+Zsim0jTZ9Whv9PidbkOVcq7qJV5znAIbvjjuOa6fTnjihlFmYbi4bAZDIEZ/f5uvXrk/e798G3gw5VmRRnooBxj09cfj93t1q7HCJA8dxG0jNkxtGeSepQ+/XHrxx6uTb0bHUgmrItz3WqWiu13aW6kkbScMCM9OD16d/X2Bov4ikmQxLYWyKF3Z3OGj9CMde3TH3TUAu55/lLB3ChjuPQnsQPX+v8XeScTizH2fykmJ3FmbaJT6qeeTkH+L73U8ZEl1EqaXxGJrEH9oeZFPI0dshzsifaWbsQMDgY/8AHeo7Y93pVpYzOyJtjKZyVzvPIxjr1z19RwO25FZFpZCzGSQ5dpRjggDHOcHt6/0qlfWsnmbmRvMu4AyruzhRyvcY6c8jlenatE7aHdTklpcl8NX0Wl6vA94rBlLA7MEBT7HkZPfjqM16bpsul6vCrwopKncAwwQfXnqeleH3ULxNlwwZExtyTgfiM+o6dhyO97StYntbqNw/zFWClCdzHt656443H5h68zOnzap6mWKwftVzwep6tdeHQJX8g/unwSG5Ocf/AFh/3z9K5PVdLWCQxfOqqT3xtH1yOw9R0GMY40PD/i27vtLXzWiku1+SRcYYNx1xxzlT9HGO2dm9tIrvypJVdy21URSPlJI5z27H8KzTlF2kcMJVKLtUPM1hgs7mG61TCRxvi3iVCQ8h4CgAD/a7D7w6dB12oxPJBAPIkjc/MA2CQfUgcdSD3+92rb8QeHbVobedkZktvmZVGSxxjOMHJwPQ9BXH65d6o9+tvYSyRaY3Ek83zTynn5FP8IHTJyegxzztFqok0V9ZdaScSrPCy3sVnAS6gATyOcDnv9AcHn0PHQ1oXH2SGyngtnHmINpBG4DGeAB349vufiGWtirRs9swZSArqGzn8fqe+PvfTMgsY4LctehemEi3AbgMc4H4cjpknK44TOvmWh4lq3gGFdRnuLSRrKYN5iQqwIDjk4HUDIOB7D32+y/D3xQ/9lQxX7g3JHztjAkOcHPYZ7Z9fwFTWtHgk02WeytIRNkOZnbb6AAHPUcHHseB2l8DaZDaaRc3kxDvcFoztPIUcHsMcjtjoPwqTTgwnSoODklZs3tR1qyj1FxFJKZHxvRUJHscnp1Az/tH8W6frsT3lv8AZHQFjuZpAevbj9fz5rK16XRNDsPtV5A0gZcugz1weAB1HXnBzxyc5rzjT/iXoer6sbe5tvsSvIot8oEUnPGWyfzPrSUE0c6VFK0na/c9k1C7XWbO+jlcEsrxLHL8sajnP6j1zlO3bz3wf4aGhaVLbKqg/aXLqSWCA5zkZGQMYI+XO0dOq7q389mVV7ZpFY4YswXOSMcg8fw9x1Ppxb3WxtbMadHOkZmDyNMyq64xuAA+gOfl6HpjiovlXKuoKj7N3SKv/CI6H/0A9M/79D/Ciu08zQP+fM/98/8A1qKy5n2MfbPz/r5nC6jrst9BZx3i5l3/ACPgjIA6Y46/Qf48tdeF7XUNVaSOdUuGPmCFhltoGMdDu79j0HJzltqWwlt7lEeVpTCuI328KcjH4kknp3rz/wATTX+h+KtP8QWkjToHCzxgnCuCAc47EEHvz199nGMk0trHZCrPCU1OPf8ADuZfxF8OvbsJgpjkT5G6nIz3OTnuOrdutdB8CdXH9oz6TqL75NqtBvfhcdQOf6j/AA9U1bR4PFPhhtSt7YP58CkkHt7fTj8u/fxLQtLTSPGVvcvLjy5wPvbSQc//AF+/+NYtKceaPoTJOtUdWHxfaPc9a+1eHr+1vrVfv42sB8pOOQRxgYxn7vU9P4fSNH1CLU9OiuoeN4+Zc/dbuDWJ4gS31DwnLNIQuxBIrZ6Y/wAn/wCtWV8Nbjbc39sCdpVJsHnnoSD74B/w6Vz1PejzdjhrJV6Lm1aUTp9U8OaPqr79Q062nfGCXQc/X1qK18KaDaSRyWukWUUkYAV0iAYAds9a2653VbjVE1iOKJR9lxu3JnI5xz/n1/HKMednFTnUl7ik18zduYvOhZM4JHWuS1iKa1AhhlWS8lQrACoBJA5bA/8ArDryK1NS1yPSbFZrwjf02Drn/IPpR4e8m7U6pJKks85wGDZVQOMJ7df88VpFOKu9jalz0U5taHlF9pt9PIk+pT3JbDRb7joDjoFwc4z0wx498syDS1aWCzulWEonmb9uGlz15Oc8Z4JYn5eDnJ9U13Q0u9XhvpZUWLYInDkAKAScgHg9cc/1Oce/0+yu1lje982BXRhNwTz0XdjnsT646eu6qcx61LMIyiktP0OQtNLlYvLaCREDn5lBGcnB5yOOoHPQ9Dji14c0+OLWluLt/kiJVWY4OfXtjPH90DJ6Y+XRu9SZpFtbCTzFiQKQmMhj249vp078ZieyaSFlldljiOW/vE89B2A5wRj6js231N3Uco2elzSgEc874AEEbnZkcsf738jnHY8+l17hYX2qAN2cDIJA/wA+x6CsSG5e8gXy3FtajJMpHzMozk88dfY9e3botEsYLUQzApvmYFI3OWY9QSfXoT/KoatucdVqG4lvJf3p8m3QonUuSVx9D+fr2461wPxauvEGg2NtDY2twbOZws95aoWKDJyuFHGeucjvwK0vFvifxLd+LU07w7YSLbRFVkneM7ccMeen07HafQ1317dyQ6DJ57AXRh2sFOOSMdse/pWsb0XGbSd+hwSqTn7qVjxX4D+GNVk1K7utTV0toiCglXG7PIGO3b8z617v+7s7iFHJ/eM2GPT6e3+ep653hSwOnabGrhldiXZTx1/yT+P4Cl421+HTYghHmSDDBBz9P6djwazqSlWqaBK85+yTvFC+IdJttWnHnwCQs2FV+RwMZ/LPr2+lY/i+S20DwvqS2bW8mqvAYbW1YgvJIflUBep5JwB7Cruma0l7osl+k0UV2I2SAu5ILnpkdSOmev49+e8OeDrnUtW0rXPERlW4tX86PcTukk3AjIPRRwAPbv30ppR1qPRdAm5xi4x6G/8ACrwanhDwtAt+qT6zKTPd3DAFt7fwhvQAAdhx2q/4ju9NmMTXNnBLJAweKWaMERP6jIz6c/qMEi9r/iHTtOhkFxeQrIiktGGy4/Ac9j6c15zqevC9cmKNg7ltm7kcdyPz5x3HT+HJKVSTnLqaYHBufvSTsSavrksr4ime63HaFCgRqM/THb0PKnj0wI0MkzSymRFcj5SMlOT3+g4+i8Htq20aBfmALMeTt5JH9M4PJ79K1dM0+3kvIHjWVZIj5m6Tlj0+9jHTA/Lv1Ot0j2rxpR0RatrWNII2eLoMoOhxz9Md/TqPTAuIPkUAYzk4xj9Mf5yeRji4iZ/eHceSRuXhe+f/ANXp+Tt8a8yKcdO2M/17jv8Ap8uVzhlO7M7ytzmXaxTaNz+n+9n8OO3zdKNQGy0DwSMiROG37TuT1469PoOOnOa2I44ZQ8kvmIVODtIA/wD1dfTr0HQVbyJCo8vAb7pxx8vt6Hqc8fe7U7kRnd6nO2CJI2448tjlQvcevT6849OT1O9DjzA5RXwTkE5GTn657/3uvfkmnbWfkuWxjC4GTwcdCRjB7HgdvztpKYoNsab+CMkgD8T7fj93p3pt3NJu+xW1HccRRAGad/nYD7oJx/nnv0OMVA0MNk080kMRSGI7Ixzz0H5nHp/F7ir0MYaOea5k2QRKST0z+PYdRxj8e1O4lhuJZpJuLeNiEVDyQB06f73/AH0efQQRevKjg77z2kYkbWZstwCfXPPfp2J4PPOGh054/tKyzKWjdWDbWyemcA8+/B3duOfn1dTuTfzMsQiitg/7uPaW3Hue+Rz1OfvH3BpSW5jjgZ3ClWwCxPyjtgnt0P58f3t/U9OL92xm2wWK/lu5b+9twxDstvJhMkHHy+uSwOSOqnHGT1Vn4sudOks1YK6pct1z84I/xPX36ms7TYBPuiZWSVkJZQuB2J2jt/iOvrBq+jNEYwsE9tA52qZjnaeTzjj165xxj1Cdm7MicKdR8sj3i3mivLSOaBg0UihlPXIrg/iJaXCaewsYmLsdjsoORGep457evboehg8B+K7XT9Nj0/VrhUZGKmRycliTye/J6+5rudWt/tNmTDhmxlWHQ5/z+tc0b0Z67Hz3JLDVeSWx5J4bu9VaVkmtVggjURQRxgAsB/GR2HUDhe3PY9L9h81he6jiRpMBB0XA9B754JzjI5GK2dJ0cRLJJIzRyEHaXX2//V2P49+V8R6Pr0uqWcouo/scAURwJtB46gsT25/IV0KSqS3SOuVZJ2ga8xB0q8iTBHl4HqR3GenP179BVHw+o+xqsS4iCgIh6jueOMfkOnvkzWRUWjR3DI+8n5FOSPVePQ56Yqa0VIIPs+3aVwGUclDjjn15z0/iP4w9E0ap2TRlahDBdW8006LJCrfJCY+Wx3wRyQc4ODnb3zluCv8Aw54OYmXU9EMbu+CIsgnOeMZxn3Oe3Br0m6mRoUWPEgZj1HUjt79Qe55Pr83P6lLFHtaVEaNQD8w3Entx69PT8eraQb2NYxU9JK4lvYaJDbwwxahdQrHhUhcNtTjgA9QOfUfeHpwuzCoIzG6ljlhJ1JAGce+eD23deMCSTU724SMNp8RUnlkjPT/P8uveqsmreU214YnUAhwF4B7Y9W6jn0FPU2UZPQzv+Edb/oKy/wDflv8ACitL+2rT/nhc/wDf8f4UVr7Wp/VjD6v/AHSVLp7a2hkvZdivEBjq2R0Y9j+vTt0Hn/h6xudQ165a6icWj3Uvm+Y/DBuyg9e4A5x/ObxPqt7c646SzyJFGozGrk+d9eu4fi39B6v8M9ElmtBqV7EElHyRopyFGAOvsAOOMEdB0EzvRhzPqR9YhBXe6GfDXUprZNW8N6gjhoS0kDgf8s2HT2wenTqPqfM8aUfFVqdXmcq1zyAmVPoSRyBkg9Oc9TnJ9i8VzR6Hps7wIiXMqmNGUYKAjnnsB+HQ14bpulQ6sk8zq8sUUjsyDKmXaeF7k5z1x3HrzlGN4uSWjFhHFym72uj1lNX+1+GDZREyb22o2dwYbhg8Z6jB4z/Kug+HEbeXeTcEMEUMP4uvX1x0/wAK8w8Pait3ZxsiMvnvgqRnvjbjnJ/76+8Oufm9l8GBU0XI6GQ5OfYc9axrrlTRGMiqVFqPUg8a6zNoNkmoIx8hWxKMD5R26/j1puneLLXUtP8AMT5ZgPnVgVwfx+nes/4qXZg8NzS+UZUi+diFPygc57Yxx3H1rw7wz49julOm3NlIhuG3W8sqkJnseB27HjkdR1FU6KnTUrHJRpU5xSludP8AECLU/E3imC0s554LSEb8IcrIvcHH16jP1OOJJtae11CPTtOid7UqqvExzsYY+ZCP4unrjaeey92kUcGg2Qt0KxTSKkso+YknJO3Gc9/X8etcZphgeWVLUq5WfMhTJywY4yT1z6Zbr+Avnuttj1sOoO+mxzHxFl8Ua/pBsYNW3W1uTJLbPlHlIJ434wSOflOM4PA6VjfDZvE/hvTtXvHJi0+W1eMW9w5IWbOA6p0BHzDqPvD159UMNuryyxlYygOZZjg+uOowe/Ve44xgcx4y0e+FnEyeY1tcLv28r5R7ZGAFAwM8Ljb26C4zvZPYn6pRnU5trl74azSC2lCMXlzksFwBu6sBjvk84H3up/i7C4gupLYxxqZBIcRkfKD0+YnnP8PTOcHk1w3g9J9L01xeyIszyMQkZONoGMDP1I6fj3PoXh8NM8azBXQhtuTkNnrgc7s56/N1HJzk4yd3zGmKXI+ZHO6rBeSappmmafHLI74ebP8Aq/KXrvPQ54GOfu9O1dNJoWq3DxyXsUK+XnaIXPH05x0yO3XpW9YXNujk7lMjMRuxg4z0zz7Y57+9azTYTJ3N39MZ/wA+1TKq1ZJHk1K8+a6RmaFpsNhE7OkhuHOGdsbjznHsMknHT5j9TcS2jnnWeVMhDuRD2PY4qhqOrJbwkyK4wOgH3fr6d/Toaz7HVru8ZvsjQOijLhn6k44GM/1+prNQe6M/ZzknI1tTmkWSR4n24XB6/n+Hr7HkdvLPEVrqWo6vPBFHJLBNGMNnaqHnOSe4Hb9B0HeX01yIy8gKx5+Yep4478e/PXt2yrv7RFDJKrPGmzaz9cjPHPrnHU8c8L0G1J8mqOqjTsrXMSwju9PRL3VIY3mhAiwXwgYZJ4xznnrjlhxzymteJtW1bKbilswwfJVkGDxkk9j6f7Q6jG4t51l2G3imZwu1YyThRn75HBGMDgheVPApkttcAr9sVs5OACce5xjtz2ydvU9Wpu7uzvhSgmnJamFZ6SbyVVheYtwQ7Rkh+mGPXP8AD3PXqc87JsLewg3eY8jOuAdoJI4xnsTjb6429ulXGhkESwqhIl5wckFu+OCD1YZ+fqOWz81aS0mv7hxFK7TINoZG+Q598nghj3b744PQl7m0ql+ugthpkV1f7bmaf7PHHuAQ7Sp/uk9uvQ45HQdB2NtFHag7INsrKFJHQDnjp9fTr785Oi2C2DO7O0twQPuMdqg8556c4PbrWogG0nB2HnGP1x/9bt19Yk7nHXlzPfQldt5Vh8yE8ckhj6/5z1/Esm6xld3LY+Xv/nCnv9DTopVVCCNsZPPOefTHr+fT8TWeZX5xKyAtlxnjJ6Zz9e/pweplGCRoh/LiAc7CgGMcAdPy/Tp/3zCLdZIB9yNzyEDnBH0PIPXnHbqOggS6jIQOsrF8FBjO4k/oDkf99dT2v3Yto4VYyIkucphQxJ9Rj69ff8AbEO8XYpu3kFvO38uW5GMjHTPfv379ulUJjLmbyWXdnawP8C+/v+X3u3e3OZTEzZVWP8XmYOPXH5dT26DpVSNVinXexDgbQpPIIBOMcYAxj+H7vaqRtBW1LcMDeSVmuGIT5hGkfAI6Ent2Pb+o57xHOERbWEkGQPIylt3ygcE/z4z9z2ytzXbyZ4Y7W0kkQjDSyEckknoCOgPHT05HWsy20sXYLTM3lZAI5Yu3X8efr97tjIqKtqzakuX3pEuk2kUqh3TCsNuM546YA/AgD/Z6f3ZNft4NsltfWJSdB8s6ZT5ecZHr94dB/Sr9s4WaUxH/AFO1WlJI+Tr8p9yBk5HXpx8tyCPzzu8xBCDvwXJYNnljn6dcDoeeyl7O4pVHzXMnw3psWmS3EqFppZkH3l2AYz07475/2uvrpXJjlhuI53JV1MTZGFYjkHk84OD371cZNuNw2EgHBGO3X68e/wB3r2qJFMlwzZXHLsWOAAOCPzyP8Km93cydTmfMznbrRrcTsyyKJQoLKFC446dsYHPb7vbGV2bGX7PHDahp/wB4TsRJW+VQDkYP484/h/JklsxnF1A6CREIDOMKB9eMc+m3r26iGKNrZtkc2Zp2yXYnCjjHGPoTx68jGVvdWHOXOtdTespXMbhTNIp5zI24Bsep9fQZ6968q+M3jg+GtPNrpzR/8JLdqGiVuRbRnP71wcjLYwqng7iSCB83rnilrzRPDF7caFpT6rqEMJMVqjAGZ8dWyRkdyBkkDABOK+IvEk+p3Gv3k3iJrka3cSGS5F3GYZSxH9xgCAAMKAMAAAdKxU+qPLqYj+TQ+grD4ueHtR1/TNJ0mzvgLpxCLqZBHHDIwyoC5LNl8LnA65yR176xti1ozSyMu4ZLjksf7x9cc+uMdR0HyJoHh/XdbuCvh3Tbu9uYGVt0SDZG+crudsKvI7n86+v7fVnQiaYJHJPgeSG37f7w4zuOT1BPt6Bxbeh04erOcXcoyWDRzSP55SEnL5AyRgjrx/tDqOg4HSoLjR4/KjkISXBIdWc/L7H/ACOvv82qZTNcDyW3KoAG3jbz39OMccY54HQN1N4gj+UioY1w3+8MjOB7ew6HpWibOtVJXRz8k6lFgiBikwQyquQ44wSeevHPP3+p6tRtILWSKURzpIwGQuCfMY4/j6H+E9+p+pfcxT6nCtpDtxKclFB45PPTpy3GD0H/AALE1PQrnSri4nutTAEaDaigjcx6rg9s57ntx3bVJbXOuFtr2ZN5Cf8APJPz/wDsqK477fqn/QSt/wDv4P8A4miteXzN+WX9XPb7zwLBea79sdEyrbiwHJHp1/DvXdW8MVpaJFEoEajAwAAfeplTBbpgnIGOn+eaZKoKNgAgjBzXmSqOdkz5WVVzsmeO/FnUJbqKVYATFjYu3gknHIB/+t39KwPCOnDSNGFpJhdx8xyBkEkY+nb36e5z6F4q0aOSSZ2TcyguhxgFhnB9z19evtx5TeXk2rWnn2Ezi3DhZEXqcEbs/Q+/TPA7ehTfPBQWyPUw0YxTl/Vi3rWoQ6WI5xvmWS5ECRRjccsOPr3656cjk59B8CaoZ9VitL0sFK7oyzkZZe3B/Q/lXCaat0sjx32IST5kcY4K4HOTxj8x0PHcdBpcM0dwylVRoQSVwcDJ9eMcA+nTn2zqx3TOyaValZ7ne+Mby3vdIutP81R5gMb5OPwB9ef/ANVfNENvDZJDot1OFhtQySMcs7yliVCAdBgA/j1BxXsV1o01/cK0qbbVVyitJvJYjqeuR19eo69BSTSBe3sUcECzXMpKqcD5sdTnkYGScknG7p/CboVFRVkcdPCQS1e24lrrd3d+HLOyuI41kAwAf4zt+8euTxnvyPoSSxJGn2W0bDthpFjHDMeu7nnuAMnoOD2uarpP9nSol04aWVsYReFz2BP4egwTxz83WxWVvaQ7YI0G0Z5Az0znP5Ht0PXqcXJLY6/aQgk4rc4seHLg7H+VmUYxJJgqO4GDwCeOoHIx0wsttPfaepHnJIoAGyVMBenIxgdccgDqeRjA1tS1OEyRR2ah9o2YIOc9Tjjk49v4RyeCKuoPJc2aROSYSM/OoILHnC+o6j+Lt9Art7minKSXMtDjSsVzqaRxsFG4kFuFHO7B7dcevfpXpem3Nte6bB5UW27RSZFxkDr8oz3wO+enOc8+d6naSwHzbZ447WPl2JwWbPr0I6nGT17dK6H4dXsl8ZTbt98tICDkIcYUY446d16NwO1TV1cvFx54cyexU0fUptT8U+I7f94slmgMaEZwpJxz+fHpj3r1e1Mq6fatKuZGQbsdjj/PSvO/CumhfiTqtiL0TYt4pbxQuAWwQvYen/jpP09aODkDGR1AqcTNXSXZfkfOVKmvc4fxEjBiynJbhF28gZAP+fc/jqxWlva2AVYo9/G1YwBjHt3PvzmsHxt4u0fQNOuEvJlkveQkaglnPp+Z98bvwPJXPiy91aPSJ9JZhbzwrLI4ONh6MpJ7jjj3+6M/NUaU5RT2R0wl7R8q6HTaveySXCQKvmS9NiseD23fr1z0H4Q3OlnIeYqmSG2h2wc/3eRgZ6dO2MYwLvhm8t760OoG3dd85gQMcYC4yc9fQcgZ2k88EpqmrRNqUi3LESkfKoXkZ+7z+GM8crwT2nVOx1wqO9oozSGtFeK3EjkY2kqFBb1CgDAOR024yemMCKOJrq7KrILfJzJu5/FSfw/Nvxma6Z5GiaYrOi7zEoxkc5P8/wBOeMDLCxSEsWMgZl+QscMQTkj15z3OMgYGMU0dcU2jV1WMLE3kyOYOhGVY9cDJOdx9sMeD6knat9OezgCFdsgxuUknaSOmc89SOTzjvXhsWp+KPDnxAm1OfT0vbV5CojLZi4J2FSOVYDaSDjPPA7eoWOtanr93EZY/srhd88Ktu8n1VmwMnjPQfdb6iqlNx66HOnOa2sl3OkDZQKRGSoxkcbecYz+P8uaR/uM6lexPOAff/PqadHFkYYkswyARj1zx39O/Tr6RP8oLDLIqnIXuOhHv3HfqPpWRn1FudgjYQuAAPvNjOe317ev8XH95sDqwjEjdRjOcjnj/ACOOnvkuJjj3bwGAbaSQcHOcdfXJ9PvfnxGo6rc6FqdzCxkk85/NjRhkMB/EPTqDwO5yR/FUY82iNadN1NEd7OqJMseyNpVG8uSBt9/yz09sk5rFvb1XdohJujB/hXP4dec8+p5H0qvYao13pJuZoUtVcFFBJJJz/gBxyflPTrVe2tpJjJN5MgyQucYI9efwIwfQcd6FG244U+W/N0LER8hgyM7pt3s8/wAuz0B745HGe/A4xWhYRG1xcyMPMfA+UZKr2wfy6YHXnsbWm+F5Qy3VyomnYBmLOWUewB9vbv3q3qKqsDwHDO33O5dvXoT39/vd+hTknojOVaMnyxdzJum82KeRRhVJRUC8j2H6+vTtnkSSLT7Vncb2UFAij7x6AY/Pr/s9KW2iljska4jYRFsCdD1JxjcM+vuep4OcEWIxmWdGAjj+aSRzyCe3sBx3H3T+LKutiiqS38q+aUWEHDBtwOMHhQP9r12jGD2GNODfBDHG0uX6At/Fz1A7D6fnwMZNjeRfYY/mJ27g2CTtx+XI9hjK9RxVyyfzpTM2WaRPu+pzjA4Pr79R+LZU4vqacs4dzsAAXqc9eB/9b1PWktSFuSGbBZhubOcAdif89KlgU5UqFbflQZCfmP17Z9/73Q93MgjTLbQVOScZxnkE/Xr+J5OeYOa/QsXUyLvXaGySAwPI/vYPbuOMduR2wtSCqY5+dqOGABG0HI4xjv1zyRkdMcW7m7SOGLahWIHaoPLf73HXH/svX0z9Yn8zSZcAguNv3uevbHXGCOp6DgdBUVqOEWjvdLvk1G1W5jA25K49x1H51j+KtKtdSt1gvrS3vbQ/6yG6iEykfRgf0965z4cma2urxI7mX7NGxMtuy5Xd6gnlfpwOfz7OWZbh+Pu4yMnv2/Hkfn275yhyTstjidP2dRroeaWPhDRvCM97d6Kk1kt7Gsc9mszPCWUkq6q2WUjLAYOOTx3rX0RG8yW4lG12+8c8r68nv1HX044+XVu7fz5j5h3Dd8pbuR0/TB79+B1N2WztotLMwA3vgZJwVA6jt0A9unbGRd7Kx2RnGnBRXUxY3WHBR23zOXLvnnJxye36YB9vlz9Zc2+qMEK+WU3b85Gc8/j3/H2wLwlje4gtJEeOOEky9xu64Ax0wD2x8o54+Vl9BamdzebvKlbac5O89Qc8++OvpjjApaM1i7S1OcvLqaHTzJHObdQm0yoFVTjpuyev1/unjnFcbqEttawJqGoXKbCSUMsnzE9OATkgY9hlffnotdtLaO08ydZJ2ZD5cecAZbC5/NeOPvHjsfHvEPhPXNU1n7RIU8ltqxO7kBV4GAMZ7jp161rey0Vzt5506fPTjzM6z+3NN9YP/Hv8KKyP+FbR/wDQSuf+/Boqub+6/v8A+AZ+3xX8i+//AIJ9j8knI4+vNBAxnHIzVXTJxPp8EihlBQcNyelWW+YYDFSSORj1968u1j5ppp2M/UrIXKMNoxjpx+R/z2ryabS4NP1trby8AMNy5xxnI7jI7de/bpXtHGTxyeTzXnHxCtCtwLiOPJK7GxwR15+nX9OvfoozfwnoYGp73JLY5fX7i2jsBcSGOOWOWNVcfIVUkYB5GMkKO3U9McVdG1S72yHZtZvuyEZBxyCenbHYdOv93D8Qade6no8kkqn7Lne/l8kdwR9COoz/AA89K7/4L6YYvDkX9sMLmZRy8p3BsnIGe+B3/wD1Drm1Cmm9TsnJUnLtb+v69TC0rSvGniXVrdbjUoYdPjfzJFto9q8cbSxGT+v3R68ewaJodrpSZjBecj55WyWY/U849qsPPb5gWOeKJM/KFYDOP4f6cVy/irxJK0cln4fuIxd7hunboMckDtn3+vWuScpVXZaI4HKrX9yOiOO+L+orZ6/Yl5WihmkWMyIQGUgYwB3OWxjjgn/gWzFdT/2bBFcSL5+w7GBxux/EB2654xjcfqeX0/SL9r6W71thOWGFY8lj7A9AOcEY6Dk9K17mS3naGO0mFyx+XdG24A5I4wMdj7/StpWSUex6saKjFRvexV094ftqyyq8kIbhipOWz39SCM9D06961pXeSdhJ80RyBt5B+h5yf++vujg0Q27wwKPKQ7wdzso2sPr69ODnvwKznuprWeaO5B8jpGD8xXpyc/UcfXg5qdzRpTehtWWjaNdwRnUUxaqpiUCVlU/iD09PqOO1YNtc6d4e1k6fps0McxZRFGJMFs88Zx3xxx949Mcb+naxbT2KQSxxBV+QBm5PHX2/TOO+efIPiB4K1PUPFlrcaKfOkuCsMib9oUEn94pGeBk5xzyMZzVQV21I53zQ5nK78j2PSdS0y21m5MUpt755g04YAPIQP4s9unQevodvoEckcq70IKkdVrwDxH4Ov9N8U6Zc3F751naWiC6uW3FmZQBvAHJJIPr1Gfb1+JGsl82DncqqST1wOCf8+vHpFenGycXuebUp+01Whi3vw28P634hm1rVbY3jyEDyndgikDGSufmznvkdKtaz4SsFjthZWUEUUAMYVPkCJg8AjtyePfPseg0y8VoSJGVHDcqOnSq/iUiWxMLSvEGcFmjbado6j8an2tRySbM6alTqe6cdp6yf2OyRicxW8xEe5RwuQSwx2OQc8dW9Mmobdm1W6vZbhJ2MYEe4ENF+HTkAHOM8Hk1Y07R4YLu5uLHUr6HTlVmZWkJRX6cZHTrz7jkYqhcwyF82MySxoRl41+99Tjrn68Ht1rV7uzPVpWbKF1cSkMNpDfwsuMt7Z/ixjI+9yB+DEP77GxwU65bt/dzngckDJ/u8DpVqR3OGUEzMQGO0HIx0PHH8Pr0PBzWdI8YwQrI+NowDgHtz0H6Hjoc8tHfFJofOU8gvHGMjHyOxCkfmOOQP4R82eOK6LwNBsszdODvlkK7ioVsDtgAAdjwB1PpkckVTytzyOzZBAGSAcHpjnjJweOcc8jPY6HdJ/ZsHCNIo+YA4B5PT9enqORxSlsTiFaFkdIsYIxu4JBOeQT/9bAPfof8AgMEiKdp3FXUBSw6gc/4f+Ojg9lExjIwykqmWJI6/4/yz0GPliuZVDqyKNi9dzH688ZHb06Hr2yR5qi7lO5VlGDHjCsF2noORkfmQMY7fSs+/tzckwvGsrg74fMXqemR7c+n8XUVsJLE42lWRTypLEjkZwAOfTn2qhfW3l8njeM5LE+xwfzH5dapM2hKzMW6E06qJj5WfunOApyPvc4x+PGW4GOL+k6mbBHDBpNvQH7ygcnr29Rx0PHGRBLbsmzKjBztBkwScnk8jjj1HBHpwl3cafYpEdQiMZGG34PGf4sAZC++B+GPlu19Dabg1ZmRovi3X/EOvNa3FxcaMICS8MB3l1GQAvHA4Jz14Hrmu3S2SMMrK5BGDv+Zie4Oc57/3uo655zp9KsoLQtabHcLuWdZfmJIGCp/L8j07Z9ja3yu8lxqdzLbjpDLsb8C2M/n/AHelVJxn8OhzRppL3NjvrWa1hjK3Ei5wQ3UgnvgknrmuL8Z6xaxae1pZlk3uZH5I2oASPcA9cccFueCCXErBWaNCWxhcsxCg++cjv6fj1rIi0mWVbmW5VdhbcSRnPJ6e3U9P4uuBxnGKTuzShQjGXPNkfhqwkv7kWykpHu85jjhfRj2yOPXv079slvEjuWBSMAK8hzkgDhfc9cDnkdOecnw+qQW0kqlQXJjZ1PLYPA/QcZPU+nDLid5JgN7B8fKnJKehJ6enXHQ+9N6sqrepLyNhZQ8mYlk8vpubr1/Tvx7rwc/Nbup0NswcjncSBzkZ+nP3v/Hup6nJt5UiEKlWL7d5VcsVHY+36fdP42JWe4C5UJATk9SSOwPr+R/qZsc7jqVHRpmbDDaGBJdTh/r6joec9+va3PtCq20E7dpwfw69ug/75xjtVWG4YTXBQq7A4LHABz/Dz0/Pv+NToqHcvOAcgHPX/OD07nr2bKaH6Qq6aZpAnysu0hT904+XA7eg4Hb1wbnhXzpZblbgiXcu9W3Z8zB6/r78EfjRKHZIDng5XvnjjjHb6HoevIq/4dZBqHlOmMJ8uOACT35/qen5qWzMasVyN9STVT9naNUyTvI565Pcn/PWs7V2nGniO3cDCZXngerfXv279OtauupsdAFJ+Y7QR6f0x/n15i+1iE37aZLOZb0qs+1VIVUJxxj19vXqOxBN6oVJppMEiH9twyxErAQVdCM7TgH+g9fu/iJNalYxSMrbgxww6/8A6zjjHPQcdq14LRbWziiWEBlcnzGHbHGc/h19TwO1HUdJaa1Miny3K4Lc/L9f09P1OXdXNlOLd2cxqt0buZWkhXYwCoc8D/a/nxx94dc85ZktZLryPtMgxykobImx1Oeg3Fie5/edemU1tbw3MVrDuSIMHKn7rHOTjg/oOw65+bGncWV8XYiSQ4UorZCDHOOTkgk/3ug68bt0tD06UE1odXtT/nvef98n/Ciuf+03X/Pyv+f+BUUrMr2K7/19x7R4M1f7dp6RSgLIo/dt0EiYGCP/AKxP1NdGRz14+lfLvg/XdY8NNFa6lb+fY2jeX5inJeM/dIxnkevPXGfX3fwl4ibUU8iZ0aUDdGWPLr2/H1/kO3FUptO6PCxeBlFe1S0Z1Mz7I2Y9BzXk2v8AiOeXUmglhJhJ2kiIkrk4z39u3ryf4vV5AZIiG3Jkc7WwR9DXP6xoGnFJJriNTnkJ3Yn07Z59O9FKSjuYYOpTpyfOrnFPNbWlqLeMgo6Aoc7hg4+uf4f731Ofmqvrn2HQQtvH5jNu/doOGwDgcd8cdT07cVf8V6XFpUVrJLva4uSVAwWL8cDjPJy3Xd97vnDZ/h+PdqU9rMWQxp5hw24nOMA+2SOMnqfx6Va3MepHllDmWp4df+KfEmuXoL3qoI2bEaDakeOdpPGMc9x+Few/CiAaxYXGoyb3EAAmhOUO7JyB6dD2Hbr253xF4CnbX2ttAupYZZ8s0ARTsJPVWONueD2xjjHWux0vUPCvhqdPCD6ikd5NGqyAHB34zy2Ov5dOvca1nFr3f+GRnzypw5W9/wCtP61NO8uread4oAG5yh6gZ9MfhyM555NY+i+F7Tw5ZQWGjCWRUkad/OfkEkcnHXgDjnp1HIqW50w6bcmCF3miL4HO4k4OOecnr2b6+mnbveto920rIZAQhkkON4I6g559uv8AQc7S0/ryOnlUUpRf9M0zqdjH4fVFIdU4YAYYuCc9+o4HX8q5fWJXLhnADDP7vn34OcYHJ4O3r09F02aOUyR2sgESnO4t7jOSSPyyO/HalaLz7hQgKQgY2Hgrg4HpjHX+H7vUdmlZl06apO4aHZ3VzaXGEZmLEKhHXPP3ccD14H3urd+i8D6DJb3M93ejybkMfKjQ7uMY3Ht3HqeOpySX6dEmmxRREsrnLMe4I6n0x17fjWp4b8QWGqTvaQSsb2Fm3LjG7HUj1HPv1HJyMzJtp2OPFVpuMuXZlmSNjcgyGPa0e3d1I/zx37fnYtYS5KsVIC84/lj/AD9PS1cxKCHIP90n/PXn+dZUcgs7gyEOGGCxc9FP9Bj26fjWa1OFSc46HMeLdXGkaoyRy7Y4F3SnrsJBwPbv1x16nHys1rxbaS2ek295Jbj7Ynm+bI5GCM7cKOck9+mM8muQ+Nmt6IkF/b/25FY62Yw4t9rSuCFBQMqqdobA5O3opOeMeaaV8TWXUdHm1LRrJo7KMwz/AGddxuFz12Nna3bIJz27AdSdK0U3r/X9dhe05WuY+jodOtWijubgi4geP5oORG/QZb+8ePf7vUdDm6lfxx3YtNKSGOJVAcINzMR1UnoNuOnPQdOtTaN420DxXp7f8I1dQMIVBltnO2YA8fNGwyfTdyDnrXPWd00PinXLSCGQOsMEpmcnY6scbQwPDAjOCe/QVnF3TbOzD+8+ZjnuLxZS8aNG4G1lUfe5Ocj/AL6/u9Rx6ZUkjSp5tyGXeDmOfMZGT3Ufj6Z3dweeilthcNuw0ZDbcseEGBxzg5HX+H7p6dqF9GsKbXDiUZAA59c8fgew+7171SZ6dOSMQNmRGggZ5WK4cplmU8DbjPqvODnnls4brdCSVREy2rW8Jj8ySSY5cHjGMk5PK92+77/Ny8LzW6BwsiKSTwoO85OSM7t2RkZ+f73U5w0o1S4b/lrLdyP8u92yH5OBgHB69Mn7/fOHppsurCU1ZHbreoYiynZkY2kjI/3efTvx90fWq1zd6gjFY44Agy290ORzyAOP9r06jnuMyzRo42eUOJCM5cjJ5GOO38J7dfzv2pZ545Qkqx4x5LDBDdcjp7HI/u9azscbgoklveTSNGkrKyvkr8mCfXpnPfoD1/K4jAwrtVGTcNxLHByeDn8uM8+hpGgtYYy06sqknkndnHUEY5788ngUySaKMmSSGTy3XBfeOhycYz3z0zzu6GkZvXZEd3pjXMRewvnsWjJcSqww3bGG6DA68fd71xo0++aWQTRXKWr5kNzMf3qj09PbOO2MjoNnUdViSdbfTv3k+cg7gx5745xn177urd+F1rxf4isL2W3sLeC5tWIxvUNI4GPmw2B3HOT+NdNJTeiG6UornZ6PpEP2PyLXS7eO7j3jfHNk5J+9g8c53Z6gei9B6ANFsBkPArF+uTwPYDt1P5mvDPBni3Vr/dcwWMNqigATPEyAODjaMtg4xzzxt7dvTdJ8S3d9dS295b7rxFBhjgGMnncCxxzweDt+6enbGvTmmc2IpzklOD0NTUNJtoEDQx7JVYsh5I5Pp6cD/PNYd7aTTr5JYbiN2zH5H3OB7/d/GtjU597xmYyDJy0b8ADoR/n26VRstStZra4lR1Z2nZdpxkAHAHv2Pf71Zq9ripSnFLqc8Y2s54wUYoxCDnvj1z2x6/w8D0srZybm3ECYkZXGNo/iwOMHqB06j0wsWvXdpdXUS200cjpy7joAQMZI6Z44z/iNC21MiLaCQyrjceq9OTjGOntnb1/u3rY65Sk4pouxRxwRBYd3mM3ORt9s4H4/99HkYwImLynbFyQSAw4JA6n8ev4npUUFxyXcnJ5Zj06ck/TBGf8AY7YwtyOSKMFhyT14wPz/ADH5dOlSY6opwWSQAr5YUoMsTjKZHb06eo+7071cHyvhlKlRll/uj/8AVnoOw57hRdRyMmx1AHQAc9fT8vTr+eXqN9DbeWp++5ysQGTjsT6dj09eR94GrBc03Y0EfzJJMr8rDhT0PGf159Tz37R2MiwXwujOFj4LEc7ien0J4+u48Gs/SblRb3BLF5nzkgjnA6Z7/d9T932ysnhKCLVtZkFxCskEMGXU/dBLEYAPY/N6dB7YbVk7hUXJFt7GvrGt2sfibR4GmBWcMiuCNquVyu76gcH68noeYvtKhHjWDVijrMYRbMAcKFUkg/r/ALXKjnitDxjDBDM1uYVK7vNiUdcjnOe2TkfjVzTYG1WKO8uYhFdSJ/qiQSHxnn17evf3FWrQimu1jmpJLVnRW7ISykDDDLZ7Y7fz79u1MkLQkBFdo8HKge/B+n5Vz1ndNFfTW8xZRAFEikY4IGOc+mB2HB+g6mGOO6tjuACkcDOCB2+mPw6VjJcu5E1ya9DkNTskh+03TgOshBi3LkbgcfdI/iz2B+8fXny/WXaPWjd2sYlRXyowTz2z1znKkg5+8eD/ABer+ILyJYH+3OiwR5k2ZzwM9fQ8H16DpXhT+KWa+1K4SPfp0MbEuI+WkOcjJ5wfmGPcGuikm02evg52XvHb/wDCV6h/s/8Afo//ABdFeQ/8JhP/ANAH/wAeop2h3/r7h/XMJ3/B/wCR3VxayIbYXS5jb5hICeQR0Prznjnp3p+n+LNW8MzwXlnHBcGB2jKPlfNRjznuOmRn+XTQ0pDNbCN5leNHAHy5Zfrnt+XTp3FXxPYILKa3ACyuFI3HODkjb+hx05UdcfLnHVWPTqclS9OaufR9rI32KKS4b53UE9M89uOtMW1jmukuLpFM4BCKTnav+PIzXkPwR17WhfjQb9DLbwxFgHXBtlHoe6k8d/r2HtWfU1w6x0e58hjKDwtVwv8A8MZ2taXbavZ/Z7uNmQsDlSNwx6GvA/iPcap8PfGtrc2KeZo7IVYytncpPQntg5x+ucmvo0GsLxf4dtPE+jyWN1lWP3ZFAyv/ANY1tRq8r5ZbMihXlSa10POPA2sWviS4e9jj8qXyQqqT8wPQk+59ePvda4CDwJbz/EBb66ubm4u5p3nSAx5WSRMcFgM4HBxxx9OPSdE8FR+E7mYWk8l6WIKygAeXgbSABnnt07DnqKsDTrs6u97YCVXEgk7ABsc9+Rkn1Iz26Vs2tUtj2VKlN8/lpfuTTRl9Gd7siK4AJeSU52c+nc9PXp9DWPJqwuLCK1sJnkXAMjSod/I+6fQj0PPA4NbPjKYvo93cXKbgrqFAPU5HHpjOOD69PXK8O/ZkMUsk0Ecs0xjRZDg44Pf6jjjrnBzlktrmlO3JzyFtbT7Jat5QjLhcghsZPU4J/nx972q3oqO15bqYxIwYcAYAI7jpnt0xw3UY+We6iZMjYVRsthR9w46/h645x1PWuZudTlsZwgHlMHzHj+MjqQB1xhumfujkfwtK5avVTSOn8Z3FzaXMHl2haKdGDtjOCCMgepxz3/Dszw4v9jSy3EMcTSyHaksq/Mqn+DI5+uc/d6euNfeKNT1iJYS0MUDD5fKX52bOM5JwMYPvz0B4VfBdo1vf6mkbv9kt5REqyZIklf5mOTg4yRxwOTxRZqOpi6TjS5ah6FLqUtzNFEVDFzt2Ln5TyDn9frx+OxfW6SW2xgSRyp75/pWNobWs0NyltcRzTxOVlC4OxsDg++CPTv1q5qM8i2DtGcyIpJA57dfr+YrFrVJHkzXvJR0sfMH7SNglp4q0rUA6+VeWf2cs5HMkLnP5rIh/A15Zb29xPcQ29tbyS3MzhYoVU7nY8gAfkc+nPSvr2ys7uW9kuJ445CW82JmiBMfGGK5zg9sjtjkdKxb3wzaHxNqmtwhjrF+I4N78iLaiqVA7A4UtnJOcYxgNbpq+5o8LzT3Kvwp8HWPhDT5b6T7Nf604AkmdMBF7xoeoUYOf7xAPTaK7vVza+R50OIHjwHCD923/AOvJHWvnvxFrHijwnqSHVLecWwfEcxOUbOCBux9CVOOp65Jb1Lw3rNzq1vbag8qxRTxI0cceSEH9fXtyOrVvOjybM6aUIN/u3saNzLuskMKI8ZGAQwyfQ8crn/gPXtg4w5HZ5FjDCWQN1yfUYJ4+h/Ppg46A2iTWUsVrb28F1JIZZnRdrSdRu9MgKQCP7q8jHy4nlLbQzebCqKjFGJP3jk7uenqMHOMjAXGFlHoUZLYzhEonDt882cB2GdntjH485+70rT0yJLa6d/sqCQLjezAkZyTjk9Mnv/CODn5slXniuGf5SWYKdoKbunU8Y69OMAn5R214nCxqplVCCMMynK5+gyD09M88HrVM6Kl7WOJudN8WeMPEbGV5dO020lIyr4Q8ngADLHrz05688+v+GdDbT9OjWa+nv7gKQbi6lLM/07Afr83WublvZrWGNLOJLd2G4DG9jnnJH4E856dT1qsddleUrfLdZb5S8bgoByCAM89Gxyeg4GCFc5SmrLRHE8PKV2mb9z+4knjLO0aZRGVcr2OSeh59/WsqZTK7b/OMS5G1o8oB6g9T9OPu9+MzWur3FiPO0oRzbAQVkUKGAPAHIwfvddvUcdgs/jK/n4uYLaWNP+WMmQQ3HIxnd1H59R/FCTGo1E/dVyvLaKkTBIJY3fl2Cg88nauODj5ucHoOTn5orfSv7QDNqBEbK2N+PLJHo3JBbrzzkY694bjxJd3bbBGrF/uIsZwOnXOcnlTxu/i9ctYjl8vTnmuH3SEbI42yQoI5PUgnHqe2cHqa1Rq1NLVDYUh0nTxHbwhoidsa4LZXPLADnk8gkj735OGuWQg/d28j3ORs35DLwBnIxg8dsd/pWXa+dczXEjPPHGFCl1G0BeRwe3GcHA7deosvZWmnQfaXWS4uWHmxwRncz+4BBzgZwMHOQMnpTdt2VyRWjLc2q6/f2bNLPFsbhRJGM4GMYx1I9cHkeuAeLm8Z2Gh+Kng8Q2F9LDOyCS6ikC7t2RwoGTjPPOeBx69zFFdao5nkIWKQjapACk9Bnk5POcc/ePH8JsyaFDHcQ3E8UEs0RBSQqDsOAB19Pl7j+L1w7jKMdGjnqpcvJHRl2+ismnf+zbIWqJ9xUUpuHfI9fvd/SqcYYYULjJyFCcNjngdue/vnPHGpbQ8Esvc8Hkjjrj8jnHbr3aMw/eVWKEt02kgjr19eD69B9ayuRGSWhDGQIxuYBWAAJ/jyB+JPA/M+mFvRb5FU7yFIyCRkgdifTjHp0/CqxtGkk+ZlKEkc4Jz3GfTqPxHB7aluuz51IyvPI4yenb3HpnPfumzObVtCCS3ypbDqOhMeVOeen6/kPXnmLzK3M7M52h8MwPJOcd++dw/EcjrXYXJVI1fOAQNrZyeO/fJ6evQ89jxOrTlnk2pxnOPUexzywxjr/D0HQ1A0w7cmP09ZQkqRSJGAMHjaD045I/2Sc469Bjjuvh1ZrDpVxOA372TapYYOxeBxgfyFefWsE90Rb2+MBkVmIOFZjtAGMHrx/D/D0r1eys00XRILNHMhjTBdurNnLHj1JP51NV6W7mOYS05Fuzn/ABhYRXUyyBikwbcGxwcdv0HT0rMh1K3t9TU7xHKG2nHGCRz9O/X1HFbOqK11A0qlfJQbt/8AD65P+e/QV8zeNPFd7D8Qbe6iuV2QSKUEZ2qRnDZ98ADt93PudKUeaNm9jGLjCF5eh9Fao32S7sbyEgq8gS7VxnfGQ3XHoen+9+WjdXJS3xaZEMiBgoGD65/z7+hxyPh/UL7VLyKFRAPPO4EZ2oDnjp1AXjHXaOT96u0+yxlsb2YhsAZ6jOMe/Q+vb04ielkx1IezlaR5n4uguNR3W3nSpHIBvZeDjIwB6dF/I8DGBgvoNrDbRW1ouyLBxDL8h4GSzMcY6Dngnaa9V1SzUzCQqymMZCjjBzxk9s8jqPvdOMLSs/D8mpy+Y6RQWwO4yt1PPBC9Mn6DhjyOBWiqWXkdlPExhHmseP8Akx/8/tj/AN+Gor2b+wLH/oIJ/wB+P/rUVXtI+f8AXyNPr0/6TOE17S7nRdZuBbOysjYQ9MAkH09cen071HqNtFqMRmfq+3Kjg5wOR6HIU/8AAep6j1Dx5pIuozMCNwXk45PsPTjv9Px4NomG6IruikyGA6Fu5B78/X734nGMk/eReGxLq04t7oy4fiBaeF9StLKcyC7t4wWZUyJARj5yPYAdzwPoPdtI1KDVrK3vbRw1tLGHzjue3sR3FfJ3xCiiudZ8uSAx3YRZIrlSNk6ns3vnnv1Aq18K/i1deE3TTry2lu9PkmzIu/Dxg8EoD1Ptkd6zr03Fppaf1/SPNxyjPV/F08+6fmfW2RS4AHoKytN1WG/liltJTLaTpuQgfdI67j29Me1apUEY7elczVjypQcHZnmXxi1G88P6bPqmlxO8rxMDhdyqRggkYwT06g8DFeTaL461JZdMnmvnuLXUHWGV5MEpN7dyuMDHP9D9OajYW+o20lvdxLLE6lWVhkEGvMtS+CnhpJ/tdgk0GxxL5PmnYSMHv0z39uK7aNamocst/wCrHTSxDi4r+t/8jU1zTpL7w7E73AQkCR4yMDIByv4ZIxx1HHY8/faJYzpp5vbZZkhkWWPr+7YegHbkkjjO8derbOlBQ10ryGNF5Jxnyxzjj0xj0+6fpXLWesm18QXGnSyEkQfabWNm+98xVj/wHHb069cpRbTR60E37j9TpNRuox5ZcSNzmNNnLdDk9c9j369e58/8Taot3cnylddrHJ+8Cew9z0/vH5Tn27p4457bdOW+ccKowx/E55yT6nkfVvPNZiaOYRojybpPK3OQxbJ9ffP47uhzmnBHdhFFSMaLxUdD8RWAv02WVvHmW4KFiSc7YxjkdMdTjA6YwPTPAvie11c6j9htbp7VJvM8xsIFLZyq9CAPw+8OBVvwx4V0PU9feHU7OG7vLKBJd2wFU3ZChvfADDpXbzabpmmWzRwQwwLuD+XEoXLdM/p19vanKpC3KlroeVicQ5VmnqinpscUU0gsrcQK6mV1VdgkJOS/4nnPvz60skzJuij2lpASzBsgjHBHX8+enX0TUriFYivl7mwQrDqPUKex6in6VBAdIVI8mWP5GSTDMpx0JPPp+f5Z9LmDdtWJaXDLG2YwVIxtzhlwMY98f+y9ugywEa6mkXaXkGD6sAT8v8xj3+7/AHt/Ro47i1aNgquHPJ5JBx/n/PGLq9rcWk4it/7+Q/8AdXHX2/Tp+FJPWxdOS5nHqY3ijRk8QaPe6Z5m9pIyoQqG8snkHkcdfb74OD1ah4P8PPoOhW2lR3kMt5Fn7O56b2OSO/HI+ueppmqxS22pyzKJIbeTasmOT3zn0HXn/Z/76pzX8dyqRQTRzAyKCIWBw3OQPzPTPUdep3V+Xl6HXGhrzp62Orh0m7jOGVFIO512kgdMEHnpgc8n5ev93D1y0uLHc7SQxF8rvyCpx0B9CMY5P8HAHRbNrfXsBxa3Ev2Xds8xm8wzZ52jkgk59/vDrxVXWUmuElmD7mGCSByy9ueO5B6/xHHtKvfU0pqalqzndNaSa7BjwkOCOAAA+OVzwR3GPlHTgVsaikxjW3iKqT/CyhAvOc5PXv2GN2feptITT4bIwXxCOG+Rm4BGOoPbtnpjb+FWoBaCYrBd2sGRgJOgcnk/dJ44Ax07D8avqbzqXeiMl7GJQFnlaQk7mKKX34AIIXPPY7ju4z15IkwYEWVYoWGSC7DkdMAkkHPA79UPHHy2fIH2v/R1X5CS8jjcXOTnPP1HOeo+tSzv52+SSYs/CoI1+99T+Ht9706K4ObMCVbeYCSK3aNVIBSNh+77ZBOMYxjov3PwWdLO6ZDvRzEc87xnAyOBj0yvA9OR0Oms7C3XyFtzKORIU59QccY6Ke31x92U3l/HbgygtB6Koxx0AI7gAep+Q+mA7sbnLoZTQG0d1mj/AH25Qy9TIxPcnrjJ45xv7dWildpJRLPL8iR4L4xsHuP1xkdScdzPfJ52otL5Un7wYYvn5MZyCfzH/AR9DlXxilmY3oT7PH/zzBy2OBnuBnIxx26VS1Ljd7mxaTrc2u7y1S3RgMkccc8DrngHOB06nqLumQ/a9TkublGmPPmLghF46Z5BxyMcn5cnPbFt3mVrOKRVRjK0ghK8IOCSSOCTgY9Nx5HUdBp2oRxWi4YeWkrsIwAeTjaXY8E9DjPY8DtL8jOomlodBAmCJXKkHG0L9Og/Ud+vQ5wZZQ3OE9cZ/EfgDnjp9/8ABsq01H9yh2Shh8xVVyUUng5PfjOPY8GtFZkMYYqyBhld3JIz+nGf++ep5rNpo4JRaepWMzAEK2CRw2Rhjnr+oPf73Xn5prNQ0RkLMSTjeSCBwOh/XqenTvTpolaM7s+ScMdwAHuP5jv/AIw/a4DMIYHEu4gBgMoOBxk/5+aj0DdaCyXEgJ2kBucY7D0+v5D5elSwT7Fxt6DIAGcZ644+vQdx175ZdVZnGHVcDOcY6c+vXB7ev0ZcXzC3Z96xgDIzwenH4/gehp8pXJcvandPJA7K0bhzzs6vnqSOeOQP4s7+h6Nxl9NNc3otLZl3thXYjdhSOB16428d9x+huXuptJvSPdJk5YsDx1yAO/OfXp0P8Ueh6ZcQ6l9qMhSaFxI2Rxk8tnHY/MPxHXvpFcu50U4qlFtndeFvDy2Nql1ehzNG/mRIQBtwOC3+HHSte/Lzgid/vE4wQR9Meowfy7duQ1Xx7AL6xiupIIY5l3FI5CWbdwpwBwD+oPpVy48S/Z7yNRbQiRtuITKGcZxhjzwOh/P8M3Tnu0eU1Oc3KW5F4sme8vYNIs5isG1luFDYGSDlSew/xHHTPjd/4Bt9T1m1n+1vDCAsYthD87gEHGSeAcg5wPvHvye/huZ7LVLi6mtVdr8uxjJ5Cn7rZ6+uAcf0N3w9biXUJ3dB8kYI45XJOQPzYZA9Of72sW4KyO72UFDllqjS0LR4NVNq14PLS3ZZkMDGMO642sQOvG0n3z16nsHiW3KSLuCnCnHJ981XtbeK3tyYkUPzkgdTnnpnJ5P/AH137ukvkMbMWUtGQ3J98f5+tYSbkzhqTcpXJL1kHDABSB74GM/09ulUbh/IQPZhJWEZUxMSEz1yABn1HHt9KddXU0RtprXTZr1p7hInCSBfLjJGZST1AwDge9V9cWK3gkkUP8uB8p79u309enTtQl0JptN8rOW/tnUf+fWH/v2P8aKr7tQ/580/I/8AxVFb8q8j0fd8vwPWdTgWW1YOpJxkADJ+leWamkNprkNrNNGrz5eONnG5wPvEL1OMrnG73Az83faz4jtdMsmkuxnK5x/n8uK5K8mtNethqNsoLRN5boRj8j6Hnjnr09eWneO/U5MEpwu2tO5gax4fstbhmNxGiPaDMMhAJUk++f59uhzlvLviF4S+wXDanZq5tWx5oP3lcdTgDgHtn9civaFZdjCY5YsUyerZGcA/U5xkfePBzk85rT2l7PNaeaizugUx7iOvIOMdTkc/Xk5y3VCTfuy1R1TpRqXRmfAbxYG8WxWV05FxeQ+QYSuFBRSRIvPcDBGO4Oe1fRYbOeOM18U+G5/7M+INg24olre5ZiCM4OD65/Xp1NfaFtJ9otlctlHXqB2NcuIhyz/rp/SPJxEnUfO/T/gk5JKkrz6E1i61qEtvp8hdUUN8hznA69emP/rVsoojRUUAIoCgAcAYqO4gjnQxyRqydTlQfcY/GsYtJ6mMJKL1R5no8DrLdI3zeZliF6kdvT3HGOvX+7kPpVxcanPql3bpDsjFrEAMl8nczewJwOM++3oO0maHT/ETBM4AwY8cFSOwHfj/AMd6nsmsSeau1UzEXO1+CGx/Fj1GPf7vUdurn/E9eNR86ktjCO57GyKHaFwhBIwcdie/XPOe/A5BpavbILPz7XCzKVUKw5KkjPOeD09OR0JOW1rmxZ9PnXlfkZmXON2ONvXjpjH04HSuRmv7m0haX97Plc+Tk8tg/J7ZJ/2fv9OpLgrvQ6ou92uh6H4Z1RnvJY3kRbeLnO7axJPIIPbpz79+pfrZZppJurA8ccL178/n79emPNPDNzreseE7i81m0ttN1oKRaFwVD5weQeRzjnvkkk9TLL8RtO06xtoPFFwtrOygSLbZf95gbmGAcrnHPzcr1NZxtbmX9WOZ0E37Vf1c7OF0K7I5PObuYzngd/f364z26C/pkCWl19rErPLIoEykjb7fj0/Lp68x4d8TaDrKh9A1G3kcr80W4+YR0+Yde2O/austZzJM8rorKMq5Axg9h9Pbjr0FU5XWhnOOl2JLP/xMWktJBGpUiWMrg7jjknPHGePbODVhr8Rea9xzkAtlvbp2H48fX0rXEBSVmQ/IxJWQDkdOfp04469+tU223D3AcSPEVUY2dD3b34A5H937x7K1xKEWriazbxagJG6W9w64KnIXAxjj9fTJ5GOOdt9LttHkRYo4IYCwwQvU5HPIOc598YPA76k161pLHFGDKrDdl1K4AyOnqMHnnGzqvRZ2iF9ayKUBVlKuuSVBHVefTn1+gq02lbobwvBeRV1S3gsNatr+AobGYKChU9Qec9eMH8dvQ5O6fW9CnEgmsLlnspP3iE5JHH3cD68HjoM5PXN1G1ub+0trUXDW7QSBhxuDg9VP1z1/2+h53LoniAQ6gNGurjyriJlmjiZjjHHBb/a684zuPLZyzSdtOgXkkpJlXUpLq103eypcbF3kDlyf7uPz/MYPSuT1eK+22c1pLmK5fy9k0YAU9dwxjJ4Pr97qOg9T1N7a4ga9sImeUHdJbStj0+YYzn6gHOOp78L4o1vTEso2jguIZF3M0camZsDAzgdh3642j1xWlJt6JGtKrf3mrGI+o6jbGLzt0iD5DnHJ/wA44OPp1FdfHIbi0hn8l49vfGGTgf4+33e/U5dnY2mraSLqznVnJzjIyrAn5SOqnPy4yOo4FWozcvILGJZI8jG1+nUHPA9/Qff69dyZ1TlGfwk67ed6RsxIIRW4xyfcE9emeg571owPJJMBEylABuIbIPPoPoR1JwRx025N5o88W2a3uo50zjeVOWJweRzuU5B78k+uS59QazRAwiVWAHyoQcE5GeenHqfudDwVVr7GTSl8Jc1yGRmRISXfHygkBc55J6Y6f7P3j6YXIWxQjcZEEMYWOHjaS3HI4HAznOOueRgitOzilvLuS5mkPkQrwg+UoDkcY6dMZ+X7nfACLdxrEYLRGEMSEybfL7gHBUcHA5A7dBkYwBO2gRly+6Z8VvIl9ICYw0eckqG+THBAPGeff7vOO+vDHGttK5+dVkMrP02nHAPIH6jGBwOtUdNgub8yG1hJhL7mJbHmY9ecY56ZP3ug6HrIvDk902ZZlhJxxGfmb2PTA74GOvalJpbkVasYfEzn9Pa584yMqh25w+Aq8cA5xg8Hjjrn3W/ctfbUaQMJmGAVU7eOuMA+3PPDe3y9Lb+G7O2jgklV9kHzbNue3p27HjHT8RrWN1b3wdYiylPkCMNp2+oX04x+Htxm6i3SOKpi1e8VdHmcukyh9ssYXPJJBweO45z26+p46gV7kNEc+TKz5xjGMEcde3X26HjsfV1063VzhACxOSR1Ppn8OnsPTitc+H7W4GHzjOdo7H/P86SrLqKOPjfVHl32vzm3SkBU+6mOen068kdB0HIrrvDugSXdstxqUflp2jYAk89T/k9e3bZtfD2laZcC8k+d1+ZPNxhCO6j+97+/vXPa34xvkZ/skEUNkRt+0nLY45+bhfyz0quZz0gVKtKv7tFfMtalp1halvMDE4/ixyfRj1HbrjqeOtZU81qY5BfyNbWkpw+R2OO2MgYxzgZ568muL1fX7qUbUuHaONizfKVQkZz1AJxhucr93tjIbayXO+cylZLlss0ki8A4PGPwboPTnuNYwtudSws1H3mdZqmmaLY+F/EJ0lxe397C7xDy8uH24VQTnI9OvTvXDfD7wXremwxTXIea+dQ1yiYcR5BCgvk5wCeARkj+Liur8ILM10ZLoyXDkowD8gu3oOfl5/2uvfqfSopBZ70h2Qx7PmbAADk9cfiP/r93KtOCcE73OCpTVCpzLVnmd/ZTw6lZ6bALV9WZw09xJIXWOL/dGMHrjOB79hFpl4W1CZC5lkDfu5lk5wvAI4wM5GTz1PuDvabossElzLH5+ZTmaaTlnUjsB0z3OB9TVC+05dO1G3mESJEzgRsTkOR1GP4iACOp7c8YCUk9DshUUlZ7nSWi5iJEskaOo2rv57dSeeuOp45zjJ3RaNr9hqHirUtCit5S+mxxNLMzAq5kz8oHXKjGc4z+pqeKdQvriyeHRLVrjVpGWMQR/IACxDHcThQBu79xxxivPNM+GvjPTtcYjWJNKa+MlzdXdtiQIO688FyTw3GOfXBFSUo8zkl5dTzK1Xlko21Z7bDr2h3VybS01nTJbpSVMMd3G0ikdioOc1Q1G5hWSWJ0LXIwEjxuJz346nr69uO9eWWPwX8HWrC48m61B8jH2qX92XODn5QDnoe+cn2z6RZWUVrJEbVBK6x7dwY5A4wCc5PGD1PQ8d6xjHl3KpU5R1kSfYdQ/uL/AJ/Girn+m/8APt+q/wCFFO/oVzSObvBBqdt5FyAVYA7sZBIHv9P0P4dNpmgW1ho5ghQLvG8kE8H+fH9O3SuFvt9sgMMn7pm+bsV47+3Tg+vTj5ew8J+IILi3hsZZAtykeVBP319fUfp0OOhAmd0rnViITULwehzHiKH7JffdACfKRnGV5zj0xz6dPrnz/UsvqM8Tsp3EHaiYcYbAPTnr255PXv7lqujLeWUn8EhbKnjr26dD/nPpwen2MWn38i3kSBt5VA4Bx179/wBce1bUqiSuVSrKcbX1RwfjLwNcSaxJc2TrLuAZoZD95ivLA8889Oc5/P3L4dajLceH7SC8lMt1BEqSluuQOv6GuG8dyO+jtdR7I/s4Al2jPy+vtzxzjqDjiqvwl1x49QaG8kVhkMCrk4Dnv6duuO/XmnV5qlJSfQyqUlUhLvue4buOh570hPXavPYZ4peACcZ9sc0EKO4IrzjyDgPEUa2usXVxIQsZAl3O3BPTH6AevzfTGdperC6so3hkMsHAOV4P1P8A+vqfbEPxijV4/JbcRIqkqrbS+05AHr3457cdM8x4G1q6GhW9uiQTbgeMfMASeOMc9fTqOvWvQVO9NTPYoS54pW6HT6fr1jqniy80e6LWAgCLA0vCyrjs4+nAOOnTsNa58PmXW7WJIFWCBcsqAfdGQPT1PTH3frXGXGk6fqE6wXMiLcW5DspJO4ZJHA9Djpjr1OMjs9Kur21iJjllaKSIYkPIUY4IH5dOpB57CZpLWJcueGsGcj4pmaQiBnwI2YENxlmJyePy6Z5655PkGq+DNQ1zUL4w2zWkdsAUvJ2LR3BbnjGST34yR3zxXqXjYBIY0MbRkufmduuO3uceuen8NX/Dmr23/CNyjUZ0tmtpdx8wn509/Q84wcdRwMUSXNFI75RXsNVdPf8ArffU4bwJ4Nbwdq41yfUZHDRmGGGNNjkMBuaTJwABghTn3r3DSb62nhR7UyOiY3bvvDvz/kdvx57VdOhvFMQmRvOIfeDwF6k+uDz6de/a9p8o0uBoXl/chQ692IxwenoPTseTnFR7OKXunBJR5Uoqx1FxDHJIofJOOFUH36/r09vxqR23lgvHNKhByEUAqSf6H+vXoRWsLuK4tYJYFRsn5SG5yO3H8+eh55+a3MCkZnDAM3bOf1/Prntx3qdjns17txuo6LFdWeIi5lIG7zR19M4+gPfjP4Ycaz2CCM7wV4yeuB0Hp29gMdB0HUaK800Zf7/9zecbQP8AHOeex9qqasbhrxv3KFEX5CBwSeuemO3pn1OOGm72CFSSfI9Uc/5IYs6mREiBZRwCvUHAI6Yz1x90epz598U9IubvTnvbRPLuYBuIhfBkUEsfrg5x+pOefTyyRwrtcIMjk8n2x0745/2TyOg53V9Zs1u4tNnWRNoAaXA2DnbjH8RB69cYPQ1vRlKMrpG7fMuVnJfDfxpJrmiSQ6mzNqQLKsjci4GPTueTnIJOT+PQ2um2l5Klw+TJ90SbyHXthsHvkcE9zXOQeF47bUmu7RhgSbxzjAIPGeB3PB9sgYzXpMNnGdKMcQy6A+oyRyT7d/T73tkVUcU7w6mqbpwtJ6nn118N9Xg1F9R8HagsUcrIZ7W4brg8kHHOeRjj2xXStB5UsUVwGRgwQqvzANg56df4gDg9Fyck7uptppbRQsbjJy0g9eevTPp+Z9OMzUpNzJjCzPNhZChbd6AAA7j04GT8p45wYdWU/iM6TcG1fQy9QKSL5TxJdSoNjhc7T1z65PPv1Hr82MlpNcXGBiOHJAXdtKg8/wAXrxxnv34J6+3sDp9qrSKDdMN7sTk9/lznoBx1H3f9r5qN5ptxfnAQsfQk8c9MenUZwO3I6slI6KdZJb6GfYQyNcpb2zTQQgbkklIBbpyPfhemP4uvbci061EDbyZw/OXAOMD9TwPXpVc6PqFmFWaITRvksp/Hgdfy5xu68Zphjmt4WRVZGBB5YkH69fbjnjPBoeuwpS5/hkaVuEt5ZJg0UTEhVGODjsPXALfTj6Ga51WeaRlVlLMcB0BG30IPXqeOnUH64RkMbEvlgo++Qev9Og69dp655yL7U3EjBSd8hziONic4x8pAPqRkZJx1OfmSjcSoc7u9TcuZ722fzTfSNApxIJZWCPn1bkDnHQd+o4Ncrrup3V626S58ua3OxJJWwpXgjDD6J1z36YyMXxZ4pbR2S2ihmv7+X5Wt7WYtnJ+6euSc4AGTyPoer0DwVr2p6V/aOsQQaXK6Bo7eWQyyIvXkAAIeTxnjd2IxWvLyLmkONbD058snqYi+IteZlifU7lEL7WHmlmUY7HqOx7dD6fL1Gk+Mddh0pRczxT8Ha8q4fjPPTnp6YyOvYQXnhdvD8RuJJo7udzhAI9iqe5x1AHJ4A+99K47xlrS+H7SB7UG5lmC43qSIc9Asf8bd+4GPcZIwVR2RpVlh5x5uVW9DqrrV59bmZL65mmBwwjB2oMjA6Y98YznK+vOfJp17rmpxWyzzSJB0G75B2ACjj39ee3bnYPDfjS80e01+KCe9vEKkWMY2ibd0BJPAUY3f7vuCfofw/pws7GJriCGO4ZF8yONdwjfncAxGSMkjPHAqKk1T0RzVcXSoK1Pft2OI0zwHFDFFNIHeaP7m8dOhHTHQ46Y6HpxjWs/BkbTF7rbjsnBA6e3XAAz7fl2FzdRQqcsNx5wOv/6v8arQ6xaSyBY5ATz8xGF/P19v5dKw9pN6o4ZYutPUqrpZhMaQpxgorbAdo9z6dvephbzArFNiQKCCexJ69fXn86Jtagt5gjkEE7chgcn0PoevX0+mW3viHTbMH7ROQQCdoQ7m+g6kjB+ntkVPvdjH95J7CTz20MbeYwD54yOp+g/PNcr4tmW4m05GeFRbN5jOCMHntz1GM9/u9ODjN8XeMiYh9jtfLSRSqs8nznI9B3BzgDPUHjqPMdQ8R2+iTQXupXc0s8JG2IsWbPUA5wfc9PvfTG9Om1qz0qGFtH2s3a3c9dW5hstSnvLLJ1PygoWYFlWMd3x90YGCePuexA1L/wAV20ml/wCl5t22ZnVMyL7qjYBbvzgdK4bwGl9q98dV0i48uJlEi3HQElRhSO69M8YOT6ZXovAvhODTdEubXWtVu9U1CSZ5J5LgAKSzZwiEk7Rjpk9D06AnGKevQwrRpxnrr6FO4vItQs91sH8psOpcY3/gcg9cf8C/PY8Bbv8AS7ieUFwNpB4O3qSR1xzn8a6GLSLOWNPk/dR/KuzKgYPQD0/wFZl3oMhkkFswY7QQJcgAZ6eo7jj25FS5qScQdaE4uGxuf2hp3/Pxb/8Afz/69FcJ/Yeqf9Apf+/S/wCFFL2ce5l7CH85Sv4vsheMh5I1O47mHyjuB0wO3YdOPTIv9MkuJXvdHnMWoRkSKi5G8DkLntnocAZ3Hk8Y2NRZnRMONpiwf909vpgj06fjVS4txZQxp5x/fcggbiCcknp9ex6fQ1opWPTSUo2Z3vhDXoNc06ORcLOVCyx91YDkf5/Oo/GumGbSZrq3Um4t08xGGScL29T0zj1FcJYLd2Dytpwd/NO58HIZh15OTnr69q3fDfxDtNS11vD04ddTRQzOVKpg8de5+7n68Vm48j5o7I8+tQlTfNBnjeleOxq3iOLT9StYo/D9zN9klP8Ay0XsMngAZwMYHQdMV3UfhGHwvqF8lgXjWUgcnI2A9Ae34Y478ZHE/Gf4aXOgahNr2kI39lyOrzYJ/cyEj5sddu7BB7E13Phi5fXfDtq2oXMkk8aKY36bgoHLDp0549O3UazlJTsvge39d7b/APBHgqkqt5z3W/z/AE7f8A9a8K6j/aOlRNK26ePCvnq3o34j+dbG3jBORyCPrXmnhW/ls9eijBfyrg+W+e7c7f5N6njt29LyehrinHldjlxdL2dTTZnN+K9Dj1RIy4BYZ+oH1/z0/PzM2baLfiOzXbHCQoOOVHt07cds4HXqfbnGUOR26Vwfibw5585eIENnKkN0OeePy/M9O/RQq/ZlsaYarb3TyzX9KS08Syaw5mnguVEpWJSTC5I5IH8JHfB69T1rsPBmstd6ebV5JfLQ/uZ5VO+XPTd13f8Ajx5I9qJdKvJ9NktXgyWypO8LkdwT9P5dutcVpHhjxRp3jka5fSyJozFoGiSQPsjAACBecDg44J45zmuipJzp6atHauWDUXt+R22p2SXFvLLGWnjccADKk+ufXgHk9uMVX0Pw4JrOdJojLZAMk8bJjPB+XHGAMHn5cbRwP4bl1baxqD/aNMjdE5ygkAYEH5Sc54Pp6Hv3reHNek+0yWep2s1nqcSqkyK4KbeMOCpwP4SenXrUKMrXRu6zcfZoxfDrNo8v9hPp9wY4N0MEjszIqgnK5YdOozxwBz/d39QmiuGtY/MC5gbaG55BAOeO+e4PDHnsXxRxapJLfLbTGJJ/LAVTg8A5x/3ycj06jtneN2sY7FYbpmW4lI3LESGXryW6Djdz9PwuL5pmVXlcUtiG1jXT9Ylm0a/BgKC4eFnMvnHHOByS2SDxu+82P9rqdM19NQXZNE9uFXY8fPyHGcj/AAPHHQdT5fbnw/qdw92tvrF3f2jlP3RKlDzkB+AR9/3Hp2rotHuBavMIl8q5jjLN5hZ2A6jLHqenp1/PWrBP1OeEXrfYPF3xct/B/ib+zV0mS8iCLI8nnBPvdkGOnHt0HHeu8s/E1t4o8KWur2NvNbpNkPHMnzKc4Ix3B55GK8aj17SfEF8t14j0GC7tERAkjR4kiTfxzxkfMCQPevT/ABRqem+GfCs1yyhLOOIfZ4UGQeu1QPqfSs6tDlaVtf6v1/Q5oNSm5t6L+v63LWmalZXLXEFrdxy3ca+Y0ZABw33SePwzz1PPauH8OWdpceMLnVdU1Pdbzxt5ULn5YZBjLPyeff1J6cVzvwqvrnUNQ1C91O1cX907O1wiD5wf4ep6AEDgngda7C9gabVQL9o/sTjZcYHucAdwcn1HX6A0l7NuPdHbGn7ZKSfmWb3WNDhu4IbG4a4gBEbXUfyxF8Z2KcjkYHHGCo6dV34LiWxDeeI1RAQyxnofQADg8eijhfTK4N/4Jsbz7JbRvKltHIsy26zFPMIwRnAztzsOBjjvXTx6feRtHsYQ5XAY4ZcZU/dI4wAvTpisZuH2So6K03cztfuNbn0Y3GgG1GqmVCIrpRtaLP7wDtnB4zn/AAsaLqCyeLQzEXEQgIWYHLKSRyfz+vzH6VDdXx0/zrVJ7i6EuAVJGFJz1z2wD9Nn/fNe3jisNdt7hI5BECIp14wQ2QV/me3Tp6TbQtU7xem56ItpbXCqUdXIHGOp/r6VZWzjjTAACnrx1rGhPkXQPn7o25C9N30/XpVua42W7MW+XGcPxkduPyrBp9zzpQltc1QinJBB59O9Ry20bZLj2P8Ahx9a8pn8YWF1rb2Ud3cQzDlDjHmqMZ2nuV4yPY9Oca0F5G8GEecsMllkkbKjHOBjI4+nTt2t0ZR3LWEmldM7DUmtYocxSrujbc0QjEm8YI2ng4HzA5HPHfJzgaVZWklyl3qSrHbsf3IkA2sx6FjyN3Pcnvycnc3yVulcyM4XPKhst39Pq36VzOu6zDCJLdNxyzebOG3eYRncNnOe/B3Zz+bhDojopUHZxT3O20zwVpWma62rxx5uSMBjk7R7Hr+dct8V/ipp3hTTzb2qvd6nOp2x7tgjXkFmJ6DIIpkU2r3ui2/2R1jMkQaOS3kKOB2BUeox1x34ripfANrb6ydS8WLdXkyBTGrtuRCPuhwv3vpjtjpWsYczvUd2uhzvCtfa1JvDmsaxqWn2l9q8Ukt68e5CU2oqkHAVe3XrjJz26V1emeGI9SeBr0v5jHeqlcE/7xOQfod33jx/eseGhp11aNfXjSiEN+7t04IUDq3PXjgdsfgOhtNT0SOGOa3lnYDOxpY5N3zcEdP94e35U5yknojqqV+VclNHSQ3EMaCPcIyFA2s2TtHp/n/E1r/U0RCBIvPOR246/wCfSs3Vrq0kgKRnznwSCM/KScZJ9+fz9xnnLmSJbcReaWkk4wSQCOpYdc549evXueeME9WctLDqWrLN1ePcws0Lq4I5+Xg5z9c9D69vwojUZDAcuMsCmSec9ycHpz6/xcDtWLP4hlvJX0y1hRIllVAyj+EAZ68HqOOvy9O4XVN6ukEMRi44wONoHTPQcAjnHTv23Ueh6MaPLpIvT6lbxNst4/tzEBkPOwN0GMDryDjgdfXDYi6xdxyMrJGsg+eQyqGMQ9QO+MD1PH50bfUYLWU2R228cz5Qk5O7nkYznJyP+BdT0MWp2supXr+Td+cXZZAwGVkxgBe+Senf7/fo1Ja2Z1QpRjuWbXSbvUdSMzeYzMx5lOdiY5zzx7emBjHWsjXvDGkokFvM32ieNuP3WQjE9CeMenOByPqPS/Dumae1rLLrZ+zFj+7T7QQCgC4wePVfz98nVvrLw7Fp0upX0KLHCjOnkOS2E5zgdxgflS9o07HJVxaTtJaIyfBNzDpGmrDKwDSMGG9tqk47fz/H8urt0jvZjJhWI+6cZx/k/WvOdE8Eap4it7e/1OZtPhdjL5LtukxuOFIHC8HGOvy9u3p+k2cdjbyRRovmN1w3DHjkn/PWorKMXo7s86rWjNuUepNFcwJsEkqAg7VO7of7v6fpVrac5PcHIH+ev+Fci2kQ6xchnkkEaN0STaCR2I/+t/F3H3ushRba0QMWIVfvMcsQKxmkttzGouXYk2r/ALH/AHxRXLf2pH63P/fNFHs2aewmcRd3Dpb7bhG55+Xvgf8A1/1688xWJe5mgunYmLb8ocdfr68Yz169qzNQ1aRLW5hkBMTY28DO3v65/wDHvrzzkXuuLLE8MaCJ0GW2fj+nX1xkYArd2W579OhOS0PS7fyoFk3rtR+CoPQfn+nt07nyLxloeoJ45tdU06WSO3dlIZM5iIPPuAQfTBPHOQTd8NeILzUEux5uVhG5SE3bhkDHY49uOvQ1217BJLDHLbgOzoG6cA4+n0zgDvyedxTakn2ehyVKKp1OWT1VmQvql5q1tJp2rPLdWoUhllwyytgc8Z4Bzjr/AA8nvi+ANKvbTXJdPefOmRuWhwcqVzwM9fTjn8OtX55P7J02W4vbcIAjSFYxxjHpzk9Ofm6Hnn5uU+GOupq3xElvsMBLbEmIA7YlyOvbPuc5p2cabXQJOnGXNHd6HodyrWV7MLfIZSpj3nhcEe49F6nseB1X0Xw7rK6ra/OPLu4x+8jJ5xn734+4HQ8V5xeTvLeNIFzhivydQecjqMdD3HVeB1GXFfXWi61FfQK5KEfKFwGXupGBgdSeFHI6gZXOcOdabkVcN7aFm9Ue6A8k447VFcRB43wnzYJ4HfFQaZfQ6hZQXUPMc6Bx9CO9XNw9ecelci7niNOLs9zzfVr+e2lYvCRk7c8DjPcnqc479+grKTxAU06cBA6IcBf4h7N79Dg478V6XrGmWOoQkXqKV7t0OPrXiuvX3h6w8STWMkhAj4yF4zkjaTxtyc4Hy/eB9K7qLU1tsejQqRqNJ6HnVx4u8dWmrqNNmvrZFyFitod0bAnPIKn9fXPOedzxT4Ou/E+hW9/5wh8QFl+12+WEUoIOWGAeRk9jnIGTkbvW1sLYQEQogO1TkqAW3DrjHHvwO/XvntcxWRhSAb18z5s/MrI3BHQ5PIP8WcHk5+bR1k23FGkMMpKSk22zQtPtGk+E7S2cK8pQZdOjDAG7uTk59eo6V5b4ltdT1jVPLt1kmDp5cuHG3jGCxyPRTjP8J4GPl9q8NwfabJ/IkDRkGSIN8xVeflLHJ9hyen5+Q2V3qlx44xo9vBCsE5SSKf7jfMOuOQTggDjkj5RjIMO2m2ug7xfNGW51vgPwFc6bYLcSkRySn5kKlRHwB0/AZ6cryD/DzPjfQtUV5F8P38NnfJJ5iyhSWPBH3scZAK5xjtk9K+grzeLZxEAMKQAOO3Qen+eleLXELyeImMkEisWA5Bx7Ej9c+xGT0E0qsqrcpGGHqc176I4T4XDSfHl2unXkU8OpQIJpEGPLnVT8xUD7vJPBH8QOR0PsvijQ4dV0uHTZYBJFGRu3AgHHQDHuB649utWPBfhHRfCGjanf+HNNigvbtWMhZi2cA4QZztUHPArw7wf8QPGUnia80rU9QEdzMJY9t1CGW2lAJHTnAPYkj0x1qaTqz3lfl2+4wjO07OOr0PQdYtLXwtBZw20AtgUJB6bASo+Y/gvBPY8HrV2wNvO7WN0ii7aNZFIUhVQ9Dns3txnA+9nnlvBR8SeI3kg8ceXJPMzBSEVWVVXpleADzxx1Bxzkbsdte2ni6FpCGYWzIFA+/hvUAe3HH3u9XF8y97c9S7jGPRnT6Laz6faGRYy3kuwwqbmPoR16hmHA7jk9GhXxxYJdGPVblLMoNzBgBu5Puc9+mfvjkcZp2/8AbS6sb281BntpIdy2YiO0KBxk4OW55wDkKeTnDRXaQ63BDaz2y7IwXMkqq+Bzg85LYJ9W6H1w8Wjf3tSeRz95mNqmvRyxXF1GyuxcmILKMsM8d/XBwSOvQdRjadqF4ZDLcSSLvKeSJukYx94jjH8J7D5D9Rr6nYWNgkcMKB9uQ5C8bfb8/UDpx61Irc3LrD5e6SZtrbef++cdM47Y+8ORjIrS2h6lJRUSazvLyzaSETyOqMP3T5JK/wCyO3TPQ/d/LpIPF93PfraS25mjGQzsv3genfk9R3zxwap6JY29xdiOeKR4YZlUs0Z+bGOvb3PXO7r6dRBpcVvqszxTCDzOFUAZXPT+hxnseDUya6nHXnTvqtTi9X8FWk85vpYo47sfvDsyAoPoOgz6cfeH4buj3FppcUaXCSMExgrwB/tbuP5ADnkY4k8W3S6LZPPe37yRZ2sD2JyABjkn2GPu4ya4C58RX93HJBFI7xn+BUUAjP3R345568DkcYfM5qzY6NGVaN+h0et+Ooy0tpZIkUCjImRgJJCB1H0xz1+6c4x8vPL4ptrOe3h+12trcbwCsgUyPEBnaM/d98kH5RwO1C80q0YCRgkUHbZhSXzyBnrzn1xkfdx8vJ614X0rXLhrizu54ZjiPcELJI68Z5xjPy8/KBnoADhpW0SOqdBQpfuY3frY9P0LxtpVugSS+db/AHf8e0abfLyfu844wT6fj1roDr2kahOkMl96tt27iT3Pf39eo5PbwvTvhF4junaVJoI7EEiWV5DkEdRs6n2NdDp/wt1fRr2C4W+iVWUjDblZu+COQQMc4B6d+tWoRe7s/U8rnlKfvQtr3X9M9SvptNivleDLqzKW2HIc+/OCT+PXp6bWl27yxpKqLCFJxvYqyLwR2HoOTjofTA49ootJ0yzIuczyOfMUZJAA6ZJ6Z469h17d/Yrb3Gg20K3BEjR7GVjliecgAkH1/unB7cAYz0LrJQirHmmpfFHSLjW7nRlkazuYZPKWaVP3LOOD079PxUdOlakr2rxG4Zp2tjkOGBLYAyxU/mM8/h1PJ+MfgjJLqLXei3BEMrkvBMMbSBkkH/ax0wB9MEDodI0bUdE0IeaMzQ4SQEkgoQMgAenHr3GBWzjC14MnDVLtxkvRkAjnuZDfRNFHbLnYhB4Huff0JGd3TvXK+LdZ8RR2jxWInjjU4+0ht4b1wAPlyOeQOvfqPQ9J0iSMLLY/Z/sxGHgcEZ9B7d+OOg45yb+naVMks1zcqsSqMsynCovP9c8kehyetEKkYO7Vzeu1KLSdmcN4Q0q48S/u2iF1DHGDLfkGNyR0C8HeCBnPP3e/bfk8N29lqbWElybe2ETpu3nAyOmc9cE4GTnb0bo2+/i62sLby9Pga4uJkOGjGBz3Gepz9evfBxxd7fPc3A+1EyFSTGxXBUnpnJ452j8TwelKU3Nt7IMPGu7qT0OK+IXgbxRc3tldJqSTW0ECxw+feEGPBbO0HoCfxzxk8ZreGW+JX2yw0HTdUeO1Nwp+2gBwM4ypcgsQM4HHVuuKybzVfFUWualo9heXSm9fzNj/ADBUJyGQkfIAOCRjpXvHwQ05LHRVW6u1N8zqzmXl5MD5cE9R19azk4yi+a+n3HDiKOspK6d9T0DVbaZEsXt726hNvOpYKeJ+Nux89u/1/KmaidTvbaGHTJY7WYsPOnZNwC9SFHqQfb/Gr4q1mGBnt8tmAedKEOGOfuqD6nnv6evOd4S+JHhnWtdPh6yujHq0e4GJkIV2XlgjdGI5yPrWCTUVKxxSXJBSktzo9E0pNPs1gVmZNzNuPUk55/U/p16l2pzBLC46YI2H8cAnvz19foe+mPmXIIwfToa5vxJciDTFu3O2IybQGH3h64/DPfv+MxbnK7HSTnNXOU3XH/PVP++x/wDFUVZ+12vt/wCO/wDxdFb8yPV5fI+eNF8WtK3kak+9GPD7eQfUnv8AjmrF/ELm+U6bqTRzHIdWIwOOx7HHuOnbtz/ifQbnRdTaJ1UxHO3Bzz6VStb57eVNincvIb+6f8ivOhiKmFm4P3l59P6/rselGoq9O1V2fdaX/r/hz0bwpaTaRclbyWCGFyPM+YF9oGMfz9BwfrXtHh+3hNmhTc0C9u3v/M/XNfP8UE9/ZjUdOMcl2qhJLdjwQOQw9OAOegweRjA9u8B6vLF4XYajA0MiKcNkYz028Hr2x7dug9GdeFSMZQ2l2/rTU8yvSlC8Xuu/VG1qdvZ6hvtWZVWQbSSOGyPQ/wC97/e798+x8NaZ4a0po9JgijY8ySKvzH8e47/n615trviC6OozXYlMXlsUCAZDDup9O/p24611uha5fy2cd1co3kP0c9OR97tj9OM9a1lSnCK1MIpNqxa0DbJe3CGQJJ5ZIzwVA6H6Aj2+7WD4yuP7PtI3uEbYJfLOP4M98D3GPw7cVYvJ/s90l9aqZFZ92ARyDgE4x9OcevJ6Vt33h+w8Q6G48wORlhkZJ9x+PB68+nQqLSkm9jsm3Bc6HfCjxFNFdrpOqsiCUbrNyf8AWj0Hqec+vNeqW08U4kETZ8tjG4/utwf5EfnXx9aeKrr/AISGO3uDHElvL5EUo5KbDwPp+nTjrn6h8FX9vrGiG8tf3U8hIuFA5jm7nB7nhh6gg98nmr01Cb/r1PPxcIVIqvB76P1NzUY2e0kVCVZlwCOx9a+XPFPh6U3N55qMbkzEoiHa+7PDZ7gbT0x9wfh9I6nrSaVJHDqCF1brMgyPrjt7/wD1q888aPDPqFpf2c0flvNgFFCnPGGPr0HPP3TyMfJvhKjp3T6kYejKenQu6E0xtUjvA3mKu3AwBgZzx9c/nUN9aqHljhZZpx8xiPAkyCRn6k98/fPXvs2txpw1N4BfWpuHx+6DjJHTBGevb8BwvQHirQUjtHvoIz5uBHIE5yMnGMdvmb8xxUKVnY7nUSmr6XLXhm1voIrhrSaPzJotwcj7p7HBJ9c88ZJ+pl0PwPp+mXX26Z5pL6RxLIXfKluuOn+SAe1eXX/jXXfD6QfZAcJvibKjHXcN2exzweMg9+pu/Dz4vz3PiF7LxPcCSK6kSO3eOIIIHJwQ3cgkjntzXLVxSpNp6EV8HiNZwtby3PdWGR1I5rB163sbaF5mEYuWPyAnlm+g5PWt0qBnJ4Hc9vevGfihqlzPqyw2/ETABZAfvew69emDnqPl550oRcpWTODCUnVnZM2YvFcMHnQ3zBoZAAFB5JOMHIPfK9fU1kXmgaPqOq/27Y2flTDDecAyuxxjJ5AJA9fc8Z4xbSxmuIXDD7U3BkKjO3PbrnnJOP8AbHynOW7rw6rTwvAWAeB8gHjggfNj39eM84J7dT9z4T1alKFP3luN0ewNteq4UgqjJsH8I7j2IwfQfL27WtcSWyiSaGzeaQNkKoyAO/bPJyPXp6cdDai0gki27VI6oeCOBz+S+33T0xxZ1GFdmCSoIzkDkdP8P07Vhz6nG8Reom0eVQX9xqN5me4ZTuKpbbNoLehHOc55zuOH785ydI168i8bXfh2/ji+zXlpvsLlAcyEYJDtk5znp2yeu7ns7+2he+klEaBRwZCcbTzkcexPf0+XvUF3p1iusWWpzwia8tUkhQr2EnLdeOck84+8ODnndSjrdHbOXMly6HN6nF5k1tNho7hVbdkkgYxjgdO3Ix0PJ70LWeSNlkUJC8MhMYVcbTnkgdex/FR04rq72xllP2qcCNFJaOMYwT/ePXJ79+p5NP0/Qbee0M8REiNu/ejoGOBk89RgdzyrdOgXNpqdarwjGzMifWWgiktIbeG4CMwJTO5yT82QeAevPOOOK6hY55rWxuLSSQ295CH2Od0qZxgZPODkD8e/fldJ0KDQ1ik1F5J0hUxyGdgWYA8ZPGSAOnH3cY7V6BLbjUtIT7JdSxmaArHOmNyBlxwCOCM8cDHHrzMnaxyYicY25VoebeO9NuLq3tbZJjcwPcEiZ/nVRtyM/mPrk8nPOJpVtC8zRgDz2fIbsRge56cHHJ4Nd/4k0O4traztJJXuyxBLyEFnIGCeh5JPPDff59W47T7WeC/bcDIgJO9vusSeh+9gnOep4J+Vs5Nxelzuw9ZSpWTNO08KC4uZGvZzb2yodxJAyecn+Y4/ug8YwMfxLbtpOr2y2iItnCBvlZADGccBe4HBx0/h9OO7Mym2kWcBuCURQBx0Bb/D/ZPWvN9SmmuLZlufNGZGZYy5whAwDj1/+J69qE29R4ZzqS956HpHgm4g1zS0urIgTqxU7DhuuNzKeOc54Bxu7Vo3to7yLcXTSPt5y47e+PqOPc8evkvhW3vl1N0sWeGb78riU/OMYIUfxd8fePK8c4b3/RJbS90qKazmacbQGdupbHf0POcf7XvznJ2Skedjo/V6ja1R59dQx3Nwby8V40JCRIcKdg7kZB6YPUdD7GtC90KW5ka7syfsoAWSCOXBVBzlCOjYHUf3V54G214j8PtqUwWWLeinKqg2/jkf55PPct0bUbjSdMGmLaoZAGEchGOD/EcfeI49/lP1D5na6JlJygnT37GPr3iaPSITBfxKUAAhnDbjg+2evBGeei/ht+G9U0nUftAi1AvNb8S+aNuwdAT/AJ79q4+LwXJq+sPc3Uk9xAxAVGbAGMZ/HgdzyvT0qa6sGgXFzZWMoildsSLHyVXpgntxkds5HWqtFqy3N/q9OfuQfvHRatrUekatdHSby12L97zF3hcjJOARkcg9u/c1xuseLtR1oRDekVqTgqI9gmxkZB9OM5Hdeo6jFvpY2u4oICZWkGAzjPm9htHfOcZAP3+vantbTXTCJN6rkHZGw5IwBjnoOO/c9MYotpod9LCU6dpS3NG01S6tCYUWDc4KEBP3gHpk9D978h0xlc/U2vE1Bnu0MaeWxSPbgEfxYBGRxnrjqPQ46vQvC97bypcXFt5bRqNrs4BT3PTkYH93lTwO2n4h8PXOpWkSw26rNuVQEBzx+A6dM4H3V5HanJbE+3pwnocboSLJBcaitn5t2irFDIV+ZVJJYZ56k578NWzZXuq39v8AvEjjtsbATCMAcc5+n8m/DtdO8MS6bokyNEhlbHmRpnEhA5APcdfX6CtO10+1s9GkRISjhS0pYYBJ/h57H+ufeo51ujjq4unJ6K+pwmjMq3CS3YaSIM0chkctIpwRyc8gAd8cpx7efn4aXVnrtprXh/VIxFBdl5FclZoAHJPI+93H8++OomvTDd3S2krGJX3AN0PI+b2HrgDvzxka+nyu1tPbqBHHcNy784bgrn8B15+77YXRTdtB18HGdnI7i28SXV3paotgySFTk9FlAHJRvfB4PPI9wOJ1nUpbqCSS5dwzSFPmk4GTk8Z4B9OOGq8WntYksZLhkhRivyuCE49c8Dg8ZHK9B0XGvvD887OQjBFAkjiZsEH1GMY9Og/h5FZcqWqDD0adOVzM86D/AJ+p/wDv3/8AXorM/suT+9/48v8AjRUc8v5f6+89H2S/m/r7j2bUfA2nalPJcXcK72OAAoOB9e30HHQ9RmvI/ib8Kmtoze6ORncS6BcA9BwBwO3p9724+h+BgtgMMck9aiu4UuLaSNgSG9OvXrn1H9KlT6TV0z5SNae1z4s0qWfTLpxMzwYyGDcBv88f5HH0X4K1bTtZ0lLWaaKKdUA3ZxvGBg+34+nbt558XfBptoGuI0dsyElNo/H/AA/D0rzHwl4luNG1Nba4XzbZ5ApU9QD1/wA964atCeGk6lLY9ieIhWjGlN+j8+z7f18vpf8A4VvYT6i13cfODwFU/Lj/ACMfh05qn8Z7K9s/h+8WgxnYjLv8tTuRB/dA4H1/yMZ/iRB4ehggj2NGoUjB5bd/kenfmu78PeONG1ayLi5gjkPDRF88/TvxXTTzC04+1338vkzz8Rgq3K+X+vkeF/DPVbjVY57C+i3zIo8puV3jnIPGMn1wSc+1d/baommsBJMYhtEbDIxz3I7/AIk4yRxyK63UdM8P6LbT3MCRxrICwORjv07ev5e1eR+Nb1dQYyQkhd37xgMjPr+n+e3oU4xqO0djejUnKneortHJ6hol0dbvI7CKG5jnvBPHOWH7sFsnnv8ATPY8c8+reDNT1Dwv4ukURmTSrtFEwP8AAw4BH5kdunfOT5jZ3NyjKtu37xz+8U/KJFU9V9PfpncfevTPBWqDVrqJJLiKR/J2lQuCCO4/Q9O55652xNLmj72q/r9Safs+RwWz/Q7f4xXYj8E3V5EnmqihlXtkn6fr+PuPGfBWtDxFplxYyAxXCZcFjuySMA+5B+p+Y+gx6b4wsZrzw/ParKnlheuDuzxwOcY6HueO3BPmHhHwtPpuqi5uh5eEIHl9GB7fhjp14HWsacUqa11THhlUpvli7xPPb3S9UsdTaKVLiO6gJMbksPMORyG9D6Z/lx9EeFtTvP8AhH7JLhPKGzCwB2PlgDgeoA/AfKOOeZtNsbJ4c30sSw9Gc4JRsnA56c9On40yUJDFP5WHEbfK55DLxg/ntOeByeeaVRxm7pajo0owbje42PSbLWpJkaUtLLMSRhRsGOFwAOODzwemTxmvLdQ+H19YeJIokJkiMnE3cEEYb064/P640dFuJ7H4l3sECyC0uHd/P4G04BGD+R7+vvXoNlLPr2trAwSV3wojC4APQsfYDd78L06rniKMZe5PY6Kc3y819Ffc9TsbeW5s4ZdQdmd0XMYbKA9+wz9SPyzivCv2gtSn0rxVFFZSPDHLaC5uXQcqqnaqg44BI5+gxjJz9BRKI7eNUbdtUAMe4HevDPjpZrfeIrDULW4gSW3ha2kRm/1gOSFJweNxU8jBGRxmpwVlU12seJB1ZT/dfgUPht4rnhDQarH9p8pVeS6gIUhGBYfJ1J+8CBjOAcHPzejWV9YarO93orBrN0y0gJGGB5A7j0PTPBya8cX7R4c1FdU1a6t/KliUM/k/Io42oFzkfw89eTzz83TeCfFM1tFfXU/kpbu0bqFUAYKj5uvTpnrjqT69ValHWUD0LSb97c7+5uPIs7idX/cQjczkdCOc++eOfc8jHy8TY/Ge0nvIbQ7HhkcRkqPmftuPp0HXr7dBuz+Ibq6O2TyFMqkPAvLKMjLE9MAB/U8D8OR1L4P6Fqzi8sLqXTY922WGMggc8Fc9OhH0AwPTKEYL+IZVVNLRXPTIHtrmIyR3KMj8RFQenocY/oOOgrkPElrrGuXl3pmiXMNpEHI80r1QfeCHsfvcgD7vckGt7whpq2sMsZuFEFmVjRiw5HYn07eg5o1TR7uDW3k0y9kR3QkLsR1IOASMj2U8ep/GYSUJGr1bin0OcJm0bxMugsvmaVLZm4uk3bo4G/gVTyQWwxI5OME+o7nwxqdjrtg0OnSFpoEVjG42kA+o/L8+2MDOsvCkK2E1vNGyCdXEjFgpJYYJx3OO/qB6VTttEutJezB1RI1ssJ9q8rE5QDGwnIUrgN1HYenDk4T66mcm3Gyd2XtTt5pZyDC8axjBIXjHtkfyx/EPYW7e4VAqxttjHRcfdHpjHse38PUZw1u+8RafKvkyXEzEqN7DgDr0wPY8/wCRXkEdw0KgvAHGUkIzlsjGSR34/NvcVlrbU1U242mrGbqsommVOrclgnoM8578k+vQfVq8Fun2sr5Lsx4Kjhdvrk8AfXHXpxmqmq2OpwWdyU2iWU4+1PIoWI9jjJ6fKcdDk/j5F4I1vW28Q6hpHim4mN0jB47iTO0EcFVxhdpBDDGOnUdrUdDpi4q0U9z1+IWKWs1xeMMQEqQyknIPG0Yxz8vYDk5zyRmR+G5dRAnRfs9rMSyuyhiQe5HOW6epPzdc1o3VhFdJALm4iiDMVcI24MMHkg+nzDp2HpldW716PSoIbHTbVZhGgjEzthRjg8cZ6Nx7+mcF30KVWcf4e5mXWl6T4ZsjPeXc0+oSY8loEznrgFc5I/PpjBzhneFNfFm7pbgpvySsiMIyevbpzkDp2/4Fnvd28mtRT3Oy5BuUdwylSwyMcdhnGR/tHg10o1Jb65MOn20MoLu0jIdphz0Ydj17fr3GtLPUiqtLVNbmrqXi6CysZLqa3EgQj93HKpz7e/8A+quHj+Idtrd8YItOS3lbBVmYvkf7QA4/M9T6Zql4h0G7vtMuRY2/lzoN0Gdrs3IAyM85GMnk8fny+i6BqOjzWw1WdbQtu3xxceaeeM+4yMZ7fk4Uojo4ehBabnqcmvXFrGyFnihiUBUgi2M+enXJ7jj68ZrgfF2nXM9+73EBhLD/AFZGSo79vT27d+/UR6v9u0+O3sbYefDwzsdzAjII56fxenUfhna9bahcWYuNyXMewBFEm8Mc5KgnuePXqfU5ErabGmG/dTvscVa2ipe291JCGUyhWKJnaOcgHkf3sdf4evfUivj4eeK6kQPcTsVG7jg5wR6ZJ9eh/CpNOgSW2gmjQFpgIyvG5JD2PPOMjrnoeD/Fp+JbWOaO3eONi0REb/JuAXHA9ueO3I79SJdEehUqptRlsdNY67Mmm29zJbiQFwjhMnPsAOc5I6Y7+uK2Y9e023t4r3WdRt7LHywwu21uegIPVunHbB9a4bRLS81bTLyxhARY9k0ceTywJAORzwNw4/OuA8R/BvWprq5uZNRE08rkqLhMghiSfmBP5d+OM01CMup4WMjytqKuz6FuE1FojKEaNW+YLv3EA/Q+n615p4um1bUbmSxtY5ngSPJaAsSxIPUg/h2HzKfQ1b8OeK9V8HeGLXSbq0l1W6hUpHdyPtgCjAXnrjpwcH9M8VL8YPEq+KRFZWOnzWkLrJOr27RFk7tkHgDcPmIPQHucz7OUW9BUKlSiuaUdXovU27DSlszCt4kpcgMybcbj0IGfx7fxDngEU5tcH2MQ20QEkLPEwU/NImQRknuCfXoTgccdXZanqXi3QbjVtW0mDSIvMKQSpcCRrhQSGKjHAHHPOSPpnmNQ0j94jOpWGZ/LiLFSzjGce2Acdu1Uk5Lseph8RGrrMbpFxf3U0NvOC8zsiLkHKKcf02ntkA9c4ru59D1mGF0fVpDL1hdVyir6Y78cdzx15wcvQ9MkhuWmELzwtGPmJIAI4yOnXJ6D+Lrya6Z9cvrqQ28FvESF4Y5J3eox1z7buvfoVZrY58TWcprk2Rx/9geJ/wDn7sPy/wDrUVof8JDqH98f9+//ALKip9m+/wCLL9rU7I9WzlSFwT27imkjkMOvY9/8+nPX807f9tB/6DRJ/qZPof5muXbU+fOa8b6bHqOmTjG5gvXbnPHT+uPc8HPPxjrdhPYa5JA6ukiSYIB9G457190ah/qx/un+bV8lfFL/AJGtP+Bf+htWslei/I3p+9aL7nO6ney3cduJslkHB4zj8OP61CuuXGnyQrHM+V6kHOfTP+e9Vp/9av1rNv8A/j4k/CvLpwU0oy2senisVUpOc4aO/wDwT0iw1W91uxeGadwjgRgBsBR1x9M4/EnjvVXR4b/w9fDesk9pIMSxHLfIevup79s49siHwB/x82/+638q9b0772jf7h/9CWvUy1xcZQkr2b9dBY1txp14O0rL01RxOv2k2k28N3aCTyXbzMOPmjT3x9DyMfd68fLf8N+IUt7zdNGBIRkFBkMccEHvgZHtgcjoOi8W/wDIM/7eW/8AQUril/1s/wBR/wCgLXqR/eRsykk1zdz1DT/ENpqeg3sMsmJJI3HmE4IYdj9Cff73QdG83+FPiWzGoS2GoSKbW5LLkuzHrkOM557Hnucg95PDH/Hpff8AXs38mrhfh/8A8jBZ/U/yNZNci5F1ZxVV+8g1pf8A4B9CShIiYjKehOQeMdifcj6Z9Wzmue1vU30y3ZluYmnYjy4HkxvBOCR/49g+w+bpWvL/AMesP/XeT+Zrl/FX3L//AIH/AFqacVKVmdcpuEG0bRsWkmiupoYfPYAsqj5WP15z1x1PXPy8V3Xg5Etb4SYVXkG1mPXGRhR+hx9eOM1yOmf8eSf9s/5Cus0r/kI2f/XEf+hCsaiurMVeTlCx37n9wSnJC8cV8meLE1CTx3qsVzLuMDkLGORtHcdPfnj0zxx9aD/VD/Pavmjx/wD8lMv/APrt/wCyipwkuXmODAQ56nKSfE63mu/DmmQWtu93E0bLdLEm9lYDIbAGTg7ucY5GSM4Mml+Hryx8MaSCVt7iRdjKxzkZ5z69enzY3dB37LSujf8AXSL+VHi//kH234f+hmur2lrQS2OmCftee+5T1G6sNN0gQQbSWAUSA5LHAxyD3yp6nqeDn5meEItUt7b7QjyPEqgFGHQcdM9Ox7Zx/FVOX/j9h/64n/0KSvULP/kX1+k3/oTVzylZep015qjHlS3PP9Z1WODR9Qls4C9zAguJIXyiMvoxB7/MPrjntVbRfGFvZz3SXNhdKZXO2IxljK3O4rjsvzc89uR0OHdf8gfVP95P/Q629T/5Hi2/3JP/AEGuiEYtNSXf9DLER5WrdkdFL4rtb/TlXSojJPglGYEkODwPQdRwT0PSs6w0TWNdjvr03atLGu1Fmcg7uCoP93+E9B369a53wr/rLb/r6T/2avUPBH/HvqX/AF3/AK1lUXsrqJEv3VNThuz5vuI7i3vTc3k15HqauySW7vh25ALIBxgYHIH8P4j0/wCHCy60JIbi4m2xvgOr4ZhyME+vDDqfujjj5eG+Kv8AyP8Ad/8AX3N/Na9A+Ev/ACEZvx/mldVeV6dyKUm4Nr+tDovinp1np3hOYQQOJmVpmlGWYhBkrn3yfTsPavmKLXbmGeOSW9kcyYYJAP8Aj3OecqQMnBx0HOemK+rfjF/yIk/+6f8A0EV8p23/ACFp/wDrnD/JazwkeelzdbnNHEVUlGMtz3LwdL/xS81xfIY3XeBMTuZsMNjdOSBtJ9CrZxjjg5tW1y41Lyl8+W2jby2aJBkoASPm4xgdRkY2nIGOO90n/kSYv+2H8xT/AAp/x83v+7F/MUSsuZ2PUozduZ7mdZ3VzBPC1yJbfAztlQYQMvbgds8jH3R9V7rw7Y6dqp3QyFwDvmSI4Z+ozjGQD83OOeOTjiXxV/yB7L/rkv8A6ElcRof/AB/Rf9dj/wChrWSjzq60Jq1XVhfY6fxrBfaXZ3fiEhLO1gUOzNIo3nOOevBz05+907Vydn8RrPWdSTS44kTzWVYHaA7uMcFjwO3OV7/Stb9pn/kTrH/r+/xrkfh//wAhG1/65t/6BWlKEZUueRyUakpu2mh6VFHhcXO+PyduI1xhOOp45xgc4HQ8jtHcLG6G1kBMTsQJFUAAc9gPm7jgH8KgH+r/AOBr/wCy0Wn+suv+uafyWsLHXa2piatpYsbqG4hxIC+2RkHyvkE7Tz15PGf4xwc5ba0eET2KrLnzw/IJ4z1BA/Hr/tdW6l93/wAesH/XVf51HF/x73H/AF1m/wDRhp7o0lUco6nm2peNL7wl8RWXRdOjvLi8sFt8sWZn3OxRlxwSOnO7nOScV3HgTVfFGu2sS+JGeHEjZjaJVk2gnuOoOOuc/LjntyWv/wDI+eDf+vi5/pXstp/x9w/Rv5UpxinzW1/4Bwzb9pK/9aJnM6zpO68hNpKxjmcq6P8AcHB//Vxj8fum7ceDLaOEzXcX2qMoTnbjDHqO52kk9j97r13O1n/mE/8AXf8Aoa7P/mAyf7h/rSdRpKwVKsoqKTPM9QmOnacdPuprHy8boBkRuMHJyeePm6ZP3+nTfiLjVrW2eDYYLZyylTxGoI556HocfL39cml4q/5H3UP+vf8A9laq/gH/AI9tU/3h/wCzV0xp/u+f0/E6Y1uWXLY73w9qt0SLQyGNo8kMQDheo+o49D93r3pt7dNMvmow8xv3Q2jPHQ/XjIxz0FYekf8AHzN/uD/0M1fm/wBVJ/uH+dZcivcbsqjsjQ85v+fg/n/9lRVSistCrH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Showing complete luminal obliteration by pink collagen (between arrows). Hematoxylin-eosin; original magnification: x20.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mandel, J, Mark, E, Hales, C. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162:1964. Official Journal of the American Thoracic Society &copy; American Lung Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_55_20342=[""].join("\n");
var outline_f19_55_20342=null;
var title_f19_55_20343="Neoplastic C-cell hyperplasia";
var content_f19_55_20343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F86205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F86205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Neoplastic C-cell hyperplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    C-cell hyperplasia and microcarcinomas in a 5-year-old boy with the Cys634Arg mutation. The expanding C-cell masses disrupt the basal membrane surrounding individual thyroid follicles (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Expert Review of Endocrinology &amp; Metabolism, September 2009, Vol. 4, No. 5, Pages 443-465 with permission of Expert Reviews Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_55_20343=[""].join("\n");
var outline_f19_55_20343=null;
var title_f19_55_20344="Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease";
var content_f19_55_20344=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/55/20344/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/55/20344/contributors\">",
"     Adam S Cheifetz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/55/20344/contributors\">",
"     Garret J Cullen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/55/20344/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/55/20344/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/55/20344/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/55/20344/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/55/20344/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salicylazosulfapyridine (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    ) was originally proposed as a treatment for rheumatoid arthritis. It was subsequently discovered that sulfasalazine was also efficacious in treating inflammatory bowel disease, particularly ulcerative colitis. The 5-aminosalicylic acid (5-ASA) medications were developed because many patients were intolerant of or allergic to sulfasalazine.",
"   </p>",
"   <p>",
"    This topic will review the pharmacology of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    and 5-ASAs, mechanism of action in inflammatory bowel disease, and side effects. The role of sulfasalazine and 5-ASAs in the treatment of inflammatory bowel disease and rheumatoid arthritis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"     \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link\">",
"     \"Management of mild to moderate ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"     \"Management of severe ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=see_link\">",
"     \"Sulfasalazine in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194952450\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    is a prodrug composed of 5-aminosalicylic acid (5-ASA) linked to sulfapyridine through an azo bond (",
"    <a class=\"graphic graphic_figure graphicRef76617 \" href=\"UTD.htm?18/17/18719\">",
"     figure 1",
"    </a>",
"    ). Sulfasalazine is partially absorbed in the jejunum after oral ingestion. The remainder passes into the colon, where it is reduced by coliform bacterial enzyme, azoreductase, to sulfapyridine and 5-ASA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of absorbed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    is excreted into bile; only a small fraction is excreted in the urine. 5-ASA is poorly absorbed from the colon and is largely excreted in the stool. Sulfapyridine is rapidly absorbed from the colon, metabolized by the liver, and excreted in the urine with only small amounts remaining in the stool.",
"   </p>",
"   <p>",
"    5-ASA is primarily responsible for the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , while sulfapyridine accounts for many of its side effects. Unconjugated 5-ASA (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    ) does not have the side effects associated with sulfapyridine, but is rapidly absorbed in the jejunum, allowing only 20 percent to reach the terminal ileum and colon. Therefore, a number of 5-ASA compounds have been developed to prevent absorption of 5-ASA in the proximal gastrointestinal tract, and thereby increase delivery to the colon (",
"    <a class=\"graphic graphic_table graphicRef86818 \" href=\"UTD.htm?2/28/2509\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194953227\">",
"    <span class=\"h2\">",
"     5-ASA formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral 5-ASA formulations differ in their mode of delivery of the active drug to the colon (",
"    <a class=\"graphic graphic_table graphicRef86818 \" href=\"UTD.htm?2/28/2509\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/2\">",
"     2",
"    </a>",
"    ]. The systemic absorption and efficacy are comparable to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , and 5-ASAs are better tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. There does not appear to be any difference in efficacy or safety between the various formulations of oral 5-ASAs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/5\">",
"     5",
"    </a>",
"    ]. Therefore, the choice of oral 5-ASA for treatment of inflammatory bowel disease should be based on the indication (eg, induction or maintenance of remission in ulcerative colitis), disease location, patient preference, ability to comply with the prescribed dosing regimen, and availability of the drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of mild to moderate ulcerative colitis\", section on 'Left-sided colitis, extensive colitis, and pancolitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following oral 5-ASA formulations have been developed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dimerization of 5-ASA has been used to develop prodrug formulations",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/3/43059?source=see_link\">",
"       olsalazine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/53/8021?source=see_link\">",
"       balsalazide",
"      </a>",
"      . Olsalazine consists of two 5-ASAs joined together with an azo bond, while balsalazide consists of one 5-ASA linked to an inert unabsorbed carrier molecule. As colonic bacteria are required to cleave the azo bond and release the 5-ASA moiety, these formulations are active only in the colon. Olsalazine is administered orally twice daily, and balsalazide is typically administered orally three times daily.",
"     </li>",
"     <li>",
"      Delayed- and controlled-release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      formulations consist of single 5-ASA molecules enclosed within an enteric coat or a semipermeable membrane that resists gastric breakdown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In delayed-release formulations, the release of 5-ASA is pH-dependent. The acrylic-base resin dissolves at a pH &ge;7, delivering 10 to 15 percent of 5-ASA to the terminal ileum and remainder in the colon. In controlled-release formulations, the release of 5-ASA is time-dependant and independent of pH. The ethylcellulose coating serves as a semipermeable membrane that releases 30 to 40 percent of 5-ASA in the duodenum and continues release throughout the colon. Delayed-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    is administered orally two to three times daily, and controlled-release mesalamine is administered orally four times daily. However, there are data that they can be prescribed once a day [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extended-release forms of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      contain mesalamine granules encased in microcrystalline cellulose that delivers mesalamine to the colon via a proprietary extended-release mechanism. The outer coating dissolves at a pH &ge;6 in the distal ileum. Upon release, the granules swell to delay transit through the colon and provide gradual, extended release of 5-ASA throughout the colon, allowing for once daily dosing.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       Mesalamine",
"      </a>",
"      pellets consist of 5-ASA microgranules with acrylic resin or ethylcellulose. Pellets pass unaltered to the distal small bowel, where they begin to release 5-ASA at pH &gt;6.0 and then continue to release 5-ASA throughout the colon. Mesalamine micropellets are administered orally once to four times daily and have the advantage that they can be sprinkled on food.",
"     </li>",
"     <li>",
"      The Multi-Matrix System (MMX)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      formulation consists of a pH-dependent coating to delay drug release until the terminal ileum and lipophilic and hydrophilic matrix. The outer coating dissolves at pH 7 in the distal ileum, exposing the matrix. The matrix expands when exposed to luminal fluid to form a gel that gradually releases 5-ASA in the ileum and colon. MMX-mesalamine has a comparable efficacy and safety profile to other 5-ASA formulations, and has the advantage of once daily dosing and possibly improved compliance [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/9-13\">",
"       9-13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of topical formulations of 5-ASA are also available and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link\">",
"     \"Management of mild to moderate ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194952457\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the precise mechanism responsible for the clinical efficacy of 5-aminosalicylic acid (5-ASA) compounds is not known, they are thought to act topically. In vitro investigations have identified many antiinflammatory and immunosuppressive properties of 5-ASA, suggesting a multifactorial basis of therapeutic action. The following mechanisms have been proposed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H382461902\">",
"    <span class=\"h2\">",
"     Inhibition of cytokine synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Downregulation of peroxisome proliferator activated receptor-gamma (PPAR-gamma) has been shown to be involved in inflammation in patients with inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Enhanced mucosal production of proinflammatory cytokines has also been correlated with active inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/16\">",
"     16",
"    </a>",
"    ]. 5-ASA medications may exert their anti-inflammatory effect by inducing PPAR-gamma gene expression and that of its target genes and suppressing the activation of cytokine NF&kappa;B and toll-like receptors (TLRs) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/17\">",
"     17",
"    </a>",
"    ]. 5-ASAs, and to some extent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , also inhibit the biologic functions of the proinflammatory cytokines interleukin 1 (IL-1), tumor necrosis factor alpha (TNFa), IL-2, IL-8, and NF kB [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4231?source=see_link\">",
"     \"Role of cytokines in the immune system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link\">",
"     \"Toll-like receptors: Roles in disease and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194952464\">",
"    <span class=\"h2\">",
"     Inhibition of prostaglandin and leukotriene synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    and 5-ASA inhibit cyclooxygenase and lipoxygenase enzymes in arachidonic acid metabolism, thereby preventing formation of proinflammatory prostaglandins and leukotrienes (eg, LTB4) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. Support for this proposed mechanism of action in inflammatory bowel disease was derived from preliminary trials with lipoxygenase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Although subsequent randomized trials have not demonstrated a clinical benefit in patients with inflammatory bowel disease, it is unclear if this lack of efficacy was due to incomplete enzyme inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194952471\">",
"    <span class=\"h2\">",
"     Free radical scavenging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactive metabolites of oxygen and nitrogen mediate tissue injury via oxidation of cellular proteins. 5-ASA is a potent free radical scavenger and antioxidant at the concentrations achieved within the intestinal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. The enhanced production of oxidized 5-ASA metabolites in the mucosa and stool of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    lends support to free radical scavenging activity as a mechanism of action [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    5-ASA may also exhibit antioxidant activity by another mechanism. In one study, for example, it augmented the thermal induction of intestinal epithelial heat shock protein (hsp72) expression, an effect that was accompanied by increased cellular protection against oxidant injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194952478\">",
"    <span class=\"h2\">",
"     Immunosuppressive activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    and 5-ASA possess immunosuppressive activity. They block lymphocyte DNA synthesis and cell cycle progression in vitro, thereby preventing clonal expansion of potential pathogenic T-cell and B-cell populations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In addition, 5-ASA prevents the accumulation of the early T-cell activation gene for IL-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/33\">",
"     33",
"    </a>",
"    ]. Thus, 5-ASA inhibits both T-cell proliferation and subsequent activation and differentiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194952485\">",
"    <span class=\"h2\">",
"     Impairment of white cell adhesion and function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphonuclear leukocyte and macrophage functions, including chemotaxis, phagocytosis, and adhesion, which are crucial to acute inflammatory processes, are also markedly inhibited by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    and 5-ASA in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. The reduction in leukocyte adhesion appears to be mediated via inhibition of the enzyme amino-imidazolecarboxamidoribonucleotide (AICAR) transformylase. This leads to the accumulation of AICAR, which results in an increase in adenosine release at inflamed sites [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/38\">",
"     38",
"    </a>",
"    ]. Adenosine reduces local inflammation by inhibiting leukocyte adhesion to endothelial cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects can occur with both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    and 5-ASA (",
"    <a class=\"graphic graphic_table graphicRef64059 \" href=\"UTD.htm?2/22/2412\">",
"     table 2",
"    </a>",
"    ), but are more common with sulfasalazine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sulfasalazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 to 25 percent of patients discontinue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    due to side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/39\">",
"     39",
"    </a>",
"    ]. The side effects associated with sulfasalazine are either idiosyncratic (eg, hypersensitivity or immune-related) or dose-related [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Idiosyncratic effects include skin rash, hepatitis, pancreatitis, pneumonitis, agranulocytosis, and aplastic anemia. When such reactions occur, the drug should be immediately stopped, and the patient not rechallenged with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Dose-related side effects include gastrointestinal, central nervous system, and mild hematologic toxicities. Symptoms and laboratory findings of such involvement include anorexia, headache, nausea, vomiting, dyspepsia, diarrhea, leukopenia, hemolytic anemia, and a megaloblastic anemia. These side effects may resolve with dose reduction to 2 to 4 g daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    include nausea, headache, fever, and rash (",
"    <a class=\"graphic graphic_table graphicRef64059 \" href=\"UTD.htm?2/22/2412\">",
"     table 2",
"    </a>",
"    ). Men treated with sulfasalazine may experience oligospermia and infertility that are reversible with drug discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most episodes of leukopenia are mild and transient, life-threatening agranulocytosis is a rare side effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Agranulocytosis typically occurs within the first three months of therapy and is almost invariably accompanied by fever and rash. Agranulocytosis may be fatal, although bone marrow recovery occurs in the majority of patients within one to two weeks of drug discontinuation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=see_link&amp;anchor=H11#H11\">",
"     \"Drug-induced neutropenia and agranulocytosis\", section on 'Sulfasalazine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complete blood cell counts and liver function tests should be performed at the initiation of therapy. Subsequent monitoring should be performed every two weeks during the first three months, then monthly for the second three months, and every three months thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    inhibits transport of reduced",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    across cell membranes in an in vitro model [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/44\">",
"     44",
"    </a>",
"    ]. This effect could cause intracellular folate deficiency and contribute to the megaloblastic anemia associated with sulfasalazine therapy. Folic acid supplementation at a dose of 1 mg daily should therefore be recommended in all patients on sulfasalazine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of mild to moderate ulcerative colitis\", section on 'Left-sided colitis, extensive colitis, and pancolitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     5-aminosalicylic acid (5-ASA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 5-ASA compounds are generally better tolerated than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    . Headache, nausea, and abdominal pain are the common side effects with 5-ASA medications (",
"    <a class=\"graphic graphic_table graphicRef64059 \" href=\"UTD.htm?2/22/2412\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/45\">",
"     45",
"    </a>",
"    ]. Although most patients who are intolerant of sulfasalazine will tolerate 5-ASA, approximately 10 percent of patients will experience similar side effects and are unable to tolerate oral 5-ASAs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mild watery diarrhea can occur in up to 8 percent of patients on oral 5-ASA preparations. Diarrhea occurs at the initiation of therapy and usually resolves in four to eight weeks due to the ability of the colon to adapt to an elevated fluid load secondary to increased absorption. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/3/43059?source=see_link\">",
"     olsalazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/53/8021?source=see_link\">",
"     balsalazide",
"    </a>",
"    can cause persistent watery diarrhea in up to 15 percent of patients by promoting ileal secretion of water and electrolytes. In such cases, olsalazine or balsalazide should be switched to another 5-ASA preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 3 percent of patients on oral 5-ASAs have a paradoxical worsening of their colitis symptoms with diarrhea, bleeding, acute abdominal pain, and in some cases fever, headache, and rash. These patients should be considered allergic to 5-ASAs, and 5-ASAs should no longer be used.",
"   </p>",
"   <p>",
"    Pancreatitis and pneumonitis have been reported due to hypersensitivity reactions to 5-ASAs. In such cases, the drug should be discontinued and should not be resumed as these side effects are likely to recur [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nephrotoxicity is rare in patients on 5-ASA medications with a mean incidence of 0.3 percent per person-year [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/49\">",
"     49",
"    </a>",
"    ]. In most cases, renal failure is caused by an acute or chronic interstitial nephritis, which is idiosyncratic and unrelated to the 5-ASA formulation and dose [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/50\">",
"     50",
"    </a>",
"    ]. Renal function should be monitored, though there is no consensus on how frequently this needs to occur. We recommend serum blood urea nitrogen and creatinine and urinalysis be measured at 6 weeks, 6 months, and 12 months after initiation of 5-ASA therapy and then annually [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/49\">",
"     49",
"    </a>",
"    ]. These drugs should be used cautiously in patients with underlying renal insufficiency with careful monitoring of renal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link&amp;anchor=H110256095#H110256095\">",
"     \"Management of mild to moderate ulcerative colitis\", section on 'Laboratory monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute interstitial nephritis\"",
"    </a>",
"    .) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18732229\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/sulfasalazine-drug-information?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    can be continued safely throughout pregnancy and nursing.",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/folic-acid-drug-information?source=see_link\">",
"     Folic acid",
"    </a>",
"    2 mg daily is recommended in pregnant women due to the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    on folate metabolism. Although there is less experience with the newer 5-aminosalicylic acid (5-ASA) agents in pregnancy, a growing body of evidence suggests that both topical 5-ASAs and non-enteric coated 5-ASAs are safe in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20344/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. The use of sulfasalazine and 5-ASAs in pregnancy and nursing is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25834?source=see_link\">",
"     \"Fertility, pregnancy, and nursing in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=see_link\">",
"       \"Patient information: Ulcerative colitis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"       \"Patient information: Ulcerative colitis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/11/17586?source=see_link\">",
"       \"Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      is a prodrug composed of 5-aminosalicylic acid (5-ASA) linked to sulfapyridine through an azo bond. 5-ASA is primarily responsible for the efficacy of sulfasalazine, while sulfapyridine accounts for many of its side effects. (See",
"      <a class=\"local\" href=\"#H194952450\">",
"       'Pharmacology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since orally ingested unconjugated 5-ASA (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      ) undergoes rapid absorption in the jejunum, various formulations have been developed to prevent proximal absorption of 5-ASA and increase bioavailability in the distal small bowel and colon (",
"      <a class=\"graphic graphic_table graphicRef86818 \" href=\"UTD.htm?2/28/2509\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H194953227\">",
"       '5-ASA formulations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      5-ASA preparations are as effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      in the treatment of inflammatory bowel disease and are better tolerated. Therefore, initial treatment choice should be based on the indication (eg, induction or maintenance of remission in ulcerative colitis), disease location, patient preference, ability to comply with the prescribed dosing regimen, and availability of the drug. (See",
"      <a class=\"local\" href=\"#H194953227\">",
"       '5-ASA formulations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      5-ASAs have antiinflammatory properties and are thought to act topically. Several different mechanisms of action have been proposed, including inhibition of cytokine, prostaglandin, and leukotriene synthesis, free radical scavenging, immunosuppressive activity, and impairment of white cell adhesion and function. (See",
"      <a class=\"local\" href=\"#H194952457\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The 5-ASA compounds are generally better tolerated than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      . Common side effects of sulfasalazine and 5-ASAs include nausea and headache. Sulfasalazine has been associated with male infertility and, rarely, agranulocytosis. Transient mild watery diarrhea can occur in patients on all oral 5-ASA preparations. However,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/3/43059?source=see_link\">",
"       olsalazine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/53/8021?source=see_link\">",
"       balsalazide",
"      </a>",
"      can cause persistent watery diarrhea. Approximately 3 percent of patients on oral 5-ASA have a paradoxical worsening of their colitis symptoms with diarrhea, bleeding, and acute abdominal pain (",
"      <a class=\"graphic graphic_table graphicRef64059 \" href=\"UTD.htm?2/22/2412\">",
"       table 2",
"      </a>",
"      ). These patients should be considered allergic to 5-ASAs, and 5-ASAs should no longer be used. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/1\">",
"      Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 1972; 181:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/2\">",
"      Ord&aacute;s I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet 2012; 380:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/3\">",
"      Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003; 17:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/4\">",
"      Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; :CD000543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/5\">",
"      Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 10:CD000544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/6\">",
"      Zhu Y, Tang RK, Zhao P, et al. Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2012; 24:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/7\">",
"      Tong JL, Huang ML, Xu XT, et al. Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis. J Dig Dis 2012; 13:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/8\">",
"      Ford AC, Khan KJ, Sandborn WJ, et al. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:2070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/9\">",
"      D'Haens G, Hommes D, Engels L, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther 2006; 24:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/10\">",
"      Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/11\">",
"      Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/12\">",
"      Sandborn WJ, Kamm MA, Lichtenstein GR, et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007; 26:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/13\">",
"      Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003; 1:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/14\">",
"      Peyrin-Biroulet L, Beisner J, Wang G, et al. Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci U S A 2010; 107:8772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/15\">",
"      Yamamoto-Furusho JK, Pe&ntilde;aloza-Coronel A, S&aacute;nchez-Mu&ntilde;oz F, et al. Peroxisome proliferator-activated receptor-gamma (PPAR-&gamma;) expression is downregulated in patients with active ulcerative colitis. Inflamm Bowel Dis 2011; 17:680.",
"     </a>",
"    </li>",
"    <li>",
"     Fiocchi C, Podolsky DK. Cytokines and growth factors in inflammatory bowel disease. In: Inflammatory Bowel Disease, 4th ed, Kirsner JB, Shorter RG (Eds), Lea &amp; Febriger, Philadelphia 1995. p.252.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/17\">",
"      Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005; 201:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/18\">",
"      Cominelli F, Zipser RD, Dinarello CA. Sulfasalazine inhibits cytokine production in human mononuclear cells: A novel anti-inflammatory mechanism. Gastroenterology 1992; 96:A96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/19\">",
"      Shanahan F, Niederlehner A, Carramanzana N, Anton P. Sulfasalazine inhibits the binding of TNF alpha to its receptor. Immunopharmacology 1990; 20:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/20\">",
"      Bantel H, Berg C, Vieth M, et al. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000; 95:3452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/21\">",
"      Sharon P, Ligumsky M, Rachmilewitz D, Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978; 75:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/22\">",
"      Hawkey CJ, Boughton-Smith NK, Whittle BJ. Modulation of human colonic arachidonic acid metabolism by sulfasalazine. Dig Dis Sci 1985; 30:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/23\">",
"      Ligumsky M, Karmeli F, Sharon P, et al. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology 1981; 81:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/24\">",
"      Miller DK, Gillard JW, Vickers PJ, et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990; 343:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/25\">",
"      Stenson WF, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest 1982; 69:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/26\">",
"      Zingarelli B, Squadrito F, Graziani P, et al. Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats. Agents Actions 1993; 39:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/27\">",
"      Bell RL, Lanni C, Malo PE, et al. Preclinical and clinical activity of zileuton and A-78773. Ann N Y Acad Sci 1993; 696:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/28\">",
"      Rask-Madsen J, Bukhave K, Laursen LS, Lauritsen K. 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents Actions 1992; Spec No:C37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/29\">",
"      Craven PA, Pfanstiel J, Saito R, DeRubertis FR. Actions of sulfasalazine and 5-aminosalicylic acid as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity. Gastroenterology 1987; 92:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/30\">",
"      Ahnfelt-R&oslash;nne I, Nielsen OH, Christensen A, et al. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 1990; 98:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/31\">",
"      Grisham MB, Granger DN. 5-Aminosalicylic acid concentration in mucosal interstitium of cat small and large intestine. Dig Dis Sci 1989; 34:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/32\">",
"      Burress GC, Musch MW, Jurivich DA, et al. Effects of mesalamine on the hsp72 stress response in rat IEC-18 intestinal epithelial cells. Gastroenterology 1997; 113:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/33\">",
"      Stevens C, Lipman M, Fabry S, et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther 1995; 272:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/34\">",
"      MacDermott RP, Schloemann SR, Bertovich MJ, et al. Inhibition of antibody secretion by 5-aminosalicylic acid. Gastroenterology 1989; 96:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/35\">",
"      Rhodes JM, Bartholomew TC, Jewell DP. Inhibition of leucocyte motility by drugs used in ulcerative colitis. Gut 1981; 22:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/36\">",
"      Neal TM, Winterbourn CC, Vissers MC. Inhibition of neutrophil degranulation and superoxide production by sulfasalazine. Comparison with 5-aminosalicylic acid, sulfapyridine and olsalazine. Biochem Pharmacol 1987; 36:2765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/37\">",
"      Rubinstein A, Das KM, Melamed J, Murphy RA. Comparative analysis of systemic immunological parameters in ulcerative colitis and idiopathic proctitis: effects of sulfasalazine in vivo and in vitro. Clin Exp Immunol 1978; 33:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/38\">",
"      Gadangi P, Longaker M, Naime D, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 1996; 156:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/39\">",
"      Box SA, Pullar T. Sulphasalazine in the treatment of rheumatoid arthritis. Br J Rheumatol 1997; 36:382.",
"     </a>",
"    </li>",
"    <li>",
"     Dougados M. Sulfasalazine. In: Therapy of Systemic Rheumatic Disorders, van de Putte LBA, Furst DE, Williams HJ, van Riel PLCM (Eds), Marcel Dekker, New York 1998. p.165.",
"    </li>",
"    <li>",
"     Azulfidine, EN-Tabs. In: Physicians Desk Reference, 52nd ed, Medical Economics Company, Montvale, NJ 1998. p.2239.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/42\">",
"      Jacobson IM, Kelsey PB, Blyden GT, et al. Sulfasalazine-induced agranulocytosis. Am J Gastroenterol 1985; 80:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/43\">",
"      Jick H, Myers MW, Dean AD. The risk of sulfasalazine- and mesalazine-associated blood disorders. Pharmacotherapy 1995; 15:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/44\">",
"      Jansen G, van der Heijden J, Oerlemans R, et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum 2004; 50:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/45\">",
"      Rao SS, Cann PA, Holdsworth CD. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine. Scand J Gastroenterol 1987; 22:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/46\">",
"      Giaffer MH, O'Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol Ther 1992; 6:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/47\">",
"      Hanauer SB, Smith M. Critical drug appraisal: Olsalazine. Drug Ther Bull 1991; 21:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/48\">",
"      Woltsche M, Woltsche-Kahr I, Roeger GM, et al. Sulfasalazine-induced extrinsic allergic alveolitis in a patient with psoriatic arthritis. Eur J Med Res 2001; 6:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/49\">",
"      Gisbert JP, Gonz&aacute;lez-Lama Y, Mat&eacute; J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007; 13:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/50\">",
"      World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant 1996; 11:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/51\">",
"      Van Staa TP, Travis S, Leufkens HG, Logan RF. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology 2004; 126:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/52\">",
"      Khosla R, Willoughby CP, Jewell DP. Crohn's disease and pregnancy. Gut 1984; 25:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/53\">",
"      Bell CM, Habal FM. Safety of topical 5-aminosalicylic acid in pregnancy. Am J Gastroenterol 1997; 92:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/54\">",
"      Marteau P, Tennenbaum R, Elefant E, et al. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther 1998; 12:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20344/abstract/55\">",
"      Beard CM, Noller KL, O'Fallon WM, et al. Cancer after exposure to metronidazole. Mayo Clin Proc 1988; 63:147.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4065 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_55_20344=[""].join("\n");
var outline_f19_55_20344=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H194952450\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H194953227\">",
"      5-ASA formulations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H194952457\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H382461902\">",
"      Inhibition of cytokine synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H194952464\">",
"      Inhibition of prostaglandin and leukotriene synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H194952471\">",
"      Free radical scavenging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H194952478\">",
"      Immunosuppressive activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H194952485\">",
"      Impairment of white cell adhesion and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sulfasalazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      5-aminosalicylic acid (5-ASA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18732229\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4065\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4065|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/17/18719\" title=\"figure 1\">",
"      Structure sulfasalazine 5 ASA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4065|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/28/2509\" title=\"table 1\">",
"      Sulfasalazine and 5-ASA formulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/22/2412\" title=\"table 2\">",
"      Side effects of sulfasalazine and aminosalicylates",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=related_link\">",
"      Drug-induced neutropenia and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25834?source=related_link\">",
"      Fertility, pregnancy, and nursing in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=related_link\">",
"      Management of mild to moderate ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=related_link\">",
"      Management of severe ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=related_link\">",
"      Overview of the medical management of mild to moderate Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/11/17586?source=related_link\">",
"      Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=related_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=related_link\">",
"      Patient information: Ulcerative colitis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4231?source=related_link\">",
"      Role of cytokines in the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=related_link\">",
"      Sulfasalazine in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_55_20345="Diagnostic assays for HIV infection";
var content_f19_55_20345=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic assays for HIV infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/55/20345/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/55/20345/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/55/20345/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/55/20345/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/55/20345/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/55/20345/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/55/20345/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of 2008, 33 million people were estimated to be living with",
"    <span class=\"nowrap\">",
"     HIV/AIDS,",
"    </span>",
"    and more than 37 million had died since the beginning of the epidemic [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/1\">",
"     1",
"    </a>",
"    ]. In terms of the recent growth of the epidemic, an estimated 2.7 million people became newly infected with HIV in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients who are unaware of their HIV diagnosis may present with an opportunistic infection as their initial clinical presentation and can unknowingly transmit infection to others, emphasizing the importance of testing.",
"   </p>",
"   <p>",
"    Since the mid 1980s, diagnostic testing for HIV has improved. This topic will address the diagnostic tests that are available for the diagnosis of HIV infection. The application of HIV testing for screening and the interpretation of HIV RNA testing and CD4 cell counts are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=see_link\">",
"     \"Serologic screening for HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=see_link\">",
"     \"Techniques and interpretation of HIV-1 RNA quantitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=see_link\">",
"     \"Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HIV infection is established by one of the following methods: detecting antibodies to the virus; detecting the viral p24 antigen; detecting viral nucleic acid (NAT); or culturing HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/2\">",
"     2",
"    </a>",
"    ]. By far, the most widely used test is the detection of antibody to HIV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Serologic response to HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serologic tests for HIV infection are based upon detection of IgG antibody against HIV-1 antigens in serum. These HIV antigens include p24 (a nucleocapsid protein) and gp 120 and gp 41 (envelope proteins).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibodies to gp41 and p24 antigens are the first detectable serologic markers following HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IgG antibodies appear 6 to 12 weeks following HIV infection in the majority of patients and by six months in 95 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/4\">",
"       4",
"      </a>",
"      ]. IgG antibodies to HIV generally persist for life.",
"     </li>",
"     <li>",
"      Positive tests should be confirmed with repeat tests or corroborating laboratory data (eg, Western blot assays).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Assays for IgM antibodies are not used because they are relatively insensitive.",
"   </p>",
"   <p>",
"    Rare cases of seronegative HIV infection have been reported with subsequent HIV seroconversion after treatment-induced immune reconstitution [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Classification of HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV has evolved into several groups: M, N, O and P; M (\"Main\") is considered the pandemic strain and comprises the vast majority of strains of HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Group O (\"Outlier\") represents far fewer strains from Cameroon, Gabon, and Equatorial Guinea. Group N",
"    <span class=\"nowrap\">",
"     (\"non-M/non-O\")",
"    </span>",
"    and group P are represented by very few isolates and have only been documented in Cameroon [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=see_link\">",
"     \"The global human immunodeficiency virus pandemic\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Viruses from group M are subsequently divided into ten distinct subtypes, or clades (A to J). HIV testing was originally developed to detect HIV clade B, the most common subtype in the United States and Europe. The estimated frequency of non-B clades in the United States is approximately 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Operating characteristics of the assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discussion below includes information about sensitivity and specificity of the various assays. However, clinicians need to be aware that the operating characteristics of a test depend not only on the test itself, but also on the likelihood that individuals will seek testing during chronic infection or during acute HIV seroconversion, when the likelihood of a false negative serologic test result increases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies of HIV diagnostic assays examine not only the sensitivity and specificity of the testing modality, but also the ability of the assay to identify isolates that are non-M type strains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     OVERVIEW OF AVAILABLE TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HIV infection can be made serologically either through standard or rapid testing methods. The specific advantages and disadvantages of each assay are discussed in detail below.",
"   </p>",
"   <p>",
"    The diagnostic accuracy of HIV infection has improved with each generation of assays. While the first generation tests were based on whole viral lysate in an indirect enzyme immunoassay, second generation tests used synthetic and recombinant peptide antigens, which led to improved sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/7\">",
"     7",
"    </a>",
"    ]. Third generation assays have used sandwich assay formats that allow simultaneous detection of IgM and IgG antibodies. Now, fourth generation assays combine antibody and antigen testing within the same diagnostic test format.",
"   </p>",
"   <p>",
"    With increasing sensitivity of these diagnostic assays, the \"window period\", wherein HIV may not be detected due to acute infection, has gradually shortened. This is particularly important when acute infection may not be suspected. In patients with symptoms or signs of acute HIV infection, direct testing with sensitive assays, such as nucleic acid testing for HIV RNA, may also be employed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=see_link\">",
"     \"Acute and early HIV infection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specificity is also important, particularly when diagnostic testing is applied for screening of patients considered to be at low risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     STANDARD HIV-1 ANTIBODY TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard test for antibodies to HIV is an enzyme immunoassay (EIA) screening assay, which first became available in 1985. A confirmatory Western blot is performed on EIA-positive specimens to exclude a false positive test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Test performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of HIV serologic testing is extremely high (",
"    <a class=\"graphic graphic_table graphicRef74816 graphicRef54839 \" href=\"UTD.htm?29/28/30157\">",
"     table 1A-B",
"    </a>",
"    ). The results are reported as positive, negative, or indeterminate. The criteria for a positive test are a repeatedly positive EIA followed by a positive Western blot.",
"   </p>",
"   <p>",
"    Slightly different criteria for the interpretation of Western blots have been proposed by the Centers for Disease Control and Prevention (CDC), the Association of State and Territorial Public Health Laboratory Directors (ASTPHLD), the World Health Organization, and others. The CDC and ASTPHLD criteria for positive serology include reactivity to HIV antigens",
"    <span class=\"nowrap\">",
"     gp120/160",
"    </span>",
"    plus either gp 41 or p24.",
"   </p>",
"   <p>",
"    Inconsistent results between laboratories are unusual. The overall results of Western blot testing according to a CDC survey of 1400 clinical laboratories showed a sensitivity of 99.3 percent and specificity of 99.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/10\">",
"     10",
"    </a>",
"    ]. These high rates of sensitivity and specificity were confirmed in another assay that had the advantage of detecting HIV-2 as well [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Incorrect results are generally attributable to variations in diagnostic criteria, weak bands that are difficult to interpret, or human error such as mistakes in transcription.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     False negative serologic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predictive value of the EIA depends upon the seroprevalence rates in the patient population being tested. For example, the chance of a false negative result in a high prevalence population (injection drug users in Baltimore, with a seroprevalence rate of about 30 percent) is about 0.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/12\">",
"     12",
"    </a>",
"    ]. In a low prevalence population, such as US blood donors, the false negative rate is 0.001 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Acute infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of a false negative result is testing between the time of viral transmission and seroconversion during acute HIV infection. Improvements in testing methodology with third generation testing have reduced this \"window period\" to approximately three to six weeks. Fourth generation tests have narrowed this window further by including both antibody and antigen testing within the same assay. The diagnosis of acute infection is discussed elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Failure to detect certain HIV subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EIA kits for HIV screening in the United States and Europe detect all M subtypes but do not consistently detect other groups [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. For example, in one report, specimens from eight probable group O infections from Cameroon were tested by ten HIV assays licensed by the Federal Drug Administration (FDA). All assays based on synthetic peptides or recombinant antigens failed to detect at least one of the infections; assays based on whole-virus lysates performed better. In addition, HIV-1 Western blot assays fail to detect subtype O in 10 to 20 percent of specimens. The newly detected P subgroup can be detected only with nucleotide sequencing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=see_link\">",
"     \"The global human immunodeficiency virus pandemic\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fourth generation HIV tests, which simultaneously detect antibody and antigen, detect group O infections with high sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H25\">",
"     'Combined antibody antigen tests'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Rare causes of false negative testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare patients with documented HIV infection are initially seropositive and then become seronegative [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], while other patients are persistently seronegative [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/23\">",
"     23",
"    </a>",
"    ]. A review of the literature identified 25 HIV-infected patients who were persistently seronegative, 12 of whom had Pneumocystis pneumonia at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/23\">",
"     23",
"    </a>",
"    ]. The clinical course of these patients was marked by severe immunosuppression, rapid disease progression, high-level viremia, and significant mortality. Whether the defective humoral immune response may be related to rapid depletion of HIV-specific CD4+ T cells during primary infection is unclear.",
"   </p>",
"   <p>",
"    Other rare causes of false negative tests include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immune dysfunction due to defective humoral response or agammaglobulinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Immunosuppression due to malignancy or medications",
"     </li>",
"     <li>",
"      Delay in seroconversion following early initiation of antiretroviral therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fulminant HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/26-28\">",
"       26-28",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     False positive serologic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of false positive tests (positive EIA and Western blot) in low prevalence populations is extremely low [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In one study of 135,187 young adults in a rural area with a low incidence of AIDS, only one result was classified as a false positive [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend repeat HIV serologic testing and HIV RNA viral load testing for further evaluation in any patient with a suspected false positive HIV test. If a negative antibody test and non-quantifiable HIV RNA results are obtained, the initial test can be considered a false positive result. If the serologic test is again reactive, and is confirmed by Western blot, then the patient should be considered to be HIV-infected, and there should be an attempt to detect low-level viremia (&lt;50",
"    <span class=\"nowrap\">",
"     c/mL);",
"    </span>",
"    these ultrasensitive techniques are available in selected research labs. Some of these patients may be \"elite controllers\" [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=see_link\">",
"     \"The stages and natural history of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     HIV vaccine recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;False positive test results for HIV infection have been documented after participation in HIV vaccine trials. In one analysis of 2176 participants who had received 1 of 25 different HIV vaccine products, 42 percent had laboratory evidence of HIV seropositivity through HIV enzyme immunoassay testing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/32\">",
"     32",
"    </a>",
"    ]. However, the occurrence of vaccine-induced seropositivity varied substantially across the various HIV vaccines that were administered (eg, 87 percent amongst recipients of adenovirus 5 vector-based vaccine compared with 6 percent among those who received a DNA vaccine). Among those who tested HIV-seropositive, 10 percent had a reactive Western blot while 66 percent had an indeterminate result.",
"   </p>",
"   <p>",
"    HIV RNA testing and risk assessment should be performed among HIV-seropositive persons with a history of participating in a HIV vaccine trial to help differentiate a serologic response after immunization from true infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Indeterminate test results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indeterminate tests usually result from a positive EIA and a single band on Western blot (usually p24). The frequency of indeterminate results among US blood donors is 1 in 5000.",
"   </p>",
"   <p>",
"    Causes of indeterminate results include partial seroconversion during acute HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/33\">",
"     33",
"    </a>",
"    ], advanced HIV infection with decreased titers of p24 antibodies, or infection with HIV-2.",
"   </p>",
"   <p>",
"    Other causes for an indeterminate test result in persons who are not infected with HIV include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cross-reacting alloantibodies from pregnancy",
"     </li>",
"     <li>",
"      Autoantibodies (collagen-vascular diseases, autoimmune diseases, and malignancy)",
"     </li>",
"     <li>",
"      Receipt of an experimental HIV-1 vaccine",
"     </li>",
"     <li>",
"      Influenza vaccination [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     How to evaluate an indeterminate serologic test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important step in evaluating an indeterminate result is assessing the patient's risk factors for HIV infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At-risk patients &mdash; For those considered at risk for HIV infection, an indeterminate test may indicate that the patient is in the process of seroconverting. In the setting of possible acute HIV infection, HIV RNA testing is particularly important, even in the absence of symptoms. Standard serology should also be repeated at three months.",
"      <br/>",
"      <br/>",
"      Patients should be counseled that they should avoid activities that could transmit the virus (by practicing safe sex",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      not sharing needles or donating blood) until results of viral load testing are available, since HIV transmission is more common in primary infection than in chronic disease because of high levels of viremia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=see_link&amp;anchor=H20#H20\">",
"       \"Acute and early HIV infection: Pathogenesis and epidemiology\", section on 'Infectivity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Low-risk patients &mdash; Patients in low-risk categories with indeterminate tests are rarely infected with either HIV-1 or HIV-2. Repeat testing usually shows persistence of a single band, the cause of which is infrequently established [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/35\">",
"       35",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The patient should have repeat standard serologic testing (eg, EIA) to confirm indeterminate results. HIV load testing should also be performed. It is also common practice to repeat standard serologic testing three months later. Low-risk patients with indeterminate results and no detectable HIV RNA should be reassured that HIV infection is extremely unlikely.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     RAPID ANTIBODY TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid HIV testing has become the preferred first assay used in diagnosing HIV infection in many parts of the world, including the United States. In 2003, the Centers for Disease Control and Prevention (CDC) implemented an initiative to expand HIV testing through the distribution of rapid test kits to 230 organizations in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Through this program, 4650 HIV infections were identified among 372,960 rapid tests administered (1.2 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid serologic tests have several practical advantages over standard HIV serologic assays:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low cost of test performance",
"     </li>",
"     <li>",
"      Results are often available within minutes since the test can be done on site and read by the provider",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Availability of test results at the same encounter also enables appropriate counseling and referral for medical care. In contrast, one survey of patients who had undergone anonymous HIV testing demonstrated delayed entry into medical care by more than 28 percent of 3900 respondents who were interviewed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid tests may not be as sensitive as second generation EIA testing for recent HIV infection. In one study using more than 14,000 specimens, 16 samples were negative by rapid testing, but were positive on EIA testing with subsequent Western blot evolution [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/9\">",
"     9",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H8\">",
"     'Test performance'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Types of rapid testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several rapid tests for the diagnosis of HIV (",
"    <a class=\"graphic graphic_table graphicRef62284 \" href=\"UTD.htm?43/10/44203\">",
"     table 2",
"    </a>",
"    ). In general, rapid testing leads to a result in 5 to 40 minutes, depending upon the assay and specimen used. The OraQuick, Uni-Gold, Reveal, Multispot, Clearview, and VITROS tests also have the ability to detect both HIV-1 and HIV-2. All patients who are tested with any of the above rapid test assays in the United States must receive a \"Subject information pamphlet\" provided with the test.",
"   </p>",
"   <p>",
"    Rapid test assays vary in the specimen types that can be utilized (eg, blood, plasma, serum, saliva):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      OraQuick Rapid",
"      <span class=\"nowrap\">",
"       HIV-1/2",
"      </span>",
"      Antibody Test (OraSure Technologies, www.orasure.com); specimens include blood, plasma, or saliva.",
"     </li>",
"     <li>",
"      OraSure HIV-1 Western Blot test (OraSure Technologies, www.orasure.com); specimens include saliva.",
"     </li>",
"     <li>",
"      Uni-Gold Recombigen HIV Test (Trinity Biotech,",
"      <span class=\"nowrap\">",
"       file://www.trinitybiotech.com/PointOfCare/Pages/HIV-USA.aspx);",
"      </span>",
"      specimens include blood, plasma, and serum.",
"     </li>",
"     <li>",
"      Reveal HIV-1 G3 Antibody Test (MedMira Laboratories, www.medmira.com); specimens include plasma and serum.",
"     </li>",
"     <li>",
"      Multispot",
"      <span class=\"nowrap\">",
"       HIV-1/HIV-2",
"      </span>",
"      (Bio-Rad Laboratories; www.bio-rad.com); serum specimens only.",
"     </li>",
"     <li>",
"      Clearview (Inverness Medical; www.invernessmedicalpd.com); blood specimens.",
"     </li>",
"     <li>",
"      VITROS Anti HIV 1 &amp; 2 (Ortho Clinical Diagnostics; www.orthoclinical.com); serum specimens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, specimen testing can include blood, plasma, or saliva. When obtaining saliva as a specimen, a specially treated cotton pad is used to swab the gums; the swab is then inserted into a vial. The amount of IgG obtained from saliva is far higher than in plasma and well above the 0.5",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    level necessary for detection of HIV antibodies (",
"    <a class=\"graphic graphic_figure graphicRef51525 \" href=\"UTD.htm?31/56/32643\">",
"     figure 1",
"    </a>",
"    ). Blood specimens are obtained by finger stick. One study found that finger stick testing of blood or swabs for saliva were equally acceptable to patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Test performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In early studies, the sensitivity and specificity of these rapid tests was greater than 99 percent (",
"    <a class=\"graphic graphic_table graphicRef62284 \" href=\"UTD.htm?43/10/44203\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/40-45\">",
"     40-45",
"    </a>",
"    ]. Since 2000, the CDC has sponsored four studies in which OraQuick whole blood and oral fluid testing was compared with ELISA (with Western blot confirmation) in more than 12,000 patients in a variety of clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/46\">",
"     46",
"    </a>",
"    ]. HIV seroprevalence for the entire population was 2.7 percent. The sensitivity of whole blood and oral specimens was very high (99.7 and 99.1 percent); the specificity for whole blood and oral specimens was also high (99.9 and 99.6 percent).",
"   </p>",
"   <p>",
"    However, problems with test performance have been reported in a few post-marketing studies that have evaluated these assays in specific patient populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of rapid HIV testing of saliva specimens among 849 patients in a Boston emergency department demonstrated that test specificity was lower than anticipated [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/47\">",
"       47",
"      </a>",
"      ]. Specifically, 39 (4.6 percent) of patients had a reactive result; of the 31 patients who agreed to confirmatory testing, only five (16 percent) were HIV-infected. The estimated rapid test specificity was 96.9 percent (CI, 95.7% to 98.1%); the sensitivity of the rapid HIV assay could not be determined because negative results were not confirmed with standard EIA testing.",
"     </li>",
"     <li>",
"      In 2005, the New York City Department of Health and Mental Hygiene (NYC DOHMH) reported an unexpected increase in the number of false-positive oral fluid tests after using this assay for approximately 15 months in multiple STD clinics [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/48\">",
"       48",
"      </a>",
"      ]. Another transient increase in false-positive results occurred in 2007. The cause for the episodic increases in false-positive oral fluid tests has not yet been determined despite careful investigation.",
"     </li>",
"     <li>",
"      A false negative rapid test result was reported in a patient who presented with late-stage AIDS [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, the sensitivity and specificity of rapid HIV tests is excellent, although the two studies above emphasize the importance of confirmatory testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Interpretation of results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results are reported as positive, negative, or indeterminate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive rapid test is considered \"preliminary\" and requires confirmation by a Western blot [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/50\">",
"       50",
"      </a>",
"      ]. The patient with a positive test should be told of the result and advised on avoiding risk of transmitting HIV while the Western blot test is pending.",
"     </li>",
"     <li>",
"      A negative rapid test is regarded as a true negative, and requires no confirmation; the patient may be informed that the test is negative.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend repeat testing with a standard EIA assay and HIV RNA testing as well in the patient with an indeterminate result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Regulations of testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Performance of these tests in the United States is regulated by the Clinical Laboratory Improvement Amendment of 1988 (CLIA). OraQuick, Clearview, and Uni-Gold are \"CLIA-waived\" tests. The advantage is that these tests can be done in laboratories, clinical settings, health fairs, mobile vans, or physicians' offices and can be interpreted by the provider on site. These tests use saliva or whole blood and consequently do not require a centrifuge. The only requirement is to obtain a certificate of waiver and follow manufacturers' instructions (more information is available at",
"    <a class=\"external\" href=\"file://www.phppo.cdc.gov/clia/regs/toc.aspx\">",
"     www.phppo.cdc.gov/clia/regs/toc.aspx",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     WHEN TO USE RAPID TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid tests represent a major advance in HIV serologic testing. Rapid testing can be offered on site in a variety of settings including clinics, mobile vans, health fairs, and places of worship. Rapid testing is becoming the test of choice for all patients who request screening due to the immediate feedback for patients and the opportunities this creates for quick intervention and counseling.",
"   </p>",
"   <p>",
"    These tests are especially attractive for use in situations in which immediate results are important in management decisions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occupational or nonoccupational exposures (since the use of antiretroviral prophylaxis is strongly influenced by the serologic status of the source) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      When patients are unlikely to return for results and seroprevalence rates are high (eg, sexually transmitted disease clinics and emergency departments, bathhouses) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/40,53-56\">",
"       40,53-56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients with an acute illness in which an HIV-related complication is being considered and serostatus is not known.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     COMBINED ANTIBODY ANTIGEN TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fourth generation tests are distinguished from the antibody tests above by their ability to detect both antibody and p24 antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/7\">",
"     7",
"    </a>",
"    ]. Multiple assays from various manufacturers are available in the United States and Europe that perform with high sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/57\">",
"     57",
"    </a>",
"    ]. The advantage of these assays is in their ability to detect HIV p24 antigen during acute infection when antibody formation may not yet be detected (eg, \"window period of acute HIV infection\").",
"   </p>",
"   <p>",
"    A study was performed of the sensitivity and specificity of six combined antibody antigen tests compared with two third generation HIV antibody tests [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/57\">",
"     57",
"    </a>",
"    ]. This study employed approximately 1900 samples including 25 seroconversion panels and more than 1000 unselected HIV-seronegative samples from four different referral laboratories. Samples from seroconversion panels during primary infection are informative in determining the sensitivity of such assays.",
"   </p>",
"   <p>",
"    This study demonstrated that four of the six combined antibody-antigen assays reduced the window period of acute HIV infection by approximately one to two days, compared with third generation antibody testing; AxSYM and Murex Combo had the highest overall performance, mainly due to their low threshold for detection of p24 antigen (ie, 7 and 5",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    respectively), which rivals that of the direct HIV p24 antigen assay (ie, 3 to 5",
"    <span class=\"nowrap\">",
"     pg/mL).",
"    </span>",
"    In addition, the specificity of all combined assays was greater than 99.5 percent; Genscreen Plus and AxSYM Combo had the highest specificity (99.9 and 99.8 percent, respectively).",
"   </p>",
"   <p>",
"    Another study was performed that compared fourth generation combination assays (AxSYM, ARCHITECT and PRISM) to three older third generation antibody assays from the same manufacturer for large scale screening. More than 40,000 samples per assay were included. Selected panels of confirmed HIV-1- and HIV-2-positive samples as well as seroconversion samples (HIV-1) from commercial panels and patient samples were used. The study demonstrated that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensitivity and specificity of the fourth generation tests were greater than 99 percent for all fourth generation assays.",
"     </li>",
"     <li>",
"      All of the fourth generation assays detected p24 antigen in 27 primary HIV infection samples that were known to be antibody-negative at the time of presentation.",
"     </li>",
"     <li>",
"      One of 40 HIV-2 samples was not identified by the combination assays.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Combination assays may also offer a less expensive alternative to pooled HIV RNA screening for the detection of acute HIV infection in other settings, such as blood bank screening, although optimal strategies are still being developed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     IN-HOME HIV SCREENING TESTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3732504\">",
"    <span class=\"h2\">",
"     Controversies regarding home testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of alternative HIV serologic tests are available to detect anti-HIV antibodies, some of which are approved for home use [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/60\">",
"     60",
"    </a>",
"    ]. Proponents of HIV testing within the home argue that such tests provide increased access, anonymity, and privacy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/61\">",
"     61",
"    </a>",
"    ]. Opponents argue that these alternative tests do not allow for face-to-face counseling or support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3732519\">",
"    <span class=\"h2\">",
"     Available screening assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of in-home diagnostic testing have been developed for in-home HIV screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3732526\">",
"    <span class=\"h3\">",
"     Consumer testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2012, the US Food and Drug Administration (FDA) approved OraQuick In-Home HIV test, the first self-administered HIV test kit to detect antibodies to HIV-1 and HIV-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/62\">",
"     62",
"    </a>",
"    ]. The test is available for consumers in drug stores at a retail price of about 40 dollars. Individuals may obtain test results within 20 to 40 minutes after collecting an oral fluid sample by swabbing the upper and lower gums inside the mouth and placing that sample into a developer vial provided as part of the kit. As with all rapid HIV assays, positive test results are preliminary and need to be confirmed with a standard HIV antibody test. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Interpretation of results'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In clinical trials, self-testing with this rapid HIV assay had a sensitivity of 92 percent and a specificity of 99.98 percent compared with the standard enzyme immunoassay (EIA) screening assay. As is typical for most antibody tests, this assay may be negative within the &ldquo;window period&rdquo; after initial infection. OraSure Technologies, the manufacturer of the OraQuick In-Home HIV Test will have a telephone consumer support center available 24 hours a day, seven days a week once the product is available for sale to the public. The center will provide education about",
"    <span class=\"nowrap\">",
"     HIV/AIDS,",
"    </span>",
"    the proper method for administering the test, and guidance on what to do once the results have been obtained. This test has the potential to identify large numbers of previously undiagnosed HIV infections, especially if the test is used by individuals who are unlikely to seek medical care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3732533\">",
"    <span class=\"h3\">",
"     Mail-in test results",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Home Access HIV-1 home collection test system is sold as either \"The Home Access HIV-1 Test System\" or \"The Home Access Express HIV-1 Test System.\"&nbsp;It allows blood samples to be taken at home using a finger stick test strip that is mailed to a laboratory for screening and confirmation. Results are obtained by phone using an individual identifier code supplied with the product.",
"   </p>",
"   <p>",
"    The sensitivity determined in clinical studies reported is estimated to be 100 percent based on the correct identification of",
"    <span class=\"nowrap\">",
"     150/150",
"    </span>",
"    positive samples compared with matched serum specimens. The specificity determined in the studies reported is estimated to be 100 percent based on the correct identification of",
"    <span class=\"nowrap\">",
"     997/997",
"    </span>",
"    negative samples compared to matched serum specimens.",
"   </p>",
"   <p>",
"    Hoffman Estates, III (800-HIV-test) is a self-test kit sold in pharmacies or is available by phone (800-448-8378) or online (www.homeaccess.com). The kit includes a lancet, filter strip, and mailer. The user obtains a drop of blood and places it on the filter strip, which is mailed to the supplier with an anonymous identifier code.",
"   </p>",
"   <p>",
"    The test consists of a double EIA and confirmatory IFA. Sensitivity and specificity approach 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/63\">",
"     63",
"    </a>",
"    ]. Results are confidential and anonymous; results and counseling are available by telephone. The cost depends on the speed of requested handling (eg, standard or one-week versus next-day results).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     VIRAL DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other methods to establish HIV infection include viral isolation or qualitative or quantitative detection of HIV antigens alone through polymerase chain reaction techniques, branched chain DNA testing, or nucleic acid sequence-based amplification (NASBA) (",
"    <a class=\"graphic graphic_table graphicRef74816 graphicRef54839 \" href=\"UTD.htm?29/28/30157\">",
"     table 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The limitations of these assays include cost, the requirement for venipuncture and more laboratory technology, and time interval between sample collection and test results. Ultrasensitive assays for the detection of p24 antigen, which is less expensive than nucleic acid sequence-based testing, can identify approximately 89 percent of individuals who seek testing during acute infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    None of these tests is considered superior to routine serologic testing; furthermore, viral detection assays should never be used to circumvent the informed consent process. However, viral detection is useful in specific situations, such as the diagnosis of neonatal HIV infection, in patients with indeterminate serologic tests, or in those who may be in the \"window period\" of HIV seroconversion. The diagnosis of primary HIV infection is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=see_link\">",
"     \"Acute and early HIV infection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tests that are rarely performed in the clinical setting include DNA-PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20345/abstract/66\">",
"     66",
"    </a>",
"    ] and viral culture of peripheral blood mononuclear cells, which have sensitivities of 95 to 100 percent.",
"   </p>",
"   <p>",
"    Techniques for monitoring HIV RNA are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=see_link\">",
"     \"Techniques and interpretation of HIV-1 RNA quantitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=see_link\">",
"       \"Patient information: HIV/AIDS (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/60/1986?source=see_link\">",
"       \"Patient information: Testing for HIV (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serologic tests for HIV infection are based upon detection of IgG antibodies against HIV-1 antigens in serum. HIV-specific IgG antibodies appear 6 to 12 weeks following HIV infection in the majority of patients and by six months in 95 percent of patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of diagnostic assays are available for HIV infection, which vary in terms of turnaround time, sensitivity and specificity, and specimen handling. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians need to be aware that the operating characteristics of a test depend not only on the test itself, but also on the likelihood that individuals will seek testing during chronic infection or during acute HIV seroconversion, when the likelihood of a false negative test result increases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Standard HIV-1 antibody tests",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The standard screening assay for detecting antibodies to HIV is an enzyme immunoassay (EIA). A confirmatory Western blot is performed if the screening test is positive to exclude a false positive test. Test results are reported as positive, negative, or indeterminate. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Serologic response to HIV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common cause of a false negative HIV antibody test in a high-risk patient is that the assay is being conducted during the \"window period\" of acute HIV infection prior to seroconversion. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Acute infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      False positive tests are very rare and usually represent labeling errors. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Standard HIV-1 antibody tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important step in evaluating an indeterminate result is assessing the patient's risk factors. Low-risk patients should be reassured that HIV infection is unlikely; repeat serologic testing and HIV RNA quantification can provide absolute assurance. In contrast, high-risk patients may be in the process of seroconversion and an HIV RNA should be performed. Patients with acute HIV infection often have high level viremia and should be counseled regarding the risk of HIV transmission. Repeat serologic testing and HIV RNA determination should be assessed within one month. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Standard HIV-1 antibody tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Positive HIV antibody tests have been reported among participants in HIV vaccine trials. We recommend HIV RNA testing and risk assessment in HIV-seropositive persons with a history of participation in a HIV vaccine trial to help differentiate a positive serologic response after immunization from true infection. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'False positive serologic tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Rapid HIV testing",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid serologic tests offer high diagnostic accuracy with the advantage of providing test results at the point of care. These tests are particularly advantageous for occupational or nonoccupational HIV exposures, for women who present in labor without prior HIV testing, and for patients who are unlikely to return for results. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Rapid antibody tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All positive rapid HIV test results must be confirmed with standard EIA antibody and Western blot testing. However, testing is complete if the rapid test is negative, unless there is clinical suspicion of acute HIV infection. In this scenario, HIV RNA testing should be performed. The patient with an indeterminate result should have repeat testing in one to two months with rapid or standard serologies. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Rapid antibody tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Combination antibody-antigen testing",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fourth generation tests simultaneously detect both antibody and p24 antigen and perform with high sensitivity and specificity. The advantage of these assays is in their ability to detect HIV p24 antigen during the window period of acute HIV infection. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Combined antibody antigen tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Viral detection assays",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other methods to establish HIV infection include viral isolation or qualitative or quantitative detection of HIV antigens alone through polymerase chain reaction techniques, branched-chain DNA testing, or nucleic acid sequence-based amplification. The major limitations of these assays include cost, the requirement for venipuncture, and time interval between sample collection and test results. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Viral detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Viral detection testing may be useful in specific situations, such as the diagnosis of neonatal HIV infection, in patients with indeterminate serologic tests, or in those who may be in the \"window period\" of HIV seroconversion. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Viral detection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     UNAIDS Annual Report 2008. Towards Universal Access. file://data.unaids.org/pub/Report/2009/jc1736_2008_annual_report_en.pdf (Accessed on July 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/2\">",
"      G&uuml;rtler L. Difficulties and strategies of HIV diagnosis. Lancet 1996; 348:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/3\">",
"      Allain JP, Laurian Y, Paul DA, Senn D. Serological markers in early stages of human immunodeficiency virus infection in haemophiliacs. Lancet 1986; 2:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/4\">",
"      Horsburgh CR Jr, Ou CY, Jason J, et al. Duration of human immunodeficiency virus infection before detection of antibody. Lancet 1989; 2:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/5\">",
"      Spivak AM, Brennan TP, O'Connell KA, et al. A case of seronegative HIV-1 infection. J Infect Dis 2010; 201:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/6\">",
"      Delwart EL, Orton S, Parekh B, et al. Two percent of HIV-positive U.S. blood donors are infected with non-subtype B strains. AIDS Res Hum Retroviruses 2003; 19:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/7\">",
"      Malm K, von Sydow M, Andersson S. Performance of three automated fourth-generation combined HIV antigen/antibody assays in large-scale screening of blood donors and clinical samples. Transfus Med 2009; 19:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/8\">",
"      Plantier JC, Leoz M, Dickerson JE, et al. A new human immunodeficiency virus derived from gorillas. Nat Med 2009; 15:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/9\">",
"      Stekler JD, Swenson PD, Coombs RW, et al. HIV testing in a high-incidence population: is antibody testing alone good enough? Clin Infect Dis 2009; 49:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/10\">",
"      Centers for Disease Control (CDC). Update: serologic testing for HIV-1 antibody--United States, 1988 and 1989. MMWR Morb Mortal Wkly Rep 1990; 39:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/11\">",
"      Urnovitz HB, Sturge JC, Gottfried TD. Increased sensitivity of HIV-1 antibody detection. Nat Med 1997; 3:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/12\">",
"      Farzadegan H, Vlahov D, Solomon L, et al. Detection of human immunodeficiency virus type 1 infection by polymerase chain reaction in a cohort of seronegative intravenous drug users. J Infect Dis 1993; 168:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/13\">",
"      Busch MP, Eble BE, Khayam-Bashi H, et al. Evaluation of screened blood donations for human immunodeficiency virus type 1 infection by culture and DNA amplification of pooled cells. N Engl J Med 1991; 325:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/14\">",
"      Van de Perre P, Simonon A, Msellati P, et al. Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. A prospective cohort study in Kigali, Rwanda. N Engl J Med 1991; 325:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Identification of HIV-1 group O infection--Los Angeles county, California, 1996. MMWR Morb Mortal Wkly Rep 1996; 45:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/16\">",
"      Loussert-Ajaka I, Ly TD, Chaix ML, et al. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet 1994; 343:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/17\">",
"      Schable C, Zekeng L, Pau CP, et al. Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections. Lancet 1994; 344:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/18\">",
"      Zouhair S, Roussin-Bretagne S, Moreau A, et al. Group o human immunodeficiency virus type 1 infection that escaped detection in two immmunoassays. J Clin Microbiol 2006; 44:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/19\">",
"      Weber B, Orazi B, Raineri A, et al. Multicenter evaluation of a new 4th generation HIV screening assay Elecsys HIV combi. Clin Lab 2006; 52:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/20\">",
"      Yeom JS, Jun G, Chang Y, et al. Evaluation of a new fourth generation enzyme-linked immunosorbent assay, the LG HIV Ag-Ab Plus, with a combined HIV p24 antigen and anti-HIV-1/2/O screening test. J Virol Methods 2006; 137:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/21\">",
"      Farzadegan H, Polis MA, Wolinsky SM, et al. Loss of human immunodeficiency virus type 1 (HIV-1) antibodies with evidence of viral infection in asymptomatic homosexual men. A report from the Multicenter AIDS Cohort Study. Ann Intern Med 1988; 108:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/22\">",
"      Sullivan JF, Kessler HA, Sha BE. False-positive HIV test: implications for the patient. JAMA 1993; 269:2847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/23\">",
"      Spivak AM, Sydnor ER, Blankson JN, Gallant JE. Seronegative HIV-1 infection: a review of the literature. AIDS 2010; 24:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/24\">",
"      Ellenberger DL, Sullivan PS, Dorn J, et al. Viral and immunologic examination of human immunodeficiency virus type 1-infected, persistently seronegative persons. J Infect Dis 1999; 180:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/25\">",
"      Apetrei C, Tamalet C, Edlinger C, et al. Delayed HIV-1 seroconversion after antiretroviral therapy. AIDS 1998; 12:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/26\">",
"      Martin-Rico P, Pedersen C, Skinh&oslash;j P, et al. Rapid development of AIDS in an HIV-1-antibody-negative homosexual man. AIDS 1995; 9:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/27\">",
"      Michael NL, Brown AE, Voigt RF, et al. Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection--evidence for highly susceptible human hosts. J Infect Dis 1997; 175:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/28\">",
"      Montagnier L, Brenner C, Chamaret S, et al. Human immunodeficiency virus infection and AIDS in a person with negative serology. J Infect Dis 1997; 175:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/29\">",
"      Burke DS, Brundage JF, Redfield RR, et al. Measurement of the false positive rate in a screening program for human immunodeficiency virus infections. N Engl J Med 1988; 319:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/30\">",
"      MacDonald KL, Jackson JB, Bowman RJ, et al. Performance characteristics of serologic tests for human immunodeficiency virus type 1 (HIV-1) antibody among Minnesota blood donors. Public health and clinical implications. Ann Intern Med 1989; 110:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/31\">",
"      Pereyra F, Palmer S, Miura T, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis 2009; 200:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/32\">",
"      Cooper CJ, Metch B, Dragavon J, et al. Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients. JAMA 2010; 304:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/33\">",
"      Belshe RB, Clements ML, Keefer MC, et al. Interpreting HIV serodiagnostic test results in the 1990s: social risks of HIV vaccine studies in uninfected volunteers. NIAID AIDS Vaccine Clinical Trials Group. Ann Intern Med 1994; 121:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/34\">",
"      Erickson CP, McNiff T, Klausner JD. Influenza vaccination and false positive HIV results. N Engl J Med 2006; 354:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/35\">",
"      Jackson JB, MacDonald KL, Cadwell J, et al. Absence of HIV infection in blood donors with indeterminate western blot tests for antibody to HIV-1. N Engl J Med 1990; 322:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/36\">",
"      Centers for Disease Control and Prevention (CDC). Rapid HIV test distribution--United States, 2003-2005. MMWR Morb Mortal Wkly Rep 2006; 55:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/37\">",
"      Lyss SB, Branson BM, Kroc KA, et al. Detecting unsuspected HIV infection with a rapid whole-blood HIV test in an urban emergency department. J Acquir Immune Defic Syndr 2007; 44:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/38\">",
"      Reed JB, Hanson D, McNaghten AD, et al. HIV testing factors associated with delayed entry into HIV medical care among HIV-infected persons from eighteen states, United States, 2000-2004. AIDS Patient Care STDS 2009; 23:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/39\">",
"      White DA, Scribner AN, Huang JV. A comparison of patient acceptance of fingerstick whole blood and oral fluid rapid HIV screening in an emergency department. J Acquir Immune Defic Syndr 2009; 52:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/40\">",
"      Irwin K, Olivo N, Schable CA, et al. Performance characteristics of a rapid HIV antibody assay in a hospital with a high prevalence of HIV infection. CDC-Bronx-Lebanon HIV Serosurvey Team. Ann Intern Med 1996; 125:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/41\">",
"      Malone JD, Smith ES, Sheffield J, et al. Comparative evaluation of six rapid serological tests for HIV-1 antibody. J Acquir Immune Defic Syndr 1993; 6:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/42\">",
"      van den Berk GE, Frissen PH, Regez RM, Rietra PJ. Evaluation of the rapid immunoassay determine HIV 1/2 for detection of antibodies to human immunodeficiency virus types 1 and 2. J Clin Microbiol 2003; 41:3868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/43\">",
"      Gallo D, George JR, Fitchen JH, et al. Evaluation of a system using oral mucosal transudate for HIV-1 antibody screening and confirmatory testing. OraSure HIV Clinical Trials Group. JAMA 1997; 277:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/44\">",
"      Kelen GD, Bennecoff TA, Kline R, et al. Evaluation of two rapid screening assays for the detection of human immunodeficiency virus-1 infection in emergency department patients. Am J Emerg Med 1991; 9:416.",
"     </a>",
"    </li>",
"    <li>",
"     Branson B. Rolling out rapid HIV tests in the United States. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA February 22-25, 2005, Abstract #53.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/46\">",
"      Delaney KP, Branson BM, Uniyal A, et al. Performance of an oral fluid rapid HIV-1/2 test: experience from four CDC studies. AIDS 2006; 20:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/47\">",
"      Walensky RP, Arbelaez C, Reichmann WM, et al. Revising expectations from rapid HIV tests in the emergency department. Ann Intern Med 2008; 149:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/48\">",
"      Centers for Disease Control and Prevention (CDC). False-positive oral fluid rapid HIV tests--New York City, 2005-2008. MMWR Morb Mortal Wkly Rep 2008; 57:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/49\">",
"      Brown P, Merline JR, Levine D, Minces LR. Repeatedly false-negative rapid HIV test results in a patient with undiagnosed advanced AIDS. Ann Intern Med 2008; 149:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/50\">",
"      Pilcher CD, Hare CB. The deadliest catch: fishing for HIV in new waters. Ann Intern Med 2008; 149:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/51\">",
"      U.S. Public Health Service. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm Rep 2001; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/52\">",
"      Kallenborn JC, Price TG, Carrico R, Davidson AB. Emergency department management of occupational exposures: cost analysis of rapid HIV test. Infect Control Hosp Epidemiol 2001; 22:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/53\">",
"      Centers for Disease Control and Prevention (CDC). HIV testing among populations at risk for HIV infection--nine states, November 1995-December 1996. MMWR Morb Mortal Wkly Rep 1998; 47:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/54\">",
"      Lubelchek R, Kroc K, Hota B, et al. The role of rapid vs conventional human immunodeficiency virus testing for inpatients: effects on quality of care. Arch Intern Med 2005; 165:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/55\">",
"      Centers for Disease Control and Prevention (CDC). Rapid HIV testing in emergency departments--three U.S. sites, January 2005-March 2006. MMWR Morb Mortal Wkly Rep 2007; 56:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/56\">",
"      Daskalakis D, Silvera R, Bernstein K, et al. Implementation of HIV testing at 2 New York City bathhouses: from pilot to clinical service. Clin Infect Dis 2009; 48:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/57\">",
"      Ly TD, Laperche S, Brennan C, et al. Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. J Virol Methods 2004; 122:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/58\">",
"      Sickinger E, Jonas G, Yem AW, et al. Performance evaluation of the new fully automated human immunodeficiency virus antigen-antibody combination assay designed for blood screening. Transfusion 2008; 48:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/59\">",
"      Daar ES, Pilcher CD, Hecht FM. Clinical presentation and diagnosis of primary HIV-1 infection. Curr Opin HIV AIDS 2008; 3:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/60\">",
"      Mylonakis E, Paliou M, Lally M, et al. Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. Am J Med 2000; 109:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/61\">",
"      Wright AA, Katz IT. Home testing for HIV. N Engl J Med 2006; 354:437.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310542.htm (Accessed on July 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/63\">",
"      Frank AP, Wandell MG, Headings MD, et al. Anonymous HIV testing using home collection and telemedicine counseling. A multicenter evaluation. Arch Intern Med 1997; 157:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/64\">",
"      Daar ES, Little S, Pitt J, et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med 2001; 134:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/65\">",
"      Fiscus SA, Pilcher CD, Miller WC, et al. Rapid, real-time detection of acute HIV infection in patients in Africa. J Infect Dis 2007; 195:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20345/abstract/66\">",
"      Taylor MM, Rotblatt H, Brooks JT, et al. Epidemiologic investigation of a cluster of workplace HIV infections in the adult film industry: Los Angeles, California, 2004. Clin Infect Dis 2007; 44:301.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3742 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-8C22B84DCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_55_20345=[""].join("\n");
var outline_f19_55_20345=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Serologic response to HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Classification of HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Operating characteristics of the assay",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      OVERVIEW OF AVAILABLE TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      STANDARD HIV-1 ANTIBODY TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Test performance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      False negative serologic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Acute infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Failure to detect certain HIV subtypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Rare causes of false negative testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      False positive serologic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - HIV vaccine recipients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Indeterminate test results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - How to evaluate an indeterminate serologic test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RAPID ANTIBODY TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Disadvantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Types of rapid testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Test performance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Interpretation of results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Regulations of testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      WHEN TO USE RAPID TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      COMBINED ANTIBODY ANTIGEN TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      IN-HOME HIV SCREENING TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3732504\">",
"      Controversies regarding home testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3732519\">",
"      Available screening assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3732526\">",
"      - Consumer testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3732533\">",
"      - Mail-in test results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      VIRAL DETECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Standard HIV-1 antibody tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Rapid HIV testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Combination antibody-antigen testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Viral detection assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3742\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3742|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/56/32643\" title=\"figure 1\">",
"      OraQuick rapid test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3742|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/41/33436\" title=\"table 1A\">",
"      Tests for diagnosing HIV I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/13/10460\" title=\"table 1B\">",
"      Tests for diagnosing HIV II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/10/44203\" title=\"table 2\">",
"      Rapid HIV tests",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=related_link\">",
"      Acute and early HIV infection: Pathogenesis and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=related_link\">",
"      Acute and early HIV infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/60/1986?source=related_link\">",
"      Patient information: Testing for HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=related_link\">",
"      Serologic screening for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=related_link\">",
"      Techniques and interpretation of HIV-1 RNA quantitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=related_link\">",
"      Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=related_link\">",
"      The global human immunodeficiency virus pandemic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=related_link\">",
"      The stages and natural history of HIV infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_55_20346="Principles of burn reconstruction: Overview of surgical procedures";
var content_f19_55_20346=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Principles of burn reconstruction: Overview of surgical procedures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/55/20346/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/55/20346/contributors\">",
"     Jorge Leon-Villapalos, MD, FRCS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/55/20346/contributors\">",
"     Peter Dziewulski, MD, FRCS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/55/20346/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/55/20346/contributors\">",
"     Marc G Jeschke, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/55/20346/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/55/20346/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/55/20346/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25963747\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following resuscitation and stabilization, management of the burn wounds becomes the next priority. The goals of reconstructive surgery for the burn patient are first to restore function, then to restore esthetic appearances. The later effects of burns, which are related to loss of normal tissue and scarring, include limitation of movement, pain, disfigurement, and social embarrassment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the surgical techniques used for burn reconstruction is reviewed here. Emergent care of patients with moderate to severe burns and the local topical antimicrobial agents and dressings for burns are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25964950\">",
"    <span class=\"h1\">",
"     CHALLENGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several challenges related to tissue loss and scarring that must be met in order to reconstruct burns [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/1\">",
"     1",
"    </a>",
"    ]. The key to longer-term local burn care is scar management, which can be achieved through surgery and physical therapy. A balance must be attained between immobilization to allow skin grafts or tissue flaps to heal and mobilization of the burned area to restore function. Successful reconstruction needs to be complemented with the integration of the patient in the multidisciplinary team and specifically with the early intervention of the therapy and rehabilitation teams to restore the patient to society as an active and functional member.",
"   </p>",
"   <p>",
"    The specific challenges for reconstruction of patients with burns include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extensive tissue loss",
"     </li>",
"     <li>",
"      Scars",
"     </li>",
"     <li>",
"      Exposed tendons and bones",
"     </li>",
"     <li>",
"      Burns to sensitive anatomic locations (eg, face, genitalia, and hands) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18409?source=see_link\">",
"       \"Primary operative management of hand burns\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Multiple sites burned",
"     </li>",
"     <li>",
"      Lack of tissue pliability",
"     </li>",
"     <li>",
"      Limited tissue donor sites",
"     </li>",
"     <li>",
"      Multiple surgical procedures required for complete skin coverage",
"     </li>",
"     <li>",
"      Intraoperative blood loss",
"     </li>",
"     <li>",
"      Postoperative pain",
"     </li>",
"     <li>",
"      Burn wound infections",
"     </li>",
"     <li>",
"      Delayed wound healing due to impaired nutrition (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11401?source=see_link\">",
"       \"Nutritional demands and enteral formulas for moderate to severe burn patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link\">",
"       \"Hypermetabolic response to severe burn injury: Recognition and treatment\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1883166\">",
"    <span class=\"h1\">",
"     TIMING OF SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of surgery for burn reconstruction is categorized as urgent (immediate), essential (early), and desirable (late) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/2\">",
"     2",
"    </a>",
"    ]. While definitive reconstruction of burn scars is generally delayed for one year, some burns require immediate reconstructive attention in order to restore function or protect vital areas. The following represents a straightforward and comprehensible approach to reconstructive options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1883187\">",
"    <span class=\"h2\">",
"     Urgent (immediate) procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent (immediate) procedures are restricted to burns in which there is no other suitable treatment, such as providing coverage for exposed or severely damaged vital structures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/2\">",
"     2",
"    </a>",
"    ]. Urgent procedures are performed to preserve function in vital areas. These procedures should be performed after all open wounds are closed and at the onset of symptoms related to the vital structures. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Release of eyelid to protect the cornea to avoid cicatricial ectropion",
"     </li>",
"     <li>",
"      Release of microstomia (severe contractures of the mouth)",
"     </li>",
"     <li>",
"      Release of compressed neurovascular bundles",
"     </li>",
"     <li>",
"      Release of synechia (severe neck contractures) that limit neck extension",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1883213\">",
"    <span class=\"h2\">",
"     Essential (early) procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Essential (early) procedures are performed to improve the burn care rehabilitation and non-vital function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/2\">",
"     2",
"    </a>",
"    ]. The essential procedures are performed for mature burn scar contractures that do not respond to splinting or aggressive physical therapy. Examples of hypertrophic scarring areas that are amenable to essential reconstruction include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Non-synechial neck contractures",
"     </li>",
"     <li>",
"      Contractures of major joints (eg, elbow, knee, ankle)",
"     </li>",
"     <li>",
"      Contractures of areas that limit mobility (eg, axilla, groin)",
"     </li>",
"     <li>",
"      Contractures of the hand",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1883241\">",
"    <span class=\"h2\">",
"     Desirable (late) procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most burn reconstructive procedures are performed as desirable (late) procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/2\">",
"     2",
"    </a>",
"    ]. These procedures are performed after the scar has matured. Late procedures address the size and shape of the mature scar as well as abnormalities in color and texture mismatched to the surrounding skin. Functional reconstructive procedures should always be performed with the goal of the best esthetic result possible, thus providing dual benefits to the burned patient [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/3\">",
"     3",
"    </a>",
"    ]. Examples of late reconstruction include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reconstruction of passive areas (eg, trunk, extremities)",
"     </li>",
"     <li>",
"      Esthetics (eg, face, breast)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8044867\">",
"    <span class=\"h1\">",
"     BURN RECONSTRUCTION PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burn reconstruction procedures are used to cover wounds and restore function and esthetics. Reconstruction can be completed in phases, depending on severity of burn scar, contracture, structure, and donor tissue availability. The surgical procedures used in burn reconstruction include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary closure",
"     </li>",
"     <li>",
"      Excision and skin grafting",
"     </li>",
"     <li>",
"      Dermal regeneration templates (skin substitutes)",
"     </li>",
"     <li>",
"      Tissue expansion",
"     </li>",
"     <li>",
"      Tissue transfer: Local, regional, distant, and free flaps",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reconstructive procedures of ascending complexity may be required depending on the nature of the area to be reconstructed and the tissue defect. Adequate knowledge and judicious use of the reconstructive ladder provides a safe guidance pathway for the reconstructive burn surgeon. An overview of local treatment, including topical agents and dressings, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8044904\">",
"    <span class=\"h2\">",
"     Primary closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary wound closure is the simplest and most direct procedure that can be used for small burn scars. Burn scars are excised and closed by immediate approximation of the wound edges. The key principle for a primary closure is that there must be no tension on the wound. This principle must be applied judiciously.",
"   </p>",
"   <p>",
"    This technique is suitable for burn scar revision in areas where the elasticity of the surrounding tissues warrant tension-free closure. The main advantage of primary closure is a theoretical improvement in esthetic outcome. The major limitation of a primary closure is tension on the wound closure, which may lead to wound dehiscence, delayed wound healing, distortion, and unsightly and painful scars. Small burn scars that cross joint lines, or involve areas close to the eyes, mouth, and nose, can be revised using a z-plasty (",
"    <a class=\"graphic graphic_figure graphicRef61176 graphicRef71491 graphicRef60824 graphicRef57321 graphicRef55030 graphicRef74115 \" href=\"UTD.htm?32/14/33002\">",
"     figure 1A-F",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11446?source=see_link\">",
"     \"Z-plasty\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22158166\">",
"    <span class=\"h2\">",
"     Early excision and skin grafting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early excision and grafting generally applies to the acute coverage of burns rather than reconstruction. However, these principles are important to managing burn reconstruction wounds as early excision and skin grafting reduces the presence of potentially necrotic and infected tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Early excision of necrotic tissue and closure of the burn wound has been one of the single greatest advancements in the treatment of patients with severe thermal injuries and a mainstay of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. A single institution retrospective analysis of 3561 burn patients attributed early wound excision and closure (day one to five) to the decrease in length of hospital stay and the reduced cost of hospital care [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of six prospective trials showed a significant reduction in mortality with early excision and grafting in burn patients without inhalation injury (RR 0.36, 95% CI 0.20-0.65) compared to conservative treatment of dressing changes and delayed skin grafts following eschar separation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/8\">",
"     8",
"    </a>",
"    ]. The pooled data showed that the mean length of hospital stay was significantly shorter for the early excision group (standardized mean difference [SMD] -8.89) and the requirement for blood transfusions was significantly higher (SMD 1.65). There was no difference in duration of sepsis, wound healing time, and skin graft take between the two groups.",
"   </p>",
"   <p>",
"    While burn wound closure within the first five days is optimal, it is not always possible. A retrospective study of 143 burn patients showed that a delayed primary wound closure (day 6 to 12) had a similar advantage of early wound closure in reducing risk of septicemia, mortality, morbidity, hospital stay, and cost of treatment, in comparison to 449 patients treated with delayed closure, a practice that allowed wounds to granulate prior to skin grafting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early wound closure is also associated with decreased severity of hypertrophic scarring, joint contractures, and stiffness, and promotes faster rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Wound closure alone, however, does not eliminate the hypermetabolic response [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8044912\">",
"    <span class=\"h2\">",
"     Free skin grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Free skin grafts, either split thickness or full thickness, are the conventional options for coverage of burns, with the exception of the smallest burn wounds and burns exposing bone and tendons devoid of a graftable vascularized layer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/13\">",
"     13",
"    </a>",
"    ]. Skin grafts are used for coverage of exposed bone and tendons only if there is vascularized periosteum or the paratenon (paratendon) is intact.",
"   </p>",
"   <p>",
"    Split thickness skin grafts (STSG) are more versatile than full thickness skin grafts (FTSG) and are used to reconstruct large burn wound areas and close donor flap sites. FTSG result in a more satisfactory esthetic appearance. The anterior and lateral surfaces of the thigh are usually the preferred donor sites, but in large surface area burns, every available site can be harvested, including the scalp and scrotum. When donor sites are plentiful, the site should be located at an inconspicuous location that is easily accessible for wound care.",
"   </p>",
"   <p>",
"    The primary limitations of skin grafting are the availability of unburned donor sites, and the elasticity and pliability of the donor skin. The use of a thin skin graft is preferred for covering burns with an unstable vascular supply, particularly if donor skin is scarce. Sheet grafts provide optimal coverage for burns of the face and hands and other anatomic sites where cosmesis and function are important, but are dependent on the availability of unburned skin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Repeat harvesting of a donor site and skin graft expansion by meshing are preferred techniques to obtain suitable skin for grafting in this situation. The quality, elasticity, and pliability of the reconstruction can be improved by combining a STSG with a dermal regeneration template. If there are limited skin donor sites, there will also be limited possibilities to used dermal regeneration templates. (See",
"    <a class=\"local\" href=\"#H8044936\">",
"     'Dermal regeneration templates'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A 1:1 mesh combines the expandable advantage of mesh grafts with the cosmetic advantage of sheet grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/15\">",
"     15",
"    </a>",
"    ]. The nonexpandable mesh adapts to uneven surfaces, allows drainage of hematomas and seromas, and provides for superior cosmetic results compared with meshed grafts. (See",
"    <a class=\"local\" href=\"#H8044920\">",
"     'Split thickness skin grafts'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10876305\">",
"    <span class=\"h3\">",
"     Tumescent infiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various techniques for tumescent infiltration to facilitate graft harvesting and reduce intraoperative blood loss and postoperative pain have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Tumescent infiltration of the donor and burn sites with subdermal injections of diluted epinephrine results in a significant reduction of intraoperative blood loss compared to a similar group of burn patients not treated with these techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/18\">",
"     18",
"    </a>",
"    ]. Tumescent infiltration with large diluted volumes of local anesthesia (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    maximum dose) in normal saline reduces intraoperative blood loss and postoperative pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/16,17,19\">",
"     16,17,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumescent infiltration of the subdermis, subcutaneous, and subeschar tissues assists with debridement of the burn and harvesting the graft from the donor site. Our standard infiltration of both burned tissue and donor sites is one liter of normal saline with an ampule of 1:1000 epinephrine. For local anesthesia, we use a mixture of 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    0.25 percent. The bupivacaine provides longer duration analgesia for donor site pain, as these areas are the most problematic for postoperative pain control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link\">",
"     \"Infiltration of local anesthetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8044920\">",
"    <span class=\"h3\">",
"     Split thickness skin grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin, in the form of a split thickness skin graft (STSG), is the most frequently used donor for tissue coverage. A STSG includes the epidermis and varying amounts of dermis, ranging between",
"    <span class=\"nowrap\">",
"     8/1000",
"    </span>",
"    of an inch (0.196 millimeters) and",
"    <span class=\"nowrap\">",
"     12/1000",
"    </span>",
"    of an inch (0.294 millimeters). STSG can be expanded by meshing techniques (1:1.5 to 1:9 expansion) when additional coverage is needed (",
"    <a class=\"graphic graphic_picture graphicRef77019 \" href=\"UTD.htm?33/63/34802\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We do not harvest STSG thicker than",
"    <span class=\"nowrap\">",
"     12/1000",
"    </span>",
"    of an inch. Harvesting thicker grafts requires a longer time for donor sites to heal and may preclude that site from repeat harvesting. In addition, thicker grafts in children, the elderly, and debilitated individuals may result in a chronic wound that will require reconstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28156906\">",
"    <span class=\"h4\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advantages of STSG include the ability to cover large surface areas with less donor skin and the donor sites may be reharvested once healing is complete. Generally, the donor site can be reharvested in 10 to 15 days. Prior to reharvesting, the patient&rsquo;s nutritional status must be optimized, and the donor site wound must show evidence of reepithelialization with no evidence of local infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4215?source=see_link\">",
"     \"Overview of nutritional support for moderate to severe burn patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15716?source=see_link\">",
"     \"Evaluating nutritional support for moderate to severe burn patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11401?source=see_link\">",
"     \"Nutritional demands and enteral formulas for moderate to severe burn patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reharvesting together with expansion of the graft by meshing techniques and combination with allograft techniques (sandwich technique: 1:2 autograft covered with 1:4 allograft) allow for coverage of larger defects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28156914\">",
"    <span class=\"h4\">",
"     Disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disadvantages include fragility, abnormal pigmentation, lack of smooth texture, alopecia, and contractures. When used to reconstruct large burns of the face, STSG may yield an undesirable masklike appearance. The donor site must re-epithelialize and frequently causes significant pain. The lack of dermal element, and subsequently a limited amount of pliability and elasticity, makes split thickness grafting one of the reconstructive options more likely to form contractures in burn reconstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28156982\">",
"    <span class=\"h4\">",
"     Key technical components",
"    </span>",
"    &nbsp;&mdash;&nbsp;The methods of STSG harvesting have evolved from free-hand with a knife or hand-held dermatome to the use of electrical and air-powered dermatomes. Dermatomes are graded in multiples of",
"    <span class=\"nowrap\">",
"     1/1000",
"    </span>",
"    of an inch and",
"    <span class=\"nowrap\">",
"     5/100",
"    </span>",
"    of a millimeter, with most grafts harvested between",
"    <span class=\"nowrap\">",
"     8/1000",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     12/1000",
"    </span>",
"    of an inch. The harvested graft can be expanded through meshing devices or alternatively used as sheets in cosmetically sensitive areas, such as the face and hands (",
"    <a class=\"graphic graphic_picture graphicRef57087 \" href=\"UTD.htm?39/0/39937\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63714 \" href=\"UTD.htm?7/6/7265\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The burn wound is debrided and must be free of a hematoma, exudate, or infection.",
"     </li>",
"     <li>",
"      Tumescent infiltration with a local anesthetic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      epinephrine mixed with saline is performed at the donor and burn wound sites. (See",
"      <a class=\"local\" href=\"#H10876305\">",
"       'Tumescent infiltration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common ratios for meshing skin grafts include: 1:1 mesh (mini mesh), 2:1 mesh and 4:1 mesh (with overlying 2:1 meshed allograft), depending on the availability of donor sites.",
"     </li>",
"     <li>",
"      The grafts can be secured to the burn with staples, suture, or tissue glue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Staples are the fastest method to secure the graft to the wound. The technique is straightforward and the staples are relatively inexpensive. However, they require removal, which is painful, and there is a risk of leaving embedded staples in the wound, which may result in non-healing wounds, infection, and pain.",
"     </li>",
"     <li>",
"      Suturing is reserved for small grafts in sensitive anatomical areas in our practice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glue fixation techniques include two types of materials: cyanoacrylates, which are used as an adhesive material to fix grafts to recipient sites, and fibrin based preparations. A review of the use of fibrin glue with skin grafts has shown reduced hemorrhage, improved graft adhesion, and a possible reduction in bacterial wound infections compared with conventional techniques [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/22\">",
"       22",
"      </a>",
"      ]. Two prospective multicenter trials found a significant decrease in hematomas and seromas and improved viability with the use of fibrin glue compared with staples [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41478?source=see_link\">",
"       \"Superficial wound repair with tissue adhesives\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The dressing in contact with the grafted burn should be nonadherent, such as a bismuth-impregnated petroleum based gauze or any other atraumatic non-adherent primary dressing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link&amp;anchor=H21593928#H21593928\">",
"       \"Local treatment of burns: Topical antimicrobial agents and dressings\", section on 'Topical antimicrobial agents'",
"      </a>",
"      .) A gauze or cotton bolster is usually applied to absorb the exudate. An alternative to the bolster or other type of secondary dressing is topical negative pressure therapy (TNP) applied to the grafted burn. Our preference is application of TNP dressings in the immediate post graft period because it helps secure graft take and prepares the area for a splint [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link&amp;anchor=H17#H17\">",
"       \"Negative pressure wound therapy\", section on 'Skin graft/flap fixation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      STSG that are placed in areas that are subjected to shear because of motion (eg, axilla, antecubital fossa, or popliteal fossa), require stabilization with a splint prior to leaving the operating room.",
"     </li>",
"     <li>",
"      The donor site is usually managed with topical dressings. (See",
"      <a class=\"local\" href=\"#H7111373\">",
"       'Management of donor sites'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31287919\">",
"    <span class=\"h4\">",
"     Post-operative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two key components of post-operative management of the burn wound include early graft inspection and early mobilization.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Close-surveillance of the grafted wound facilitates early detection of graft shearing, hematomas, seromas, or any other problems that may affect graft survival. We inspect all grafts on postoperative day two.",
"     </li>",
"     <li>",
"      A fundamental component to postoperative management is the initiation of occupational therapy and physical therapy. A careful balance must be achieved between graft protection and preservation of motion in joints. Early mobilization is necessary to preserve function, but excessive early joint mobilization before full graft take or adequate wound healing will shear and destroy grafts by interfering with graft adhesion and compromise the reconstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our experience, immobilization of the reconstructed grafted wound is only necessary until graft take is achieved four or five days postoperatively. This period of rest allows successful graft adhesion and revascularization. Postoperatively, splinting provides for anatomical and functional preservation and minimizes early abnormal scar formation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28156930\">",
"    <span class=\"h4\">",
"     STSG survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The take rate, or survival, of STSG theoretically should be 100 percent providing that wound vascularity is optimal, the wound is free of infection, and the patient has optimal nutrition and infection control. The survival of split thickness sheet grafts and meshed grafts is 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several local and systemic factors that influence successful grafting, in the same way that wound healing is affected [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17384?source=see_link\">",
"     \"The surgical patient taking glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Local factors of the burn wound that are associated with decreased STSG survival include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inadequate vascularity, such as exposed unvascularized bone or tendon",
"     </li>",
"     <li>",
"      Inadequate hemostasis, such as a hematoma or seroma under the graft",
"     </li>",
"     <li>",
"      Excessive mobilization",
"     </li>",
"     <li>",
"      Areas of high contact or friction, such as the back, anorectal area, and genitalia",
"     </li>",
"     <li>",
"      Local tissue hypoxia caused by smoking or previous radiation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systemic factors that may decrease STSG survival include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Advanced patient age",
"     </li>",
"     <li>",
"      Malnutrition",
"     </li>",
"     <li>",
"      Comorbidities such as diabetes and immunosuppression",
"     </li>",
"     <li>",
"      Steroid use",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8044928\">",
"    <span class=\"h3\">",
"     Full thickness skin grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reconstruction with full thickness skin grafts (FTSG) provides an esthetic advantage for burns of the face and hands. Donor sites used for FTSG are from areas of redundant and pliable skin and include the supraclavicular, groin, lower abdominal, or lateral thoracic skin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. STSG from the scalp can be used for resurfacing the face and improves the color match of the skin paddle for patients previously treated with a free flap [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FTSG are reserved for reconstruction of areas of special anatomical and functional importance requiring a more pliable reconstruction than that offered by STSG. This is specifically important in cosmetically sensitive areas such as in the head, eyelids, perioral areas, and neck and extremely important functional areas such as the hands.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28157187\">",
"    <span class=\"h4\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;In terms of quality, FTSG present obvious advantages by transferring both epidermis and dermis to the burn wound. FTSG provide improved texture, pliability, elasticity, esthetics, and color match and are more resistant to secondary contracture in comparison to split thickness skin grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/33\">",
"     33",
"    </a>",
"    ]. There is also greater patient satisfaction with FTSG for both the recipient site and donor site, which is closed primarily [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28157203\">",
"    <span class=\"h4\">",
"     Disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major limitations and disadvantages of using FTSG include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limited availability of high quality donor skin &ndash; FTSG donor sites lack the ability to self-regenerate. Reharvesting in the same area is limited by the elasticity of surrounding skin. For example, there is sufficient laxity and pliability of the skin in the supraclavicular and groin areas to permit mobilization of the surrounding tissues and achieve a primary close the donor site. Hence, this site may be harvested a second time. Sites with insufficient laxity cannot be closed primarily. The limited availability of FTSG requires careful decision making to avoid wasting valuable elastic and pliable skin.",
"     </li>",
"     <li>",
"      Limited vascularity of the burn wound &ndash; The graft survival rate is also lower for a FTSG in comparison to a STSG [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/34\">",
"       34",
"      </a>",
"      ]. FTSG have a higher metabolic rate compared with STSG, therefore, their take or survival is compromised in areas of limited vascularity.",
"     </li>",
"     <li>",
"      Color, texture, and thickness match &ndash; Not all areas of the body are suitable as donor sites since a FTSG should ideally match the recipient site for color, skin thickness, and texture. A drawback of applying a FTSG to the face is the potential color mismatch, with results varying from hypopigmentation to hyperpigmentation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inability to drain accumulating fluids &ndash; Lack of interstices in FTSG makes the grafts more prone to non-take due to hematoma and seroma formation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28157211\">",
"    <span class=\"h4\">",
"     Key technical components",
"    </span>",
"    &nbsp;&mdash;&nbsp;The method of FTSG harvesting differs from that of harvesting a STSG. A FTSG is harvested free-hand, without the use of a dermatome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The burn wound is debrided and must be free of a hematoma, exudate, or infection.",
"     </li>",
"     <li>",
"      Tumescent infiltration with a local anesthetic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      epinephrine mixed with saline is performed at the donor and burn wound sites. (See",
"      <a class=\"local\" href=\"#H10876305\">",
"       'Tumescent infiltration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The donor skin graft is created free-hand using a blade.",
"     </li>",
"     <li>",
"      All subcutaneous adipose tissue is removed from the dermis of the FTSG.",
"     </li>",
"     <li>",
"      The donor site is managed by primary closure. (See",
"      <a class=\"local\" href=\"#H7111373\">",
"       'Management of donor sites'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Small incisions are made to perforate the FTSG to facilitate evacuation of blood exudate without compromising graft integrity.",
"     </li>",
"     <li>",
"      Quilting sutures can be used to fix the graft to the recipient site. Bolstering and tie-over of the grafts may help in protecting the grafted areas, though their usefulness in applying pressure in the interface between recipient and graft area to ensure better take has been questioned [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Topical negative wound pressure (TNP) is another fixation option in selected patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link&amp;anchor=H17#H17\">",
"       \"Negative pressure wound therapy\", section on 'Skin graft/flap fixation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28157219\">",
"    <span class=\"h4\">",
"     FTSG survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Theoretically, the FTSG survival or take rate should be close to 100 percent in fully debrided recipient burn wound sites. The main factor that prevents a complete take is the lack of initial adhesion to the recipient site due to the presence of a hematoma or seroma that inhibits revascularization. Even small perforations in the FTSG may not be sufficient to drain accumulating fluid. The same local and systemic factors that decrease the survival of STSG also decrease the survival of FTSG. (See",
"    <a class=\"local\" href=\"#H28156930\">",
"     'STSG survival'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8044936\">",
"    <span class=\"h2\">",
"     Dermal regeneration templates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of dermal regeneration template (biosynthetic skin substitutes) has increased the number of reconstructive options for burn surgeons. The common purpose of these skin substitutes is to replicate the properties of normal skin by adding a dermal component to the reconstruction to add pliability and is supplemented with a thin split skin autograft [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition to primary burn reconstruction, dermal regeneration templates can be used to cover burn reconstruction defects following release of multiple and extensive severe postburn contractures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18409?source=see_link&amp;anchor=H18#H18\">",
"     \"Primary operative management of hand burns\", section on 'Dermal regeneration templates'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link&amp;anchor=H21594043#H21594043\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\", section on 'Biosynthetic dressings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ideal dermal template should be able to [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Protect the wound from infection",
"     </li>",
"     <li>",
"      Protect the wound from fluid loss",
"     </li>",
"     <li>",
"      Provide a stable and biodegradable template for the synthesis of neodermal tissue",
"     </li>",
"     <li>",
"      Host or enable the influx of cells that will function as dermal cells",
"     </li>",
"     <li>",
"      Produce dermal tissue rather than scar tissue",
"     </li>",
"     <li>",
"      Allow ease of handling",
"     </li>",
"     <li>",
"      Resist tear forces",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our practice, we use both Integra and Matriderm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11839652\">",
"    <span class=\"h3\">",
"     Integra",
"    </span>",
"    &nbsp;&mdash;&nbsp;Integra Dermal Regeneration Template is a bilayer membrane system for skin replacement, not an independent full thickness skin substitute. The indications for using Integra include acute burn wound coverage and burn defect reconstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18409?source=see_link&amp;anchor=H18#H18\">",
"     \"Primary operative management of hand burns\", section on 'Dermal regeneration templates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Integra is available as a standard two-stage or one-stage dermal template. The template serves as a scaffold for neovascular and cellular infiltration from the wound bed. This scaffold gradually degrades; following a period of two to three weeks, the silicone epidermal layer is removed and the burn wound is covered with a thin STSG. Use of Intregra has been gradually extended from the acute coverage of full thickness burns to a versatile additional tool for reconstruction. In our practice, we use it more often in the reconstructive phase than in the acute cover period.",
"   </p>",
"   <p>",
"    One drawback of a dermal regeneration template is the potential for infection. A prospective multicenter trial that included 216 burn patients found that the rate of invasive infection at Integra treated sites was 3 percent and the superficial wound infection rate was 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/40\">",
"     40",
"    </a>",
"    ]. The median take rate of Integra was 95 percent, the median take rate of the epidermal autografts covering the Integra template was 98 percent.",
"   </p>",
"   <p>",
"    A systematic review of 20 prospective trials of several bioengineered skin substitutes found inadequate methodological detail and small numbers of patients in most trials to assess efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/41\">",
"     41",
"    </a>",
"    ]. In two trials, Integra treated burns had a significantly faster time to healing (11 versus 14 days) compared with autografts, allografts, or xenografts but a significantly lower proportion of patients with &ge;75 percent of wound closure. No high quality data from prospective trials is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11839689\">",
"    <span class=\"h4\">",
"     Key technical components: Two staged procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sequence of application of the Integra dermal regeneration template is as follows.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The burn is debrided and hemostasis is performed.",
"     </li>",
"     <li>",
"      Integra can be applied as a sheet or meshed 1:1 without overexpansion. Meshing the template allows fluid accumulation under the graft to escape, therefore reducing the possibility of a hematoma or an infected collection. This also allows better adaptation of the dermal template to any potential irregular surface.",
"     </li>",
"     <li>",
"      The prepared sheet or meshed Integra is secured to the burn reconstruction site with staples.",
"     </li>",
"     <li>",
"      After applying the Integra, we apply a double layer of dressing of polyethylene glycol and povidone-iodine (Inadine, Johnson and Johnson Medical) as an interface antiseptic layer. Use of povidone-iodine is controversial because of its purported destructive properties on fibroblasts [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The reconstructed burn area is connected to a topical negative wound pressure device [",
"      <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link&amp;anchor=H17#H17\">",
"       \"Negative pressure wound therapy\", section on 'Skin graft/flap fixation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The template is evaluated every 48 to 72 hours, and any fluid collection is carefully evacuated. Any defect in the silicone layer can be replaced with pieces of allograft.",
"     </li>",
"     <li>",
"      Evidence of neovascularization occurs in two to three weeks. At this time, a thin STSG",
"      <span class=\"nowrap\">",
"       (8/1000",
"      </span>",
"      of an inch) is applied after removal of the silicone layer.",
"     </li>",
"     <li>",
"      A negative pressure device is applied and remains in place until the grafted burn is evaluated at five days.",
"     </li>",
"     <li>",
"      Splints are applied to immobilize grafted joints.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11839781\">",
"    <span class=\"h4\">",
"     Key technical components: One stage procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of one-stage options shortens the timing and duration of reconstruction without compromising the quality of results. In the case of a single layer, one stage procedure, the dermal regeneration template is applied to the debrided burn wound or defect. The template is grafted immediately, and a negative pressure template is applied and remains in place as described above. (See",
"    <a class=\"local\" href=\"#H11839689\">",
"     'Key technical components: Two staged procedure'",
"    </a>",
"    above.).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11839667\">",
"    <span class=\"h3\">",
"     Matriderm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Matriderm is a highly porous dermal scaffold constituted by bovine collagen (collagen type I, III, and V) cross-linked to an elastin hydrolysate, and is available in sheets of 1 and 2 mm thickness. The matrices are treated with irradiation (approximately 1000 Gy) and stored at room temperature. The main advantages of Matriderm are that it can be used as a one stage procedure with a STSG and that it may minimize loss in pliability and elasticity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The application process is straightforward. One option is to moisten the sheet of Matriderm with normal saline prior to applying it to the burn defect. Another option that we have found useful is to apply the dry template to the burn, then wet it with saline. This reduces the difficulty in handling. A thin STSG is applied to the reconstruction template. Our clinical experience has revealed no dramatic differences in terms of pliability and scar quality between the one-stage procedure and the two-staged procedure.",
"   </p>",
"   <p>",
"    A prospective study of 42 paired burn wounds and 44 paired scar reconstructions found that burn patients treated with the",
"    <span class=\"nowrap\">",
"     collagen/elastin",
"    </span>",
"    dermal template with a STSG had no statistical difference for elasticity, scar contraction, Vancouver Burn Skin Score, and patient&rsquo;s impression at one year compared to burn patients treated with the conventional STSG alone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/45\">",
"     45",
"    </a>",
"    ]. Despite short-term benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/44\">",
"     44",
"    </a>",
"    ], Matriderm did not yield statistical evidence for a long-term clinical effectiveness of dermal substitution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1453206\">",
"    <span class=\"h2\">",
"     Tissue expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue expansion is a technique that gradually expands an area of pliable skin in preparation for its use as coverage of a burn defect or contracture [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Indications for tissue expansion include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Limited availability of tissue for reconstruction",
"     </li>",
"     <li>",
"      Reconstruction of specialized hair bearing areas such as the scalp",
"     </li>",
"     <li>",
"      Reconstruction of sensitive cosmetic areas such as the head and neck and breast &nbsp;",
"     </li>",
"     <li>",
"      Reconstructed site requires skin matched for color, thickness,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      texture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Typically, the expanded donor site is located in the immediate vicinity to the defect to reconstruct, and covers it by advancement, rotation, or transposition when possible. Pre-expanded free flaps are an effective but underutilized reconstruction method. Advantages of pre-expanded free flaps include the ability to cover larger wounds and improved donor site scars [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tissue expansion occurs by prolonged, gradual stretching of skin by inserting a prosthesis into an area of unburned skin immediately adjacent to the area to be covered. This procedure utilizes the vascularity and elastic properties of the unburned skin. This technique has been applied to multiple anatomical areas and is particularly useful in the head and neck areas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The advantage of this procedure is that the expanded skin matches the burned area in terms of color, consistency, elasticity, pliability, presence of hair, and sensate properties. A 10-year review of tissue expansion procedures used in 82 burn patients identified complications in 22 percent of the procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/51\">",
"     51",
"    </a>",
"    ]. The most frequent complications were expander exposure (50 percent), infection (24 percent), and malfunction of the expander (13 percent).",
"   </p>",
"   <p>",
"    A retrospective analysis of 102 tissue expanders in 57 burn patients reported major and minor complications in 9.8 and 18.6 percent of procedures, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/52\">",
"     52",
"    </a>",
"    ]. The total failure rate was 7.8 percent",
"    <span class=\"nowrap\">",
"     (8/102",
"    </span>",
"    procedures) and was highest at the head (20 percent) and with higher volume of expander (400 and 800 mL).",
"   </p>",
"   <p>",
"    Clinical experience supports these 10 rules for successful tissue expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/53\">",
"     53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Choice of expander &ndash; Rectangular expanders increase expansion surface compared to round expanders.",
"     </li>",
"     <li>",
"      Size of expander &ndash; Select the largest expander possible.",
"     </li>",
"     <li>",
"      Use prophylactic antibiotics to cover perioperative expander insertion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H7#H7\">",
"       \"Overview of control measures to prevent surgical site infection\", section on 'Antimicrobial prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Make the incision to insert the expander in healthy skin, along largest border of defect.",
"     </li>",
"     <li>",
"      The pocket is placed in the subcutaneous tissue, and is larger than the tissue expander. Irrigate pocket with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"       povidone iodine",
"      </a>",
"      diluted with normal saline.",
"     </li>",
"     <li>",
"      Use drains to reduce dead space and to drain hematomas.",
"     </li>",
"     <li>",
"      Use a two layer closure to minimize risk of extrusion.",
"     </li>",
"     <li>",
"      Intra-operatively, expand 10 percent of full expander volume once wounds are closed.",
"     </li>",
"     <li>",
"      The expander port should be placed on a solid anatomical location away from the expander.",
"     </li>",
"     <li>",
"      Once the incision is healed, start expanding the expander until it is uncomfortable for the patient or blanching of edges.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A new generation of self-inflating, osmotic expanders have been introduced that obviate the need for repeated injections, eliminate port site problems, and may potentially reduce infection. Despite being an attractive option because of the avoidance of repeated injections, a higher than expected complication rate in terms of infection, migration, and tissue necrosis highlights the need for a cautious approach to this option [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1453120\">",
"    <span class=\"h2\">",
"     Flap reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flap reconstruction is the ideal option if tissues are available. For patients with extensive burns, the options for reconstruction may be limited to skin grafting, skin substitutes, or sequential tissue expansion. While skin grafting may represent the primary option for skin coverage of burns, an assessment of the entire area to be reconstructed should include the skin, subcutaneous tissue, fascia, muscle, blood vessels, nerves, cartilage, and bone. Once the defect is analyzed, the selection of a reconstructive option is based on the relative importance of replacing each part of the defect [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple classifications have been described, but, in general, flaps for reconstruction can be classified according to [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/56\">",
"     56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Circulation &ndash; Random flaps and axial flaps, perforator flaps",
"     </li>",
"     <li>",
"      Composition &ndash; Cutaneous, fascial, fasciocutaneous, muscular, musculocutaneous, osseus, osteocutaneous",
"     </li>",
"     <li>",
"      Contiguity &ndash; Based on whether the flap is from tissues adjacent to the defect, from the same region, or from a different part of the body and include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Local pedicled flaps",
"     </li>",
"     <li>",
"      Regional pedicled flaps",
"     </li>",
"     <li>",
"      Distant pedicled flaps &nbsp;",
"     </li>",
"     <li>",
"      Free flaps, which are completely detached together with their blood supply from the donor area and anastomosed to recipient vessels close to the defect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contour &ndash; Based on how the flap is transferred to the defect:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Advancement",
"     </li>",
"     <li>",
"      Transposition",
"     </li>",
"     <li>",
"      Rotation",
"     </li>",
"     <li>",
"      Interpolation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8044944\">",
"    <span class=\"h3\">",
"     Local flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin flaps are created by using a segment of full thickness skin with the intrinsic epidermal and dermal components intact, including adjacent subcutaneous tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/13\">",
"     13",
"    </a>",
"    ]. These include interdigitating flaps based on the z-plasty principle, the alphanumeric flaps (eg, 4-flap plasty, 5-flap plasty), and propeller and bilobed flaps. The skin flap represents the gold standard of reconstruction by providing coverage of burns with tissue that matches the burned site in color, texture, and hair bearing qualities.",
"   </p>",
"   <p>",
"    The limitation to the use of skin flaps includes the availability of healthy, pliable, well vascularized donor tissue. When donor sites are limited, local flaps can be used from previously burned and grafted sites. In a retrospective review of 238 local skin flaps harvested from previously burned and grafted sites, there was no difference in complication rates compared to 115 sites of unburned donor flaps [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111241766\">",
"    <span class=\"h4\">",
"     Interdigitating flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interdigitating skin flaps are composed of tissue immediately adjacent to the burn. Small contractures or defects can be reconstructed with flaps based in the z-plasty principle of transposing interdigitating flaps. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11446?source=see_link\">",
"     \"Z-plasty\"",
"    </a>",
"    .) There are several variations of the z-plasty technique (eg, Y-V plasty, V-M plasty, propeller flap), and they can be combined with advancement or rotation flaps [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/58-62\">",
"     58-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The z-plasty principle, in which interdigitating flaps are used, has three main advantages in burn scar or contracture reconstruction (",
"    <a class=\"graphic graphic_figure graphicRef61176 graphicRef71491 graphicRef60824 graphicRef57321 graphicRef55030 graphicRef74115 \" href=\"UTD.htm?32/14/33002\">",
"     figure 1A-F",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It increases the length of the scar.",
"     </li>",
"     <li>",
"      It breaks a straight line in the area of contracture.",
"     </li>",
"     <li>",
"      It realigns the scar.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H553839\">",
"    <span class=\"h3\">",
"     Regional and distant flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several other reconstructive tissue options that are available when a skin graft or local skin flap cannot provide adequate coverage of a burn or contracted scar. Regional and distant flaps that may contain full thickness skin, subcutaneous tissue, muscle, and other tissues, and a well defined arterial supply. In composition, they can include cutaneous, fasciocutaneous, muscular, musculocutaneous, osseus, and osteocutaneous tissues.",
"   </p>",
"   <p>",
"    Regional flaps are pedicle flaps that derive the vascular supply from the same anatomical area of the defect to be reconstructed. For example, a pedicle radial forearm flap, whose pedicle is the radial artery, is used to cover a defect in the hand. Distant flaps are pedicle flaps that cover defects in a different anatomical region. For example, pedicle transverse rectus abdominal flap, whose pedicle is the superior epigastric artery, is used to cover a defect in the breast.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1453430\">",
"    <span class=\"h3\">",
"     Free microvascular tissue transfer",
"    </span>",
"    &nbsp;&mdash;&nbsp;A free microvascular tissue transfer flap, free flap, may consist of skin, subcutaneous tissue, muscle,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone and is free of any connection to the donor site. It is always detached from the donor site with its accompanying vascular pedicle, which is anastomosed to a recipient vascular pedicle. The creation of a free flap is complex and requires a substantial level of training, planning, and surgical expertise.",
"   </p>",
"   <p>",
"    Approximately one percent of surgically treated burns will require a free flap [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/63\">",
"     63",
"    </a>",
"    ]. We performed a retrospective review of 5726 burn patients admitted to the St. Andrews Centre for Plastic Surgery and Burns in Chelmsford, Essex, UK. Only 19 patients (0.3 percent) required a free flap for coverage of exposed tendons, bones, blood vessels, and resurfacing following release of secondary contractures. Thirty percent (1717) had failed previous skin graft coverage (unpublished data, presented at 2010 annual meeting of the British Association of Plastic, Reconstructive and Aesthetic Surgeons, Sheffield, UK).",
"   </p>",
"   <p>",
"    In our practice, we have found that free flaps have a small but definite role in burn reconstruction. We use a free flap in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When less complex reconstructive methods (eg, STSG, FTSG) have failed.",
"     </li>",
"     <li>",
"      When deep structures (eg, calvarium, frontal sinus, nasal pyramid, tibial crest, neurovascular structures, tendons) are exposed.",
"     </li>",
"     <li>",
"      When there is an absolute need&nbsp;to combine reconstruction with cosmetic appearance, such as the facial structures or the female breast.",
"     </li>",
"     <li>",
"      Unsalvageable deep burns.",
"     </li>",
"     <li>",
"      Resurfacing following release of scar contractures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A free flap preserves exposed deep structures and reconstructed burn scars by providing coverage with well vascularized, pliable tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/64\">",
"     64",
"    </a>",
"    ]. In a review of 53 free flap reconstruction procedures for otherwise unsalvageable burn injuries or contracted burn scars, 50 patients (94 percent) had a successful outcome with a good esthetic and functional result [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/65\">",
"     65",
"    </a>",
"    ]. In a retrospective review of 38 free fasciocutaneous flaps used to reconstruct hand burns, all flaps survived at least in part and three flaps experienced partial skin loss due to infection and were later skin grafted [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Timing of free flap reconstruction and type of burn injury may be important to the success rate of the free flap. In a review of 75 free flaps in 60 severely burned patients, the overall flap failure rate was 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/67\">",
"     67",
"    </a>",
"    ]. Eight of the 10 flap failures occurred in the group that was reconstructed between 5 and 21 days post burn. None of the free flaps failed when the procedure was performed immediately (within five days) or as a secondary reconstructive procedure six weeks or greater post burn. The free flap survival rate was lower in the electrical high voltage group (81 percent) compared to the burn injury group (90 percent). However, during the critical time period between 5 and 21 days, the survival rate for the flaps in the high voltage group was higher (44 percent) compared to the burn injury group (25 percent).",
"   </p>",
"   <p>",
"    Extensive burns limit tissue availability for accessible donor sites. A case study showed acutely burned donor skin can be harvested successfully as coverage for another burned site. As an example, a tensor fascia lata free flap harvested from an acutely burned donor site provided satisfactory coverage [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/68\">",
"     68",
"    </a>",
"    ]. Further studies to evaluate the survival of free flaps created from burned donor sites should be performed before any definitive statement can be made regarding the safety and efficacy of this procedure.",
"   </p>",
"   <p>",
"    In a retrospective review of 16 free transfer flaps in patients sustaining electrical burns, only one flap failed due to vascular erosion and secondary hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/69\">",
"     69",
"    </a>",
"    ]. Meticulous attention to wound debridement and a microvascular anastomosis performed well away from the burn will help ensure free flap survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H553861\">",
"    <span class=\"h3\">",
"     Perforator flap concept",
"    </span>",
"    &nbsp;&mdash;&nbsp;A perforator flap consists of skin and subcutaneous tissue that is vascularized by a perforator artery (eg, myocutaneous or septocutaneous) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/64,70,71\">",
"     64,70,71",
"    </a>",
"    ]. This type of flap and its versatility and variability has enabled the reconstruction of burns and scars of multiple anatomic sites.",
"   </p>",
"   <p>",
"    The major advantage of perforator flaps is that a large cutaneous flap can be obtained from the same region of a conventional musculocutaneous flap without the need to include the muscle, which might not be expendable. Limitations of perforator flaps include a burned subdermal plexus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    main perforator, difficult dissection, obesity, bleeding, and damage to the perforator pedicle.",
"   </p>",
"   <p>",
"    Perforator flap surgery requires careful planning to reduce the risk of flap failure. In our practice, we follow these principles to prevent complications with perforator flaps [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/64\">",
"     64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preoperative mapping and localization of perforating arteries by a hand-held Doppler",
"     </li>",
"     <li>",
"      Identification of the main perforator by making a limited exploratory incision",
"     </li>",
"     <li>",
"      Preservation of each perforator until encountering a large one",
"     </li>",
"     <li>",
"      Select the best perforator",
"     </li>",
"     <li>",
"      Perform the easiest dissection",
"     </li>",
"     <li>",
"      Do not discard any perforators until finished dissecting",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7111373\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF DONOR SITES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple options for atraumatic dressings and management of the donor site. Donor sites can be quite painful, so analgesia is important. The regenerated skin may be reharvested; hence, meticulous care is warranted for maintaining tissue availability and integrity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7111348\">",
"    <span class=\"h2\">",
"     Split thickness skin graft",
"    </span>",
"    &nbsp;&mdash;&nbsp;STSG donor sites are managed by meticulous hemostasis followed by coverage with a nonadherent dressing. Intraoperatively, hemostasis is achieved with gauze soaked in a solution of one liter normal saline and one ampule of 1:1000 epinephrine. Local anesthesia (generally",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    0.5 percent with epinephrine) is infiltrated to provide long term postoperative pain relief. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link\">",
"     \"Infiltration of local anesthetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our unit, we place a nonadherent dressing pad, such as Telfa&trade; Clear (polyethylene terephthalate), Mepitel&reg; (silicone), or Jelonet&trade; (paraffin gauze) as the contact layer on the donor site, covered with a layer of thick gauze to absorb any fluid, and secured with a cr&ecirc;pe wrap bandage, Elastoplast&reg; elastic bandage, or Tegaderm&trade; adhesive dressing. A pilot study assessing pain and ease of removal of the donor site dressings found Telfa Clear was easier to remove and less painful compared with Jelonet, however, donor sites covered with Jelonet appeared to heal faster [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/72\">",
"     72",
"    </a>",
"    ]. High quality data from prospective trials are not available.",
"   </p>",
"   <p>",
"    For donor sites on the back, we use Biobrane&reg; as the primary contact dressing, covered with a layer of Jelonet,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"     povidone iodine",
"    </a>",
"    soaked gauze, dry gauze, and a securing dressing. The donor site is evaluated every 72 hours until healed.",
"   </p>",
"   <p>",
"    Extracorporeal shock wave therapy (ESWT) enhances revascularization and repair of healing soft tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/73\">",
"     73",
"    </a>",
"    ]. A prospective trial of 28 patients with burns or acute traumatic wounds found that the delivery of a single treatment of ESWT to the donor site immediately after harvesting significantly reduced the time to re-epithelialization compared with standard topical therapy (13.9 versus 16.7 days). Time to re-epithelialization was defined as the time from STSG harvest to first documentation of greater than 95 percent re-epithelialization.",
"   </p>",
"   <p>",
"    Another option to treat donor sites is a keratinocyte cell spray that may improve healing and patient comfort. ReCell (Avita Medical) is a rapid, autologous cell harvesting procedure that enables the cells from a STSG biopsy to be processed into an immediate cell population and is applied as a spray to cover the wound to be treated as well as the biopsy donor site [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/74\">",
"     74",
"    </a>",
"    ]. In a randomized trial of 82 patients with deep partial thickness burns, patients treated with ReCell had similar esthetic and functional outcomes compared with patients treated with the conventional STSG [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/75\">",
"     75",
"    </a>",
"    ]. Patients treated with ReCell had significantly less postoperative pain by the visual-analogic scale (3.3 versus 6.8) and smaller STSG donor sites (2.2 versus 110 cm",
"    <sup>",
"     2",
"    </sup>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7111356\">",
"    <span class=\"h2\">",
"     Full thickness skin grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;FTSG donor sites are managed by meticulous hemostasis and primary closure with absorbable or nonabsorbable sutures, without tension on the wounds. Steri-Strips&trade; are applied to the suture line, followed by dry gauze, and secured with a wrap bandage or adhesive dressing.",
"   </p>",
"   <p>",
"    Physical activity is limited until the wound is healed to avoid rebleeding, a hematoma, or dehiscence. The dressing is removed and wound examined at five days after the procedure, and sutures are removed depending on the donor site and condition of the wound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7111364\">",
"    <span class=\"h2\">",
"     Flap defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defects that are created by harvesting a flap are managed by meticulous hemostasis and a primary closure. Skin grafting is rarely necessary. The donor site is closed in layers to minimize postoperative wound dehiscence, and without tension on the suture line. Drains are used for larger wounds.",
"   </p>",
"   <p>",
"    Steri-Strips are applied to the suture line, followed by dry gauze, and secured with a wrap bandage or adhesive dressing. Physical activity is limited until the wound is healed to avoid rebleeding, a hematoma, or dehiscence. The wound is examined every 48 hours and the drain removed once the drainage is less than 30cc per 24hrs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1886262\">",
"    <span class=\"h1\">",
"     FACE TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The facial transplantation procedure, a new and controversial reconstructive technique, offers hope to patients with severe facial burns. Facial transplantation is an experimental technique and its therapeutic value has not been validated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/76\">",
"     76",
"    </a>",
"    ]. Restrictions to this procedure include a limited availability of fascial tissue allografts, inherent complexity of the technique, required presence of a skilled multidisciplinary surgical team, and a lifelong requirement for immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/77\">",
"     77",
"    </a>",
"    ]. In a review of the first seven patients, postoperative sensory recovery occurs between three and six months and acceptable motor recovery occurs between 9 and 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/55/20346/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8044844\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of reconstructive surgery for the burn patient is to restore function then cosmesis. There are special challenges for reconstruction of burns. A balance must be achieved between immobilization to allow for skin grafts or tissue flaps to heal and mobilization to restore function. (See",
"    <a class=\"local\" href=\"#H25964950\">",
"     'Challenges'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Split thickness skin grafts (STSG) are more versatile than full thickness skin grafts (FTSG) and are used to reconstruct large burn wound areas and close donor flap sites. FTSG result in a more satisfactory esthetic appearance due to their pliability. (See",
"      <a class=\"local\" href=\"#H8044912\">",
"       'Free skin grafts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of dermal regeneration templates (biosynthetic skin substitutes) has increased the number of reconstructive options for burn surgeons. The common purpose of these skin substitutes is to replicate the properties of normal skin by adding a dermal component to the reconstruction that is supplemented with a thin split skin autograft. (See",
"      <a class=\"local\" href=\"#H8044936\">",
"       'Dermal regeneration templates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tissue expansion is a technique that expands an area of skin in preparation for its use as coverage of a burn defect or contracture. Tissue expansion occurs by prolonged, gradual stretching of skin by inserting a prosthesis into an area of unburned skin immediately adjacent to the area to be covered. (See",
"      <a class=\"local\" href=\"#H1453206\">",
"       'Tissue expansion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Flap reconstruction is the ideal option if tissues are available. Multiple classifications have been described, but, in general, flaps for reconstruction can be classified according to circulation, composition, contiguity, and contour. (See",
"      <a class=\"local\" href=\"#H1453120\">",
"       'Flap reconstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      STSG donor sites are infiltrated with a long acting local anesthetic for pain control and covered with a nonadherent dressing. FTSG donor sites and flap defects are managed by meticulous hemostasis and primary wound closure, without tension. (See",
"      <a class=\"local\" href=\"#H7111373\">",
"       'Management of donor sites'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Facial transplantation procedure is a new and controversial reconstructive technique that offers hope to patients with severe facial burns, along with a lifetime requirement of immunosuppressive therapy. (See",
"      <a class=\"local\" href=\"#H1886262\">",
"       'Face transplantation'",
"      </a>",
"      above.) Long term therapeutic benefits have not been validated.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/1\">",
"      Shelley OP, Dziewulski P. Late management of burns. Surgery Oxford 2006; 24:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/2\">",
"      Barret JP. Burns reconstruction. BMJ 2004; 329:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/3\">",
"      Shelley OP, Van Niekerk W, Cuccia G, Watson SB. Dual benefit procedures: combining aesthetic surgery with burn reconstruction. Burns 2006; 32:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/4\">",
"      Xiao-Wu W, Herndon DN, Spies M, et al. Effects of delayed wound excision and grafting in severely burned children. Arch Surg 2002; 137:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/5\">",
"      Kennedy P, Brammah S, Wills E. Burns, biofilm and a new appraisal of burn wound sepsis. Burns 2010; 36:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/6\">",
"      Herndon DN, Tompkins RG. Support of the metabolic response to burn injury. Lancet 2004; 363:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/7\">",
"      Hart DW, Wolf SE, Mlcak R, et al. Persistence of muscle catabolism after severe burn. Surgery 2000; 128:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/8\">",
"      Ong YS, Samuel M, Song C. Meta-analysis of early excision of burns. Burns 2006; 32:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/9\">",
"      Munster AM, Smith-Meek M, Sharkey P. The effect of early surgical intervention on mortality and cost-effectiveness in burn care, 1978-91. Burns 1994; 20:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/10\">",
"      Prasanna M, Mishra P, Thomas C. Delayed primary closure of the burn wounds. Burns 2004; 30:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/11\">",
"      Atiyeh BS, Dham R, Kadry M, et al. Benefit-cost analysis of moist exposed burn ointment. Burns 2002; 28:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/12\">",
"      Ramzy PI, Barret JP, Herndon DN. Thermal injury. Crit Care Clin 1999; 15:333.",
"     </a>",
"    </li>",
"    <li>",
"     Huang, T. Overview of burn reconstruction. In: Total Burn Care, 3rd editon, Herndon, D (Eds), WB Saunders, Philadelphia 2007. p.674.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/14\">",
"      Archer SB, Henke A, Greenhalgh DG, Warden GD. The use of sheet autografts to cover extensive burns in patients. J Burn Care Rehabil 1998; 19:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/15\">",
"      Koljonen V, Gerdin B, Vuola J, Low JF. Nonexpandable mesh grafts combine the advantages of mesh grafts and sheet grafts. Dermatol Surg 2007; 33:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/16\">",
"      Mackie IP, Greenwood J. A simple technique to facilitate tumescence in burn eschar and donor sites. J Burn Care Res 2009; 30:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/17\">",
"      Bussolin L, Busoni P, Giorgi L, et al. Tumescent local anesthesia for the surgical treatment of burns and postburn sequelae in pediatric patients. Anesthesiology 2003; 99:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/18\">",
"      Robertson RD, Bond P, Wallace B, et al. The tumescent technique to significantly reduce blood loss during burn surgery. Burns 2001; 27:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/19\">",
"      Fujita K, Mishima Y, Iwasawa M, Matsuo K. The practical procedure of tumescent technique in burn surgery for excision of burn eschar. J Burn Care Res 2008; 29:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/20\">",
"      Burget GC, Menick FJ. The subunit principle in nasal reconstruction. Plast Reconstr Surg 1985; 76:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/21\">",
"      GONZALEZ-ULLOA M, CASTILLO A, STEVENS E, et al. Preliminary study of the total restoration of the facial skin. Plast Reconstr Surg (1946) 1954; 13:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/22\">",
"      Currie LJ, Sharpe JR, Martin R. The use of fibrin glue in skin grafts and tissue-engineered skin replacements: a review. Plast Reconstr Surg 2001; 108:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/23\">",
"      Gibran N, Luterman A, Herndon D, et al. Comparison of fibrin sealant and staples for attaching split-thickness autologous sheet grafts in patients with deep partial- or full-thickness burn wounds: a phase 1/2 clinical study. J Burn Care Res 2007; 28:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/24\">",
"      Foster K, Greenhalgh D, Gamelli RL, et al. Efficacy and safety of a fibrin sealant for adherence of autologous skin grafts to burn wounds: results of a phase 3 clinical study. J Burn Care Res 2008; 29:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/25\">",
"      Chang KP, Tsai CC, Lin TM, et al. An alternative dressing for skin graft immobilization: negative pressure dressing. Burns 2001; 27:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/26\">",
"      Moisidis E, Heath T, Boorer C, et al. A prospective, blinded, randomized, controlled clinical trial of topical negative pressure use in skin grafting. Plast Reconstr Surg 2004; 114:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/27\">",
"      Edgar D, Brereton M. Rehabilitation after burn injury. BMJ 2004; 329:343.",
"     </a>",
"    </li>",
"    <li>",
"     Serghiou, MA, Farmer, SA.. A practical approach to acure burn rehabilitation. In: Principles and practice of burn surgery, Barret Nerin, JP, Herndon, DN, Dekker, M. (Eds), New York 2005. p.317.",
"    </li>",
"    <li>",
"     Thorne, C. Techniques and principles in plastic surgery. In: Grabb and Smith's Plastic Surgery, Wolters Kluwer, 2007. p.8.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/30\">",
"      Celik&ouml;z B, Deveci M, Duman H, N��anci M. Recontruction of facial defects and burn scars using large size freehand full-thickness skin graft from lateral thoracic region. Burns 2001; 27:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/31\">",
"      Jabaiti, SK. Use of lower abdominal full-thickness skin grafts for coverage of large skin defects. European Journal of Scientific Research 2010; 39:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/32\">",
"      Lannon DA, Novak CB, Neligan PC. Resurfacing of colour-mismatched free flaps on the face with split-thickness skin grafts from the scalp. J Plast Reconstr Aesthet Surg 2009; 62:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/33\">",
"      Iwuagwu FC, Wilson D, Bailie F. The use of skin grafts in postburn contracture release: a 10-year review. Plast Reconstr Surg 1999; 103:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/34\">",
"      Adams DC, Ramsey ML. Grafts in dermatologic surgery: review and update on full- and split-thickness skin grafts, free cartilage grafts, and composite grafts. Dermatol Surg 2005; 31:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/35\">",
"      Holavanahalli RK, Helm PA, Kowalske KJ. Long-term outcomes in patients surviving large burns: the skin. J Burn Care Res 2010; 31:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/36\">",
"      Seymour FK, Giele HP. Tie-overs under pressure. Br J Plast Surg 2003; 56:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/37\">",
"      van der Veen VC, van der Wal MB, van Leeuwen MC, et al. Biological background of dermal substitutes. Burns 2010; 36:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/38\">",
"      Figus A, Leon-Villapalos J, Philp B, Dziewulski P. Severe multiple extensive postburn contractures: a simultaneous approach with total scar tissue excision and resurfacing with dermal regeneration template. J Burn Care Res 2007; 28:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/39\">",
"      Jeng JC, Fidler PE, Sokolich JC, et al. Seven years' experience with Integra as a reconstructive tool. J Burn Care Res 2007; 28:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/40\">",
"      Heimbach DM, Warden GD, Luterman A, et al. Multicenter postapproval clinical trial of Integra dermal regeneration template for burn treatment. J Burn Care Rehabil 2003; 24:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/41\">",
"      Pham C, Greenwood J, Cleland H, et al. Bioengineered skin substitutes for the management of burns: a systematic review. Burns 2007; 33:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/42\">",
"      Cooper ML, Laxer JA, Hansbrough JF. The cytotoxic effects of commonly used topical antimicrobial agents on human fibroblasts and keratinocytes. J Trauma 1991; 31:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/43\">",
"      Stiefel D, Schiestl CM, Meuli M. The positive effect of negative pressure: vacuum-assisted fixation of Integra artificial skin for reconstructive surgery. J Pediatr Surg 2009; 44:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/44\">",
"      Ryssel H, Gazyakan E, Germann G, Ohlbauer M. The use of MatriDerm in early excision and simultaneous autologous skin grafting in burns--a pilot study. Burns 2008; 34:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/45\">",
"      van Zuijlen PP, Vloemans JF, van Trier AJ, et al. Dermal substitution in acute burns and reconstructive surgery: a subjective and objective long-term follow-up. Plast Reconstr Surg 2001; 108:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/46\">",
"      Gil T, Metanes I, Aman B, et al. Six tissue expansion sessions of the scalp for reconstruction of post-burn alopecia. J Burn Care Res 2008; 29:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/47\">",
"      Di Mascio D, Castagnetti F, Mazzeo F, et al. Overexpansion technique in burn scar management. Burns 2006; 32:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/48\">",
"      Motamed S, Niazi F, Atarian S, Motamed A. Post-burn head and neck reconstruction using tissue expanders. Burns 2008; 34:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/49\">",
"      Tavares Filho JM, Belerique M, Franco D, et al. Tissue expansion in burn sequelae repair. Burns 2007; 33:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/50\">",
"      De Agustin JC, Morris SF, Zuker RM. Tissue expansion in pediatric burn reconstruction. J Burn Care Rehabil 1993; 14:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/51\">",
"      Cunha MS, Nakamoto HA, Herson MR, et al. Tissue expander complications in plastic surgery: a 10-year experience. Rev Hosp Clin Fac Med Sao Paulo 2002; 57:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/52\">",
"      Bozkurt A, Groger A, O'Dey D, et al. Retrospective analysis of tissue expansion in reconstructive burn surgery: evaluation of complication rates. Burns 2008; 34:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/53\">",
"      Hudson DA, Grob M. Optimising results with tissue expansion: 10 simple rules for successful tissue expander insertion. Burns 2005; 31:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/54\">",
"      Chummun S, Addison P, Stewart KJ. The osmotic tissue expander: a 5-year experience. J Plast Reconstr Aesthet Surg 2010; 63:2128.",
"     </a>",
"    </li>",
"    <li>",
"     Mathes, SJ, Nahai, F.. The reconstructive triangle: A paradigm for decision making.. In: Reconstructive surgery: Principles, anatomy and technique, New York 1997. p.9.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/56\">",
"      Masia J, Kosutic D, Cervelli D, et al. In search of the ideal method in perforator mapping: noncontrast magnetic resonance imaging. J Reconstr Microsurg 2010; 26:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/57\">",
"      Barret JP, Herndon DN, McCauley RL. Use of previously burned skin as random cutaneous local flaps in pediatric burn reconstruction. Burns 2002; 28:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/58\">",
"      Murakami M, Hyakusoku H, Ogawa R. The scar band rotation flap. Burns 2005; 31:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/59\">",
"      Gokrem S, Baser NT, Akbuga UB, et al. Nine-flap z-plasty: a new modification of five-flap z-plasty. Burns 2008; 34:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/60\">",
"      Coban YK. Moderate axillary postburn contracture release using the VM-plasty. Burns 2007; 33:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/61\">",
"      Schwarz RJ. Management of postburn contractures of the upper extremity. J Burn Care Res 2007; 28:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/62\">",
"      Aslan G, Tuncali D, Cigsar B, et al. The propeller flap for postburn elbow contractures. Burns 2006; 32:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/63\">",
"      Platt AJ, McKiernan MV, McLean NR. Free tissue transfer in the management of burns. Burns 1996; 22:474.",
"     </a>",
"    </li>",
"    <li>",
"     Blondeel, PN, Neligan, PC. Complications: Avoidance and treatment. In: Perforator Flaps. Anatomy, Technique and Clinical applications, Blondeel, PN, Morris SF, Hallock, GG, Neligan, PC (Eds), Quality Medical Publishing, St. Louis 2006. p.115.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/65\">",
"      De Lorenzi F, van der Hulst R, Boeckx W. Free flaps in burn reconstruction. Burns 2001; 27:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/66\">",
"      Pan CH, Chuang SS, Yang JY. Thirty-eight free fasciocutaneous flap transfers in acute burned-hand injuries. Burns 2007; 33:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/67\">",
"      Baumeister S, K&ouml;ller M, Dragu A, et al. Principles of microvascular reconstruction in burn and electrical burn injuries. Burns 2005; 31:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/68\">",
"      Aky&uuml;rek M, Safak T. Transfer of a free flap from an acutely burned donor site. Scand J Plast Reconstr Surg Hand Surg 2004; 38:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/69\">",
"      Koul AR, Patil RK, Philip VK. Early use of microvascular free tissue transfer in the management of electrical injuries. Burns 2008; 34:681.",
"     </a>",
"    </li>",
"    <li>",
"     Neligan, PC, Blondeel, PN, Morris, SF, et al. Perforator Flaps: Overview, Classification, and nomenclature. In: erforator Flaps. Anatomy, Technique and Clinical applications, Blondeel, PN, Morris SF, Hallock, GG, Neligan, PC (Eds), Quality Medical Publishing, Inc., St. Louis 2006. p.37.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/71\">",
"      Hallock GG. A history of the development of muscle perforator flaps and their specific use in burn reconstruction. J Burn Care Rehabil 2004; 25:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/72\">",
"      Ghosh K, Ponniah AJ, Jones I, et al. The ideal donor-site dressing: are we clear yet? Plast Reconstr Surg 2010; 126:279e.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/73\">",
"      Ottomann C, Hartmann B, Tyler J, et al. Prospective randomized trial of accelerated re-epithelization of skin graft donor sites using extracorporeal shock wave therapy. J Am Coll Surg 2010; 211:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/74\">",
"      Navarro FA, Stoner ML, Park CS, et al. Sprayed keratinocyte suspensions accelerate epidermal coverage in a porcine microwound model. J Burn Care Rehabil 2000; 21:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/75\">",
"      Gravante G, Di Fede MC, Araco A, et al. A randomized trial comparing ReCell system of epidermal cells delivery versus classic skin grafts for the treatment of deep partial thickness burns. Burns 2007; 33:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/76\">",
"      Siemionow M, Gordon CR. Overview of guidelines for establishing a face transplant program: a work in progress. Am J Transplant 2010; 10:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/77\">",
"      B��ogowski W. Facial transplantation as an option in reconstructive surgery: no mountains too high? ANZ J Surg 2009; 79:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/55/20346/abstract/78\">",
"      Gordon CR, Siemionow M, Papay F, et al. The world's experience with facial transplantation: what have we learned thus far? Ann Plast Surg 2009; 63:572.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14990 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_55_20346=[""].join("\n");
var outline_f19_55_20346=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8044844\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25963747\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25964950\">",
"      CHALLENGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1883166\">",
"      TIMING OF SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1883187\">",
"      Urgent (immediate) procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1883213\">",
"      Essential (early) procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1883241\">",
"      Desirable (late) procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8044867\">",
"      BURN RECONSTRUCTION PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8044904\">",
"      Primary closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22158166\">",
"      Early excision and skin grafting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8044912\">",
"      Free skin grafts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10876305\">",
"      - Tumescent infiltration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8044920\">",
"      - Split thickness skin grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28156906\">",
"      Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28156914\">",
"      Disadvantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28156982\">",
"      Key technical components",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H31287919\">",
"      Post-operative management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28156930\">",
"      STSG survival",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8044928\">",
"      - Full thickness skin grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28157187\">",
"      Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28157203\">",
"      Disadvantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28157211\">",
"      Key technical components",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28157219\">",
"      FTSG survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8044936\">",
"      Dermal regeneration templates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11839652\">",
"      - Integra",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11839689\">",
"      Key technical components: Two staged procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11839781\">",
"      Key technical components: One stage procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11839667\">",
"      - Matriderm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1453206\">",
"      Tissue expansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1453120\">",
"      Flap reconstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8044944\">",
"      - Local flaps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H111241766\">",
"      Interdigitating flaps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H553839\">",
"      - Regional and distant flaps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1453430\">",
"      - Free microvascular tissue transfer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H553861\">",
"      - Perforator flap concept",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7111373\">",
"      MANAGEMENT OF DONOR SITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7111348\">",
"      Split thickness skin graft",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7111356\">",
"      Full thickness skin grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7111364\">",
"      Flap defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1886262\">",
"      FACE TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8044844\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/14990\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14990|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/14/4335\" title=\"figure 1A\">",
"      Classic z-plasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/45/21201\" title=\"figure 1B\">",
"      Compound z-plasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/13/36063\" title=\"figure 1C\">",
"      Four flap z-plasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/12/10433\" title=\"figure 1D\">",
"      Five flap z-plasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/1/25616\" title=\"figure 1E\">",
"      Six flap z-plasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/20/3392\" title=\"figure 1F\">",
"      Double opposing z-plasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14990|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/63/34802\" title=\"picture 1\">",
"      Harvested STSG meshed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/0/39937\" title=\"picture 2\">",
"      Split thickness skin graft and skin mesher",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/6/7265\" title=\"picture 3\">",
"      Split thickness skin graft meshing process",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15716?source=related_link\">",
"      Evaluating nutritional support for moderate to severe burn patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=related_link\">",
"      Hypermetabolic response to severe burn injury: Recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=related_link\">",
"      Local treatment of burns: Topical antimicrobial agents and dressings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11401?source=related_link\">",
"      Nutritional demands and enteral formulas for moderate to severe burn patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4215?source=related_link\">",
"      Overview of nutritional support for moderate to severe burn patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18409?source=related_link\">",
"      Primary operative management of hand burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41478?source=related_link\">",
"      Superficial wound repair with tissue adhesives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17384?source=related_link\">",
"      The surgical patient taking glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11446?source=related_link\">",
"      Z-plasty",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_55_20347="Diff dx pediatric MS";
var content_f19_55_20347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F70259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F70259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of pediatric multiple sclerosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        CNS infection",
"       </td>",
"       <td>",
"        Acute bacterial or viral infections, Lyme disease, West Nile virus, syphilis, and HIV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Mitochondrial disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leukodystrophies",
"       </td>",
"       <td>",
"        Metachromatic leukodystrophy, X-linked adrenoleukodystrophy, Alexander's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin deficiency",
"       </td>",
"       <td>",
"        B12, folate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CNS malignancy",
"       </td>",
"       <td>",
"        Lymphoma, high grade glioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Granulomatous diseases",
"       </td>",
"       <td>",
"        Neurosarcoidosis, granulomatosis with polyangiitis (Wegener's)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inflammatory disease",
"       </td>",
"       <td>",
"        ADEM/MDEM, SLE, antiphospholipid antibody syndrome, Sjogren's disease, Behcet's disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ADEM: acute disseminated encephalomyelitis; HIV: human immunodeficiency virus; MDEM: multiphasic disseminated encephalomyelitis; SLE: systemic lupus erythematosus; CNS: central nervous system.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_55_20347=[""].join("\n");
var outline_f19_55_20347=null;
var title_f19_55_20348="Causes of vaginal bleeding";
var content_f19_55_20348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of vaginal bleeding in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        At any time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Before normal menarche",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hormonal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Neonatal bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Exogenous estrogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Precocious puberty",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Nonhormonal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Urethral prolapse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Genital warts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lichen sclerosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Infectious vaginitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Foreign body",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        After menarche",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleeding diathesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pelvic infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Endocrinologic problem",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Midcycle spotting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dysfunctional uterine bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hormonal contraception",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Axis immaturity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Polycystic ovary syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ovarian cyst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ectopic pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous abortion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placenta previa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abruptio placentae",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Paradise JE. Vaginal bleeding. In: Textbook of Pediatric Emergency Medicine, 6th edition, Fleisher GR, Ludwig S (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_55_20348=[""].join("\n");
var outline_f19_55_20348=null;
var title_f19_55_20349="SIDS resources";
var content_f19_55_20349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sudden unexpected infant death/Sudden infant death syndrome resources",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Association of SIDS and Infant Mortality Programs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        112 E. Allegan, suite 500",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lansing, MI 48933",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-800-930-7437",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        email:&nbsp;",
"        <a href=\"mailto:info@asip1.org\">",
"         info@asip1.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        website:",
"        <a href=\"file://www.asip1.org\">",
"         www.asip1.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National SUID/SIDS Resource Center",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2115 Wisconsin Avenue, NW",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suite 601",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Washington DC, 20007",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-866-866-7437 or 1-202-687-7466",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        email:",
"        <a href=\"mailto:info@sidscenter.org\">",
"         info@sidscenter.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         website:",
"         <a href=\"file://www.sidscenter.org\">",
"          www.sidscenter.org",
"         </a>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        First Candle/SIDS Alliance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (a national network of SIDS support groups)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1314 Bedford Avenue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suite 210 Baltimore, MD 21208",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-800-221-7437 or 1-410-653-8226",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        email:",
"        <a href=\"mailto:info@firstcandle.org\">",
"         <span style=\"color: #0000ff;\">",
"          info@firstcandle.org",
"         </span>",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        website:",
"        <a href=\"file://www.firstcandle.org\">",
"         www.firstcandle.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Foundation for the Study of Infant Deaths",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Artillery House",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11-19 Artillery Row",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        London, SWIP IRT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        020 7233 2090",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        email:",
"        <a href=\"mailto:fsid@fsid.org.uk\">",
"         fsid@fsid.org.uk",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        website:",
"        <a href=\"file://www.fsid.org.uk\">",
"         www.fsid.org.uk",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Canadian Foundation for the Study of Infant Deaths (CFSID)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        586 Eglinton Avenue East",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suite 308",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toronto, Ontario, Canada M4P 1P2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-800-363-7437 (toll-free) or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-416-488-3260 or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-416-488-3864 (fax)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        email:",
"        <a href=\"mailto:sidsinfo@sidscanada.org\">",
"         sidsinfo@sidscanada.org",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        website:",
"        <a href=\"file://www.sidscanada.org\">",
"         www.sidscanada.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National SIDS Council of Australia, Ltd.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suite 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        98 Morang Road",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hawthorn, VIC 3122, Australia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        03 9819 4595 or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        03 9818 4596 (fax)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        email:",
"        <a href=\"mailto:national@sidsandkids.org\">",
"         national@sidsandkids.org",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        website:",
"        <a href=\"file://www.sidsandkids.org\">",
"         www.sidsandkids.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        SIDS Family Association Japan (SIDSFAJ)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        email:",
"        <a href=\"mailto:englishcontact@sids.gr.jp\">",
"         englishcontact@sids.gr.jp",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        website:",
"        <a href=\"file://www.sids.gr.jp\">",
"         www.sids.gr.jp",
"        </a>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: the National Institute of Child Health &amp; Human Development Fact Sheet: Sudden infant death syndrome (www.nichd.nih.gov/publications/pubs/sidsfact.htm).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_55_20349=[""].join("\n");
var outline_f19_55_20349=null;
var title_f19_55_20350="OA knee preop";
var content_f19_55_20350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F50213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F50213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteoarthritis of the knee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 221px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This preoperative radiograph (x-ray) shows severe loss of cartilage affecting the medial compartment of the knee.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mark L Robbins, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_55_20350=[""].join("\n");
var outline_f19_55_20350=null;
var title_f19_55_20351="Hypermature cataract";
var content_f19_55_20351=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypermature cataract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 183px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dilated penlight photo of a hypermature cataract reveals a brown nucleus (arrow) sinking in an opaque, white, liquified cortex. There is no view of the posterior pole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah S Jacobs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_55_20351=[""].join("\n");
var outline_f19_55_20351=null;
